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CHD congenital heart disease
CI confidence interval
CIDS Canadian Implantable Defibrillator Study
CMR cardiac magnetic resonance
COMPANION Comparison of Medical Therapy, Pacing, and
Defibrillation in Heart Failure
CPG Committee for Practice Guidelines
CPVT catecholaminergic polymorphic ventricular
tachycardia
CRT cardiac resynchronization therapy
CRT-D cardiac resynchronization therapy defibrillator
CRT-P cardiac resynchronization therapy pacemaker
CT computed tomography
DCM dilated cardiomyopathy
DEFINITE DEFIbrillators in Non-Ischemic cardiomyop-
athy Treatment Evaluation
DFT defibrillation threshold
DIAMOND Danish Investigators of Arrhythmia and
Mortality oN Dofetilide
ECG electrocardiogram / electrocardiographic
EHRA European Heart Rhythm Association
EPS electrophysiological study
ESC European Society of Cardiology
GWAS genome-wide association study
HCM hypertrophic cardiomyopathy
HF heart failure
HFpEF heart failure with preserved ejection fraction
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ICD implantable cardioverter defibrillator
ILCOR International Liaison Committee On
Resuscitation
IRIS Immediate Risk stratification Improves Survival
LBBB left bundle branch block
LMNA lamin A/C
LQTS long QT syndrome
LQTS1 long QT syndrome type 1
LQTS2 long QT syndrome type 2
LQTS3 long QT syndrome type 3
LV left ventricle / left ventricular
LVEF left ventricular ejection fraction
LVOT left ventricular outflow tract
MADIT Multicenter Automatic Defibrillator Implant-
ation Trial
MIRACLE Multicenter InSync Randomized Clinical
Evaluation
MRA mineralocorticoid receptor antagonist
ms millisecond
MUSTT Multicenter UnSustained Tachycardia Trial
NSTEMI non–ST-segment elevation myocardial
infarction
NSVT non-sustained ventricular tachycardia
NYHA New York Heart Association




PRESERVE-EF risk stratification in patients with preserved
ejection fraction
PVC premature ventricular complex
PVS programmed ventricular stimulation
QTc corrected QT
RAFT Resynchronization–Defibrillation for Ambu-
latory Heart Failure Trial
RBBB right bundle branch block
RCT randomized controlled trial
REVERSE REsynchronization reVErses Remodeling in
Systolic left vEntricular dysfunction
REVERSE MIRACLE
ICD




RVOT right ventricular outflow tract
SA-ECG signal-averaged ECG
SADS sudden arrhythmic death syndrome
SCD sudden cardiac death
SCD-HeFT Sudden Cardiac Death in HEart Failure Trial
SCORE Systematic Coronary Risk Evaluation
SIDS sudden infant death syndrome
SMASH-VT Substrate Mapping and Ablation in Sinus
Rhythm to Halt Ventricular Tachycardia
SPECT single-photon emission computed tomography
SQTS short QT syndrome
STEMI ST-segment elevation myocardial infarction
SUDEP sudden unexpected death in epilepsy
SUDI sudden unexplained death in infancy
SUDS sudden unexplained death syndrome





VTACH Ventricular Tachycardia Ablation in Coronary
Heart Disease
WCD wearable cardioverter defibrillator
WPW Wolff–Parkinson–White
1. Preamble
Guidelines summarize and evaluate all available evidence on a par-
ticular issue at the time of the writing process, with the aim of assist-
ing health professionals in selecting the best management strategies
for an individual patient with a given condition, taking into account
the impact on outcome, as well as the risk–benefit ratio of particu-
lar diagnostic or therapeutic means. Guidelines and recommenda-
tions should help health professionals to make decisions in their
daily practice. However, the final decisions concerning an individual
patient must be made by the responsible health professional(s) in
consultation with the patient and caregiver as appropriate.
A great number of Guidelines have been issued in recent years by
the European Society of Cardiology (ESC) as well as by other soci-
eties and organisations. Because of the impact on clinical practice,
quality criteria for the development of guidelines have been estab-
lished in order to make all decisions transparent to the user. The re-
commendations for formulating and issuing ESC Guidelines can be
found on the ESC website (http://www.escardio.org/Guidelines-
&-Education/Clinical-Practice-Guidelines/Guidelines-development/
Writing-ESC-Guidelines). ESC Guidelines represent the official pos-
ition of the ESC on a given topic and are regularly updated.
Members of this Task Force were selected by the ESC to re-
present professionals involved with the medical care of patients
with this pathology. Selected experts in the field undertook a
comprehensive review of the published evidence for management
(including diagnosis, treatment, prevention and rehabilitation) of
a given condition according to ESC Committee for Practice
Guidelines (CPG) policy. A critical evaluation of diagnostic and
therapeutic procedures was performed, including assessment of
the risk–benefit ratio. Estimates of expected health outcomes for
larger populations were included, where data exist. The level of
evidence and the strength of the recommendation of particular
management options were weighed and graded according to prede-
fined scales, as outlined in Tables 1 and 2.
The experts of the writing and reviewing panels provided declara-
tions of interest forms for all relationships that might be perceived as
real or potential sources of conflicts of interest. These forms were
compiled into one file and can be found on the ESC website (http://
www.escardio.org/guidelines). Any changes in declarations of interest
that arise during the writing period must be notified to the ESC and
updated. The Task Force received its entire financial support from the
ESC without any involvement from the healthcare industry.
The ESC CPG supervises and coordinates the preparation of new
Guidelines produced by task forces, expert groups or consensus
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panels. The Committee is also responsible for the endorsement
process of these Guidelines. The ESC Guidelines undergo extensive
review by the CPG and external experts. After appropriate revi-
sions the Guidelines are approved by all the experts involved in
the Task Force. The finalized document is approved by the CPG
for publication in the Europace. The Guidelines were developed
after careful consideration of the scientific and medical knowledge
and the evidence available at the time of their dating.
The task of developing ESC Guidelines covers not only integra-
tion of the most recent research, but also the creation of education-
al tools and implementation programmes for the recommendations.
To implement the guidelines, condensed pocket guidelines versions,
summary slides, booklets with essential messages, summary cards
for non-specialists, and an electronic version for digital applications
(smartphones, etc.) are produced. These versions are abridged and
thus, if needed, one should always refer to the full text version,
which is freely available on the ESC website. The National Societies
of the ESC are encouraged to endorse, translate and implement all
ESC Guidelines. Implementation programmes are needed because it
has been shown that the outcome of disease may be favourably in-
fluenced by the thorough application of clinical recommendations.
Surveys and registries are needed to verify that real-life daily
practice is in keeping with what is recommended in the guidelines,
thus completing the loop between clinical research, writing of guide-
lines, disseminating them and implementing them into clinical
practice.
Health professionals are encouraged to take the ESC Guidelines
fully into account when exercising their clinical judgment, as well as
in the determination and the implementation of preventive, diagnos-
tic or therapeutic medical strategies. However, the ESC Guidelines
do not override in any way whatsoever the individual responsibility
of health professionals to make appropriate and accurate decisions
in consideration of each patient’s health condition and in
consultation with that patient and the patient’s caregiver where ap-
propriate and/or necessary. It is also the health professional’s re-
sponsibility to verify the rules and regulations applicable to drugs
and devices at the time of prescription.
2. Introduction
The present document has been conceived as the European update
to the American College of Cardiology (ACC)/American Heart As-
sociation (AHA)/ESC 2006 Guidelines for management of patients
with ventricular arrhythmias (VA) and the prevention of sudden car-
diac death (SCD).1 In light of the very recent consensus documents
for the management of patients with VA released by the major inter-
national heart rhythm societies,2,3 the ESC Guidelines Committee
decided to focus the content of this document on the prevention
of SCD. The update is timely, considering the new insights into
the natural history of diseases predisposing to SCD and the comple-
tion of major studies that will impact management strategies for
heart failure (HF) involving both drug and device therapies.
Table 1 Classes of recommendations
Classes of 
recommendations
Suggested wording to use
Class I Evidence and/or general 
agreement that a given treatment 





divergence of opinion about the 
Conflicting evidence and/or a
usefulness/efficacy of the given
favour of usefulness/efficacy.
Usefulness/efficacy is less well
treatment or procedure. 
Class IIa Weight of evidence/opinion is in Should be considered
Class IIb
established by evidence/opinion. 
May be considered
Class III Evidence or general agreement 
that the given treatment or 
procedure is not useful/effective,  
and in some cases may be harmful. 
Is not recommended
Table 2 Levels of evidence
Level of 
evidence A 
Data derived from multiple randomized 
clinical trials or meta-analyses. 
Level of 
evidence B 
Data derived from a single randomized 




Consensus of opinion of the experts and/
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2.1 Structure of the guidelines
The document is divided in sections that cover specific topics. The
risk evaluation scheme and treatment offered should be tailored in
consideration of co-morbidities, limitation of life expectancy, impact
on quality of life and other circumstances.
While preparing this update, the committee reviewed the most
recent recommendations for each topic and modified the class
and/or the strength of recommendations, considering whether
new results from randomized trials, meta-analyses or clinical evi-
dence would call for a change. Special care was taken to maintain
consistency in the use of language with existing guidelines. Occa-
sionally, however, wording changes were made to render some of
the original recommendations more user friendly and precise.
The committee was composed of physicians and associated
healthcare providers who are experts in the areas of SCD and
prevention, complex VA, interventional electrophysiology, coron-
ary artery disease (CAD), HF and cardiomyopathy, paediatric
cardiology and arrhythmias, device therapy, cardiovascular care, car-
diovascular genetics and nursing. Experts in different subspecialties
in cardiology were identified with the help of the related working
groups of the ESC.
All members of the writing committee approved the guideline re-
commendations. Seventy-four peer reviewers reviewed the docu-
ment. An extensive literature survey was conducted that led to
the incorporation of 810 references. The guidelines reviewed con-
cerning prevention of SCD are listed in Web Table 1.3 – 13
3. Definitions, epidemiology
and future perspectives for
the prevention of sudden cardiac
death
The definitions used for sudden death, aborted cardiac arrest, idio-
pathic ventricular fibrillation (VF) and for the prevention of sudden
death are detailed in Table 3.
3.1 Epidemiology of sudden cardiac death
In the past 20 years, cardiovascular mortality has decreased in high-
income countries19 in response to the adoption of preventive
measures to reduce the burden of CAD and HF. Despite these
encouraging results, cardiovascular diseases are responsible for ap-
proximately 17 million deaths every year in the world, approximate-
ly 25% of which are SCD.20 The risk of SCD is higher in men than in
women, and it increases with age due to the higher prevalence of
CAD in older age.21 Accordingly, the SCD rate is estimated to range
from 1.40 per 100 000 person-years [95% confidence interval (CI)
0.95, 1.98] in women to 6.68 per 100 000 person-years (95% CI
6.24, 7.14) in men.21 SCD in younger individuals has an estimated in-
cidence of 0.46–3.7 events per 100 000 person-years,22,23 corre-
sponding to a rough estimate of 1100–9000 deaths in Europe and
800–6200 deaths in the USA every year.24
Table 3 Definitions of commonly used terms
Term Ref a
Sudden death Non-traumatic, unexpected fatal event occurring within 1 hour of the onset of symptoms in an apparently healthy 
subject.
If death is not witnessed, the  applies when the victim was in good health 24 hours before the event.
1
SUDS and SUDI Sudden death without an apparent cause and in which an autopsy has not been performed in an adult (SUDS) or in an 
infant <1 year of age (SUDI). 
14
SCD The term is used when:
• A congenital, or acquired, potentially fatal cardiac condition was known to be present during life; OR
• Autopsy has  a cardiac or vascular anomaly as the probable cause of the event; OR
• No obvious extra-cardiac causes have been  by post-mortem examination and therefore an arrhythmic event  
is a likely cause of death.
1, 14, 
15
SADS and SIDS Both autopsy and toxicology investigations are inconclusive, the heart is structurally normal at gross and histological 




Unexpected circulatory arrest, occurring within 1 hour of onset of acute symptoms, which is reversed by successful 
resuscitation manoeuvres (e.g.  
-
Idiopathic ventricular Clinical investigations are negative in a patient surviving an episode of ventricular 17, 18
Primary prevention 
of SCD
Therapies to reduce the risk of SCD in individuals who are at risk of SCD but have not yet experienced an aborted 




Therapies to reduce the risk of SCD in patients who have already experienced an aborted cardiac arrest or life-
threatening arrhythmias.
1
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3.1.1 Causes of sudden cardiac death in different age groups
Cardiac diseases associated with SCD differ in young vs. older indivi-
duals. In the young there is a predominance of channelopathies and
cardiomyopathies (Web Table 2),21,25–48 myocarditis and substance
abuse,49 while in older populations, chronic degenerative diseases pre-
dominate (CAD, valvular heart diseases and HF). Several challenges
undermine identification of the cause of SCD in both age groups: older
victims, for instance, may suffer from multiple chronic cardiovascular
conditions so that it becomes difficult to determine which contributed
most to SCD. In younger persons, the cause of SCD may be elusive
even after autopsy, because conditions such as inherited channelopa-
thies or drug-induced arrhythmias that are devoid of structural abnor-
malities are epidemiologically relevant in this age group.
3.2 Autopsy and molecular autopsy in
sudden death victims
Indications for autopsy and molecular autopsy in
sudden death victims
Recommendations Classa Levelb Ref.c
An autopsy is recommended to
investigate the causes of sudden
death and to define whether SCD is
secondary to arrhythmic or
non-arrhythmic mechanisms (e.g.
rupture of an aortic aneurysm).
I C 17
Whenever an autopsy is performed,
a standard histological examination of
the heart is recommended and it
should include mapped labelled
blocks of myocardium from
representative transverse slices of
both ventricles.
I C 17
The analysis of blood and other
adequately collected body fluids for
toxicology and molecular pathology is




analysis of potentially disease-causing
genes should be considered in all sudden










Identification of the cause of an unexpected death provides the fam-
ily with partial understanding and rationalization of the unexpected
tragedy, which facilitates the coping process and allows an under-
standing of whether the risk of sudden death may extend to family
members. Accordingly, it appears reasonable that all unexplained
sudden death victims undergo post-mortem expert examination
to investigate whether a cardiac origin should be suspected.
Although CAD accounts for a large proportion of sudden deaths,
especially for persons .40 years of age, other causes should be
taken into account, including genetic disorders that affect either
the integrity of the heart’s muscle (see section 7) or its electrical
function (see section 8). Every time a heritable disease is identified
in a deceased individual, the relatives of the victim may be at risk of
being affected and dying suddenly unless a timely diagnosis is made
and preventive measures taken.
Unfortunately, even when an autopsy is performed, a proportion
of sudden deaths, ranging from 2 to 54%,48 remain unexplained
(Web Table 2): this broad range of values is likely due to heterogen-
eity of the autopsy protocols. To promote a common standard for
autopsy, targeted guidelines have been developed to define proto-
cols for heart examination and histological sampling, as well as for
toxicology and molecular investigation.17,50 Overall, a properly con-
ducted autopsy should provide answers to the following issues:
(i) whether the death is attributable to a cardiac disease, (ii) the na-
ture of the cardiac disease (if present), (iii) whether the mechanism
of death was arrhythmic, (iv) whether there is evidence of a cardiac
disease that may be inherited and thus requires screening and coun-
selling of relatives and (v) the possibility of toxic or illicit drug use or
other causes of unnatural deaths.
A standard histological examination of the heart should
include mapped labelled blocks of myocardium from representative
transverse slices of both ventricles. We encourage pathologists to
contact specialized centres and send the heart to them for examin-
ation. The pathologist should perform a standard gross examination
of the heart, including a transverse apical section, and take tissues,
blood and other fluids for toxicology and molecular pathology before
fixing the heart in formalin. Furthermore, the collection and storage
of biological samples for DNA extraction to allow a ‘molecular’ aut-
opsy is encouraged.17 Molecular autopsy is an important addition to
the standard autopsy, as it allows the diagnosis post-mortem of the
presence of cardiac channelopathies that may explain 15–25% of sud-
den arrhythmic death syndrome (SADS) cases.17 The value of the
post-mortem diagnosis in a victim of SCD lies in extending genetic
screening to the family members of SADS or SIDS victims. Recent ex-
pert consensus documents for the diagnosis and management of in-
heritable arrhythmias state that the use of a focused molecular
autopsy/post-mortem genetic testing should be considered for
SCD victims when the presence of channelopathies is suspected.
We endorse this recommendation and refer interested readers to
the most recent consensus documents on this topic.14,52
3.3 Risk prediction of sudden cardiac
death
Prediction of SCD is the philosopher’s stone of arrhythmology, and
attempts to provide reliable indicators of SCD have fuelled one of
the most active areas of investigation in arrhythmology during re-
cent decades.53 It is now clear that the propensity to die suddenly
originates as a ‘perfect storm’—interaction of a vulnerable substrate
(genetic or acquired changes in the electrical or mechanical proper-
ties of the heart) with multiple transient factors that participate in
triggering the fatal event. In the next section we provide a brief over-
view of the paucity of risk-stratification schemes for SCD in normal
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3.3.1 Individuals without known heart disease
Approximately 50% of cardiac arrests occur in individuals without a
known heart disease, but most suffer from concealed ischaemic heart
disease.54 As a consequence, the most effective approach to prevent
SCD in the general population resides in quantification of the individ-
ual risk of developing ischaemic heart disease based on risk score
charts, followed by the control of risk factors such as total serum
cholesterol, glucose, blood pressure, smoking and body mass index.55
Approximately 40% of the observed reduction in SCD is the direct
consequence of a reduction of CAD and other cardiac conditions.56
Several studies57–61 have provided evidence that there is a genet-
ic predisposition to die suddenly. The research group led by X. Jou-
ven was one of the first to investigate the predictive value of familial
recurrence of sudden death. The authors demonstrated, in the Paris
study published in 1999,57 that one parental history of sudden death
had a relative risk (RR) of sudden death of 1.89, which increased to
9.44 in those with two parental histories of sudden death (P ¼ 0.01).
At the same time, Friedlander et al.58 confirmed, in a case-based co-
hort study from the Framingham study, an almost 50% increase [RR
1.46 (95% CI 1.23, 1.72)] in the likelihood of sudden death in the
presence of a family history of SCD. In 2006, Dekker et al.59 showed
that familial sudden death occurs significantly more frequently in in-
dividuals resuscitated from primary VF than in controls [odds ratio
(OR) 2.72 (95% CI 1.84, 4.03)]. The impressive consistency of these
results suggests that the predisposition to die suddenly is written in
the genes, even in the absence of a Mendelian disease, and en-
courages molecular investigations to identify DNA markers to pre-
dict SCD in the general population.
Among the studies that have searched for single nucleotide poly-
morphisms that predispose to SCD, the results of two genome-wide
association studies (GWAS) are relevant: the Arrhythmia Genetics in
the NEtherlandS (AGNES) study,61 which involved patients with a
first myocardial infarction and VF and compared them with a cohort
of patients with a first myocardial infarction without VF. Only one sin-
gle nucleotide polymorphism located in the 21q21 locus achieved
genome-wide significance, with an OR of 1.78 (95% CI 1.47, 2.13;
P ¼ 3.36 × 10210). This common single nucleotide polymorphism
(47% frequency of the allele) is in an intergenic region and the closest
gene, CXADR (98 kb away), encodes a viral receptor implicated in
viral myocarditis. The second GWAS study62 was a very large study
that identified a strong signal at the 2q24.2 locus, which contains three
genes with unknown function that are all expressed in the heart. This
locus increases the risk of SCD by 1.92 (95% CI 1.57, 2.34). The study
did not, however, replicate the results of the AGNES study, raising
concerns that either the size or the design of the AGNES study pre-
sented limitations. These genetic data are not yet being applied in
clinics, but they show that genetics may evolve into a promising ap-
proach to quantify the risk of SCD early in life. The availability of novel
technologies that allow faster and cheaper genotyping may soon pro-
vide data on very large populations and deliver the statistical power
required for these investigations.
3.3.2 Patients with ischaemic heart disease
For more than two decades investigators throughout the world have
envisioned a broad range of ‘indicators’ for SCD occurring in the set-
ting of ischaemic heart disease. Several non-invasive markers of risk of
SCD have been proposed for patients with myocardial ischaemia,
including, among others, programmed ventricular stimulation (PVS),
late potentials, heart rate variability, baroreflex sensitivity, QT interval
dispersion, microvolt T-wave alternans and heart rate turbulence.
However, despite the promising outcomes of the early studies,
none of these ‘predictors’ has influenced clinical practice. As a conse-
quence, the only indicator that has consistently shown an association
with increased risk of sudden death in the setting of myocardial infarc-
tion and left ventricular (LV) dysfunction is LV ejection fraction
(LVEF).63,64 This variable has been used for more than a decade to tar-
get the use of an implantable cardioverter defibrillator (ICD) for pri-
mary prevention of SCD, often in combination with New York Heart
Association (NYHA) class. Despite the fact that LVEF is not an
accurate and highly reproducible clinical parameter, it is still used to
select patients for ICD implantation in the primary prevention of SCD.
Among emerging variables that look promising for predicting
SCD are biochemical indicators such as the B-type natriuretic pep-
tide and N-terminal pro-B-type natriuretic peptide, which have
shown encouraging results in preliminary investigations.65,66
3.3.3 Patients with inheritable arrhythmogenic diseases
The availability of risk stratification schemes is highly heterogeneous
among the different channelopathies and cardiomyopathies: for ex-
ample, while the duration of the corrected QT (QTc) interval is a
reliable indicator of risk of cardiac events in long QT syndrome
(LQTS),67 and septal hypertrophy predicts outcome in hypertroph-
ic cardiomyopathy (HCM),68 in other diseases, such as Brugada syn-
drome or short QT syndrome (SQTS), risk stratification metrics are
not robust, leaving uncertainties on how to target the prophylactic
use of the ICD. So far, genetic information may be used to guide risk
stratification only in a few diseases such as LQTS and lamin A/C di-
lated cardiomyopathy.69– 71
3.4 Prevention of sudden cardiac death
in special settings
3.4.1 Screening the general population for the risk of
sudden cardiac death
Vigilance for electrocardiographic (ECG) and echocardiographic signs
of inheritable arrhythmogenic diseases seems to be an important part
of clinical practice and can contribute to the early identification of
patients at risk of SCD. Whether such a careful approach should
be extended to mass screening in populations at risk of sudden death
is currently unclear. Italy and Japan have implemented ECG screening
systems, which may identify asymptomatic patients with inheritable
arrhythmogenic diseases.72 – 74 While consensus exists among
experts in Europe and the United States (US) that support pre-
participation screening in athletes (an approach that has been
endorsed by the International Olympic Committee),75–77 a recent
study reported no change in incidence rates of SCD in competitive
athletes following implementation of screening programs in Israel.78
Similarly, there are no clear data supporting the benefit of broad
screening programs in the general population. Narain et al.79 screened
12 000 unselected healthy individuals 14–35 years of age. Screening
was performed at a cost of GB£35 per individual and consisted of a
health questionnaire, 12-lead ECG and consultation with a cardio-
logist. Individuals with abnormalities underwent a transthoracic echo-
cardiogram on the same day or were referred for further evaluation.
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Although the screening identified only a few patients with inheritable
channelopathies or cardiomyopathies (4/12 000), the authors con-
cluded that the cost to identify individuals at increased risk of SCD
might still support a mass-screening programme.
It is clear that the cost–benefit assessment of ECG population
screening is influenced largely by the cost of identifying a single af-
fected individual. Such a cost has not been determined by the Italian
national healthcare system despite the fact that a universal screening
programme has been in place for the past 35 years, and will vary de-
pending on the regional organization of healthcare. The US cost es-
timate for screening athletes ranges from US$300 million–US$2
billion per year according to Kaltman et al.80
Overall, we cannot provide recommendations for population
screening at this time because the consequences of screening strat-
egies that detect a still-undefined number of ‘false positives’ and miss
an unknown percentage of affected cases (‘false negatives’) have not
been established. This inability to derive a recommendation from
the evidence obtained from existing screening programmes illus-
trates the need for further work to collect quantitative data on
the cost–benefit profile of performing ECG screening in different
populations and in different healthcare systems and settings. Con-
versely, in consideration of the higher risk of arrhythmias and the
worsening of structural or genetic diseases in individuals exposed
to intense physical exercise,81,82 we do support the existing recom-
mendations for pre-participation screening in athletes. In Europe
there is consensus that clinical evaluation, personal or family history
taking and a baseline 12-lead ECG should be performed in this
population (refer to section 12.7).
3.4.2 Screening family members of sudden death victims
The diagnosis of an inheritable arrhythmogenic disorder is estab-
lished in up to 50%83 of families with a SADS victim, especially chan-
nelopathies [e.g. LQTS, Brugada syndrome and catecholaminergic
polymorphic ventricular tachycardia (CPVT)] and occasionally
subtle forms of cardiomyopathy [HCM and arrhythmogenic right
ventricular cardiomyopathy (ARVC) in particular] or familial hyper-
cholesterolaemia. As a consequence of these findings, when an
autopsy is either not available for the victim (i.e. SUDS or SUDI)
and/or when the post-mortem examination fails to detect structural
abnormalities and toxicology results are normal (i.e. SADS or SIDS),
first-degree relatives of the victim should be informed of the poten-
tial risk of similar events to themselves and should undergo cardiac
evaluation. A family history of recurrent premature SUDS or inher-
itable heart disease represents a ‘red flag’ that makes familial evalu-
ation strongly recommended.
Family screening of first-degree relatives of victims of sudden
death is an important intervention to identify individuals at risk, ad-
vise on available treatment and adequately prevent sudden
death.14,84 Currently only 40% of family members are screened,85
partially due to a lack of adequate screening infrastructure, but
also due to the anxiety and distress associated with the personal ex-
perience of a life-threatening arrhythmia or a recent family bereave-
ment from an inheritable cardiac condition.86,87 The psychosocial
needs of these patients and their families should be evaluated and
a multidisciplinary approach within specialized centres should be
followed, as recently recommended.14,84,88 The value of this ap-
proach has been demonstrated.89,90
Various protocols have been proposed for screening family mem-
bers of sudden death victims.14,91 These protocols usually follow a
stepwise approach, starting with lower-cost and higher-yield inves-
tigations and moving on to further examinations based on both the
initial findings and the family history.91 Whenever a diagnosis is sus-
pected, based on the presence of structural or electrical abnormal-
ities, the standard procedure for the diagnosis of the suspected
disease should be followed.
Accurate history taking is the first step to reach a post-mortem
diagnosis, preliminary to active exploration of the family members.
When the victim is young, the focus should be on cardiomyopathies
and channelopathies. The evaluation of premonitory cardiac symp-
toms (including syncope or ‘epilepsy’), together with an exhaustive
exploration of the circumstances of death and the collection of
ante-mortem clinical cardiac investigations, is recommended.
When the victim is .40 years of age, the presence of risk factors
for CAD should be assessed (e.g. active or passive smoking, dyslipo-
proteinaemia, hypertension or diabetes). In addition, a complete
three-generation pedigree should be created, recording all sudden
deaths and cardiac diseases.14 Efforts to retrieve old medical re-
cords and/or post-mortem examinations should be made. Family
members with symptoms suggestive of the presence of a cardiac
condition, such as syncope, palpitations or chest pain, should be
prioritized for evaluation.
The recommended core evaluation of a first-degree relative of a
sudden death victim is illustrated in Table 4. In the absence of a diag-
nosis in the family, very young children should be screened at least
with a baseline ECG and an echocardiogram.
As many inheritable arrhythmogenic diseases are characterized
by age-related penetrance and incomplete expression, younger in-
dividuals should be followed-up at regular intervals. Asymptomatic
and fully grown adults can be discharged from care unless symp-
toms appear or new information from the family becomes
available.
When an inheritable arrhythmogenic disease is suspected, DNA
samples from the victim are the best source of information when
performing a molecular autopsy. If there is a positive result, family
members should be offered the opportunity to undergo predictive
genetic screening, in a cascade fashion. The ‘right not to know’ and
the possibility to decline molecular screening should be included in
any pre-informative communication with the relatives.
In the absence of biological samples from the deceased person,
targeted molecular screening in first-degree relatives may be consid-
ered when there is the suspicion of the presence of an inheritable
disease in family members. Conversely, genetic screening of a large
panel of genes should not be performed in SUDS or SADS relatives
without clinical clues for a specific disease after clinical evaluation.
This is especially true in SIDS cases, where molecular autopsy iden-
tifies a lower burden of ion channel disease compared with SADS
and sporadic genetic disease as a cause of sudden death may be
more frequent.
3.4.3 Screening patients with documented or suspected
ventricular arrhythmias
3.4.3.1 Clinical history
Palpitations (or sensation of sudden rapid heartbeats), presyncope
and syncope are the three most important symptoms that
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require a thorough clinical history taking and possibly further in-
vestigations to rule out a relation to VAs. Palpitations related to
ventricular tachycardia (VT) are usually of a sudden onset/offset
pattern and may be associated with presyncope and/or syncope.
Episodes of sudden collapse with loss of consciousness without
any premonition must raise the suspicion of bradyarrhythmias or
VA. Syncope occurring during strenuous exercise, while sitting
or in the supine position should always raise the suspicion of a car-
diac cause, while other situational events may indicate vasovagal
syncope or postural hypotension.92 Symptoms related to under-
lying structural heart diseases, such as chest discomfort, dyspnoea
and fatigue, may also be present and should be sought. Thorough
inquiries about a family history of SCD and drugs, including
dosages used, must be included in the evaluation of patients sus-
pected of having a VA. A positive family history of SCD is a strong
independent predictor of susceptibility to VA and SCD.57,58 Al-
though physical examination is seldom revealing, it may sometimes
give valuable clues.
3.4.3.2 Non-invasive and invasive evaluation
Non-invasive evaluation of patients with suspected or
known ventricular arrhythmias
Recommendations Classa Levelb Ref.c
Resting 12-lead ECG
Resting 12-lead ECG is recommended in
all patients who are evaluated for VA.
I A 1
ECG monitoring
Ambulatory ECG is recommended to
detect and diagnose arrhythmias.
Twelve-lead ambulatory ECG is
recommended to evaluate QT-interval
changes or ST changes.
I A 93
Cardiac event recorders are
recommended when symptoms are
sporadic to establish whether they are
caused by transient arrhythmias.
I B 94
Implantable loop recorders are
recommended when symptoms, e.g.
syncope, are sporadic and suspected
to be related to arrhythmias and
when a symptom–rhythm correlation
cannot be established by conventional
diagnostic techniques.
I B 95
SA-ECG is recommended to
improve the diagnosis of ARVC in
patients with VAs or in those who




Exercise stress testing is
recommended in adult patients with
VA who have an intermediate or greater
probability of having CAD by age and
symptoms to provoke ischaemic
changes or VA.
I B 98
Exercise stress testing is
recommended in patients with
known or suspected exercise-induced
VA, including CPVT, to achieve a
diagnosis and define prognosis.
I B 99
Exercise stress testing should be
considered in evaluating response to





Echocardiography for assessment of
LV function and detection of
structural heart disease is
recommended in all patients with




Table 4 Diagnostic approach for family members of sudden unexplained death syndrome or sudden arrhythmic death
syndrome victims
Approach Actiona
History taking and physical examination • Personal clinical history
• Family history focused on cardiac diseases or sudden deaths
ECG • Baseline 12-lead ECG with standard and high precordial leads
• 24-hour ambulatory ECG 
• Exercise stress test
• Signal-averaged ECG
• Provocative test with  (when Brugada syndrome is suspected)
Cardiac imaging • Two-dimensional echocardiography and/or CMR (with or without contrast)
Genetic testing • Targeted molecular testing and genetic counselling if there is the clinical suspicion of a  disease
• Referral to a tertiary centre specialized in evaluation of the genetics of arrhythmias
CMR ¼ cardiac magnetic resonance; ECG ¼ electrocardiogram.
aThe recommendations in this table are based on the consensus of this panel of experts and not on evidence-based data.
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Echocardiography for assessment of
LV and RV function and detection
of structural heart disease is
recommended for patients at high
risk of developing serious VAs or
SCD, such as those with dilated,
hypertrophic or RV
cardiomyopathies, survivors of acute
myocardial infarction or relatives of
patients with inherited disorders
associated with SCD.
I B 100
Exercise testing plus imaging
(exercise stress echocardiography test
or nuclear perfusion, SPECT) is
recommended to detect silent
ischaemia in patients with VAs who have
an intermediate probability of having
CAD by age or symptoms and in
whom an ECG is less reliable (digoxin
use, LV hypertrophy, .1-mm
ST-segment depression at rest, WPW
syndrome, or LBBB).
I B 102
Pharmacological stress testing plus
imaging modality is recommended to
detect silent ischaemia in patients with
VAs who have an intermediate
probability of having CAD by age or
symptoms and are physically unable to
perform a symptom-limited exercise test.
I B 103
CMR or CT should be considered in
patients with VAs when
echocardiography does not provide
accurate assessment of LV and RV
function and/or evaluation of structural
changes.
IIa B 1
ARVC ¼ arrhythmogenic right ventricular cardiomyopathy; CAD ¼ coronary
artery disease; CMR ¼ cardiac magnetic resonance; CPVT ¼ catecholaminergic
polymorphic ventricular tachycardia; CT ¼ computed tomography; ECG ¼
electrocardiogram; LBBB ¼ left bundle branch block; LV ¼ left ventricular; RV¼
right ventricular; SA-ECG ¼ signal-averaged ECG; SCD ¼ sudden cardiac death;
SPECT ¼ single-photon emission computed tomography; VA ¼ ventricular




Invasive evaluation of patients with suspected or
known ventricular arrhythmias
Recommendations Classa Levelb Ref.c
Coronary angiography
Coronary angiography should be
considered to establish or exclude
significant obstructive CAD in patients
with life-threatening VAs or in survivors
of SCD, who have an intermediate or




Electrophysiological study in patients
with CAD is recommended for
diagnostic evaluation of patients with
remote myocardial infarction with




Electrophysiological study in patients
with syncope is recommended when
bradyarrhythmias or tachyarrhythmias
are suspected, based on symptoms (e.g.
palpitations) or the results of
non-invasive assessment, especially in
patients with structural heart disease.
I C 106
Electrophysiological study may be
considered for the differential diagnosis
of ARVC and benign RVOT tachycardia
or sarcoidosis.
IIb B 107
ARVC ¼ arrhythmogenic right ventricular cardiomyopathy; CAD ¼ coronary
artery disease; RVOT ¼ right ventricular outflow tract; SCD ¼ sudden cardiac




A standard resting 12-lead ECG may reveal signs of inherited dis-
orders associated with VAs and SCD such as channelopathies
(LQTS, SQTS, Brugada syndrome, CPVT) and cardiomyopathies
(ARVC and HCM). Other ECG parameters suggesting underlying
structural disease include bundle branch block, atrio-ventricular
(AV) block, ventricular hypertrophy and Q waves consistent
with ischaemic heart disease or infiltrative cardiomyopathy. Elec-
trolyte disturbances and the effects of various drugs may result
in repolarization abnormalities and/or prolongation of the QRS
duration.
Exercise ECG is most commonly applied to detect silent
ischaemia in adult patients with ventricular VAs. Exercise-induced
non-sustained VT was reported in nearly 4% of asymptomatic
middle-age adults and was not associated with an increased risk
of total mortality.108 Exercise testing in adrenergic-dependent
rhythm disturbances, including monomorphic VT and polymorphic
VT such as CPVT, is useful for diagnostic purposes and evaluating
response to therapy. Exercise testing in patients with life-
threatening VAs may be associated with arrhythmias requiring car-
dioversion, intravenous (i.v.) drugs or resuscitation, but may still be
warranted because it is better to expose arrhythmias and evaluate
risk under controlled circumstances. It should be performed
where resuscitation equipment and trained personnel are immedi-
ately available.
Continuous or intermittent ambulatory recording techniques
can aid in relating symptoms to the presence of the arrhythmia. Si-
lent myocardial ischaemic episodes may also be detected. A 24- to
48-h continuous Holter recording is appropriate whenever the ar-
rhythmia is known or suspected to occur at least once a day. For
sporadic episodes, conventional event recorders are more useful
because they can record over extended periods. Implantable sub-
cutaneous devices that continuously monitor the heart rhythm
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and record events over a timeframe measured in years can record
on patient activation or automatically for pre-specified criteria.
They may be very useful in diagnosing serious tachyarrhythmias
and bradyarrhythmias in patients with life-threatening symptoms
such as syncope. The new ‘injectable’ loop recorders do not re-
quire conventional surgical preparations.
Signal-averaged ECG (SA-ECG) improves the signal:noise ratio of
a surface ECG so that low-amplitude (microvolt level) signals, re-
ferred to as ‘late potentials’, can be identified at the end of the
QRS complex. Late potentials indicate regions of abnormal myocar-
dium with slow conduction, a substrate abnormality that may allow
for re-entrant ventricular tachyarrhythmias. SA-ECG is recom-
mended for differential diagnosis of structural heart disease, such
as ARVC, in patients with VAs.
Echocardiography is the most commonly used imaging tech-
nique because, compared with cardiac magnetic resonance
(CMR) and cardiac computed tomography (CT), it is inexpensive,
readily available and provides accurate diagnosis of myocardial,
valvular and congenital heart disorders associated with VA
and SCD.109 In addition, LV systolic function and regional wall mo-
tion can be evaluated in a majority of patients. Therefore echo-
cardiography is indicated in patients with VA suspected of having
structural heart disease and in the subset of patients at high risk
for the development of serious VA or SCD, such as those with di-
lated, hypertrophic or right ventricular (RV) cardiomyopathies,
survivors of acute myocardial infarction or relatives of patients
with inherited disorders associated with SCD. The combination
of echocardiography with exercise or pharmacological stress
(commonly known as ‘stress echo’) is applicable to a selected
group of patients who are suspected of having VA triggered by is-
chaemia and who are unable to exercise or have resting ECG ab-
normalities that limit the accuracy of the ECG for ischaemia
detection.
Advances in CMR have made it possible to evaluate both the
structure and function of the beating heart. The excellent image
resolution obtained with current techniques allows for accurate
quantification of chamber volumes, LV mass and ventricular func-
tion. This is of particular value to patients with suspected ARVC,
in whom CMR provides excellent assessment of RV size, function
and regional wall motion.
CT allows precise quantification of LV volumes, ejection fraction
and mass, with results comparable with CMR, but in addition provides
segmental images of the coronary arteries from which the extent of
calcification can be quantified. Cardiac CT can be used in selected
patients in whom evaluation of cardiac structures is not feasible
with echocardiography and CMR is not available. An anomalous ori-
gin of coronary arteries can be detected by CT or other imaging
techniques.
Myocardial perfusion single-photon emission CT (SPECT) using
exercise or pharmacological agents is applicable for a selected group
of patients who are suspected of having VA triggered by ischaemia
and who are unable to exercise or have resting ECG abnormalities
that limit the accuracy of the ECG for ischaemia detection. Accurate
quantification of LVEF is possible with gated radionuclide
angiography (multiple-gated acquisition scan) and may be helpful
in patients for whom this measurement is not available with
echocardiography.
Coronary angiography plays an important diagnostic role in estab-
lishing or excluding the presence of significant obstructive CAD in
patients with life-threatening VA or in survivors of SCD.
An electrophysiological study (EPS) with PVS has been used to
document the inducibility of VT, guide ablation, assess the risks of
recurrent VT or SCD, evaluate loss of consciousness in selected pa-
tients with arrhythmias suspected as a cause and assess the indica-
tions for ICD therapy. The yield of EPS varies fundamentally with the
kind and severity of the underlying heart disease, the presence or
absence of spontaneous VT, concomitant drug therapy, the stimula-
tion protocol and the site of stimulation. The highest induction rates
and reproducibility are observed in patients after myocardial infarc-
tion, and recommendations for its use in selected cases are given in
this document.
To evaluate patients with VAs, most centres use eight ventricu-
lar stimuli at drive cycle lengths between 600 ms and 400 ms at the
RV apex, at twice-diastolic threshold and a pulse duration of 0.5–
2 ms, delivering one to three ventricular extrastimuli at baseline.
This test may be repeated during isoproterenol infusion.110 The
prematurity of extrastimuli is increased until refractoriness or in-
duction of sustained ventricular tachyarrhythmia is achieved.
Because premature ventricular stimulation with a very short coup-
ling interval is more likely to induce VF as opposed to mono-
morphic VT, it may be reasonable to limit the prematurity of the
extrastimuli to a minimum of 180 ms when studying patients for
whom only inducible sustained monomorphic VT would be con-
sidered a positive endpoint. EPS may be repeated at the RV out-
flow tract (RVOT) or LV.
EPS may be used to document the arrhythmic cause of syncope
and should be used to complement a full syncope workup. It is most
useful in patients with CAD and LV dysfunction. EPS can be used to
document or provoke bradyarrhythmias or AV block when other in-
vestigations have failed to provide conclusive information. The diag-
nostic yield varies greatly with the selected patient populations111
and is low in the absence of structural heart disease or abnormal
ECG. In patients with syncope, chronic bundle branch block and re-
duced ejection fraction (, 45%), VT may be induced during EPS in
up to 42% of cases. In patients with syncope and bundle branch
block, false-negative EPS is common.112 EPS can provoke non-
specific tachyarrhythmic responses in patients with preserved LV
function who do not have structural heart disease.
The utility of EPS to determine prognosis and to guide therapy in
patients with cardiomyopathies and inherited primary arrhythmia
syndromes is discussed in sections 7 and 8. Briefly, EPS might play
a role in ARVC113,114 or DCM patients,115 while it does not contrib-
ute to identifying high-risk patients in HCM (class III).116 Among the
channelopathies, EPS is not indicated in LQTS,117 CPVT14 and
SQTS,118,119 while its utility is debated in Brugada syndrome.120
Syncope in patients with structural heart disease and, in par-
ticular, significant LV dysfunction is ominous. Non-sustained VT
on Holter monitoring, syncope and structural heart disease
are highly sensitive for predicting the presence of inducible VT.
Syncope associated with heart disease and reduced ejection frac-
tion has high recurrence and death rates,121 even when EPS results
are negative. EPS is useful in patients with LV dysfunction due to a
previous myocardial infarction (ejection fraction ,40%) but is
not sensitive in patients with non-ischaemic cardiomyopathy.
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Induction of polymorphic VT or VF, especially with aggressive
stimulation techniques, is not specific. In CAD, the diagnostic yield
may reach 50%.
Figure 1 illustrates the proposed diagnostic workflow for patients
who survived an aborted cardiac arrest, while the management
of cardiac arrest in the setting of specific conditions is described
in sections 5–12. Web Table 3 presents the nomenclature adopted
when referring to VAs across this document.122 Investigations that
may reveal disease-specific findings are detailed in Web Table 4.
4. Therapies for ventricular
arrhythmias
4.1 Treatment of underlying heart disease
A fundamental aspect of the successful management of VA and the
prevention of SCD is effective management of underlying diseases
and co-morbidities. Acute worsening and progressive deterioration
of these conditions must be avoided. Co-morbidities that may
 
Clinical History
• Angina pectoris or shortness of breath
• Family history of premature SCD (age <40 years) or ealy-onset heart disease
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• Assess risk for SCD
Consider to





















• Autopsy in collaboration with pathologists
• Obtain blood and tissue samples
• Molecular autopsy after autopsy
• Offer family councelling and support
• Refer family for cardiology / SCD workup
Further patient assessment, e.g.b
• Stress test, Holter 48 hours,
• Consider coronary angiogram
• Refer patients to experienced centers for risk evaluation,
   catheter ablation, drugs and ICD
• Drug challenges, EPS
• CMR, CT, myocardial biopsy
• Signal averaged ECG, TOE based on suspected disease
ACEi = angiotensin-converting enzyme inhibitors; CAD = coronary artery disease; CMR = cardiac magnetic resonance; CT = computed tomography; DCM = dilated cardiomyopathy; 
ECG = electrocardiogram; EPS = electrophysiological study; GL = guidelines; ICD = implantable cardioverter  
LVEF = left ventricular ejection fraction; NSTEMI = non-ST-segment elevation myocardial infarction; SCD = sudden cardiac death; 
STEMI = ST-segment elevation myocardial infarction; TOE = transoesophageal echocardiography; VF = ventricular  
VT = ventricular tachycardia.
aClinical history of chest pain, dyspnoea, and symptoms associated with certain cardiac conditions and family tree. 
bThe need for further tests and evaluations will be guided by the initial assessment and by suspected cardiovascular diseases.
Figure 1 Diagnostic workup in patients presenting with sustained ventricular tachycardia or ventricular fibrillation.
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encourage triggers for or contribute to the development of a sub-
strate that will sustain a VA must also be controlled. The treatment
of heart disease has changed considerably since the seminal trials of
anti-arrhythmic drugs and the ICD were undertaken. As there is lit-
tle prospect of repeating such trials, the therapeutic implications of
the original trials must be extrapolated to the modern context.
Nevertheless, up-to-date management of underlying cardiovascular
disease must be optimized (relevant ESC Guidelines can be
found at http://www.escardio.org/Guidelines-&-Education/Clinical-
Practice-Guidelines/listing).
4.2 Pharmacotherapy for ventricular
arrhythmia and prevention of sudden
cardiac death
4.2.1 General management
The selection of appropriate therapy for the management of VA and
for prevention of SCD is focused on arrhythmia, the associated
medical conditions that may contribute to and/or exacerbate ar-
rhythmia, the risk posed by arrhythmia and the risk–benefit aspects
of potential therapy. Management of a manifest arrhythmia may in-
volve discontinuation of offending pro-arrhythmic drugs (see sec-
tion 12.5) and appropriate anti-arrhythmic therapy with drugs,
implantable devices, ablation or surgery. For specific recommenda-
tions on pharmacotherapy, see the text and recommendation tables
for the various indications detailed in later sections of this guideline.
4.2.2 Anti-arrhythmic drugs
With the exception of beta-blockers, currently available anti-
arrhythmic drugs have not been shown in randomized clinical trials
(RCTs) to be effective in the primary management of patients with
life-threatening VAs or in the prevention of SCD. Occasional studies
with amiodarone have shown positive results, but this is not a con-
sistent finding.123,124 As a general rule, anti-arrhythmic agents may
be effective as adjunctive therapy in the management of arrhythmia-
prone patients under specific circumstances. Because of potential
adverse effects of anti-arrhythmic drugs, they must be used with
caution. This section provides an overview of pharmacotherapy
for VAs to prevent recurrent VT (Table 5).
Each drug has a significant potential for causing adverse events,
including pro-arrhythmia. Many marketed cardiac and non-cardiac
drugs induce sinus bradycardia and AV block, some impair His–Pur-
kinje conduction and produce AV or bundle branch block, whereas
others prolong ventricular repolarization and the QT interval. Thus
anti-arrhythmic drugs may have the potential to precipitate life-
threatening ventricular tachyarrhythmias, similar (but with a higher
prevalence) to some non-cardiovascular drugs, which may also pro-
long the QT interval or slow intraventricular conduction.125,126
Of relevance to the cardiologist, class IA (e.g. quinidine, disopyra-
mide) anti-arrhythmic drugs that block the sodium current also block
the rapid component of the delayed rectifier potassium current and
may therefore prolong the QT interval. For this reason a warning on
the use of sodium channel blockers in patients on QT-prolonging
medication or who are affected by the genetically transmitted
LQTS has been issued. Recently, however, it has been demonstrated
that some sodium current blockers (predominantly class IB like mex-
iletine and class IC like flecainide) actively inhibit both the peak so-
dium current and the late component of the sodium current. In
doing so, these agents may induce an abbreviation of the QT interval
in patients with LQTS type 3 because this form is caused by mutations
that enhance the late sodium current.127 For this reason, these drugs
may be considered to abbreviate the QT interval in patients with type
3 LQTS (see section 8.1). Whether drug-induced QT prolongation
and other genetic variants of LQTS also respond to late sodium cur-
rent blockers with shortening of the QT interval is still unknown.
Recently a German study using an active surveillance approach re-
ported a crude incidence of drug-induced LQTS leading to torsade
de pointes (TdP) of 3.2 per million per year.128 Once it is appre-
ciated that a VA may be due to ‘anti-arrhythmic’ drug therapy, the
possible offending therapies should be discontinued and appropri-
ate follow-up ECG monitoring carried out.
In light of the results of the Cardiac Arrhythmia Suppression Trial
(CAST),129 showing an excessive mortality or non-fatal cardiac ar-
rest rate (7.7%) among post–myocardial infarction patients treated
with encainide or flecainide compared with that in placebo-treated
patients (3.0%), a contraindication for the use of class IC sodium
channel blockers after myocardial infarction has been issued. The
contraindication has been extended to other class I anti-arrhythmic
agents, because even if they do not increase mortality, when used to
reduce the arrhythmic burden in post–myocardial infarction pa-
tients they fail to reduce mortality (for references and discussion
of results see section 5).
The use of drugs for inherited primary arrhythmia syndromes
(LQTS, SQTS, Brugada syndrome) and cardiomyopathies is an off-
label indication.
4.2.2.1 Beta-blockers
The mechanism of anti-arrhythmic efficacy of beta-blockers includes
competitive beta-adrenoreceptor blockade of sympathetically
mediated triggering mechanisms, slowing of the sinus rate and pos-
sibly inhibition of excess calcium release by the ryanodine receptor
channel.
Beta-blockers are effective in suppressing ventricular ectopic beats
and arrhythmia as well as in reducing SCD in a spectrum of cardiac
disorders in patients with and without HF. Beta-blockers are effective
and generally safe anti-arrhythmic agents that can be considered the
mainstay of anti-arrhythmic drug therapy. Recently, however, a regis-
try study in 34 661 patients with ST-segment elevation myocardial in-
farction (STEMI) or non-STEMI (NSTEMI) found that in patients with
two or more risk factors for shock (e.g. age .70 years, heart rate
.110 bpm, systolic blood pressure ,120 mmHg), the risk of shock
or death was significantly increased in those treated with beta-
blockers [NSTEMI: OR 1.23 (95% CI 1.08, 1.40), P ¼ 0.0016; STEMI:
OR 1.30 (95% CI 1.03, 1.63), P ¼ 0.025].130
Overall, beta-blockers are first-line therapy in the management of
VA and the prevention of SCD.
4.2.2.2 Amiodarone
Amiodarone has a broad spectrum of action that includes blockade
of depolarizing sodium currents and potassium channels that con-
duct repolarizing currents; these actions may inhibit or terminate
VAs by influencing automaticity and re-entry.
The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)
trial showed a lack of survival benefit for treatment with amiodarone
vs. placebo in patients with LVEF ≤35%.64 Unlike sodium channel
blockers,131 however, amiodarone can be used without increasing
mortality in patients with HF.132
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Common or important 
adverse effects
Indications Cardiac contra-indications and warnings
Amiodarone (III) 200–400 Pulmonary  hypothyroidism 
and hyperthyroidism, neuropathies, 
corneal deposits, photosensitivity, 
skin discolouration, hepatotoxicity, 
sinus bradycardia, QT prolongation, 
and occasional TdP.
VT, VF Conditions and concomitant treatments associated with QT 
interval prolongation; inherited LQTS; sinus bradycardia (except in
cardiac arrest); sinus node disease (unless a pacemaker is present);
severe AV conduction disturbances (unless a pacemaker is present);
decompensated HF or cardiomyopathy.
Beta-blocker (II) Various Bronchospasm, hypotension, sinus 
bradycardia, AV block, fatigue, 
depression, sexual disturbances.
PVC, VT, LQTS Severe sinus bradycardia and sinus node disease (unless a pacemaker
is present); AV conduction disturbances (unless a pacemaker is
present); acute phase of myocardial infarction (avoid if bradycardia,
hypotension, LV failure); decompensated HF; Prinzmetal’s angina.
Disopyramide (IA) 250–750 Negative inotrope, QRS 
prolongation, AV block, 
pro-arrhythmia (atrial  
monomorphic VT, occasional TdP), 
anticholinergic effects.
VT, PVC Severe sinus node disease (unless a pacemaker is present); severe
AV conduction disturbances (unless a pacemaker is present); severe
intraventricular conduction disturbances; previous myocardial 
infarction; CAD; HF; reduced LVEF; hypotension.
Flecainide (IC) 200–400 Negative inotrope, QRS widening, 
AV block, sinus bradycardia, 
pro-arrhythmia (atrial  
monomorphic VT, occasional TdP), 
increased incidence of death after 
myocardial infarction.
PVC, VT Sinus node dysfunction (unless a pacemaker is present); 
(without the concomitant use of AV-blocking agents); severe AV
conduction disturbances (unless a pacemaker is present); severe
intraventricular conduction disturbances; previous myocardial infarction; 
CAD; HF; reduced LVEF; haemodynamically  valvular heart
disease; Brugada syndrome; inherited LQTS (other than LQTS3);
concomitant treatments associated with QT-interval prolongation.
Mexiletine (IB) 450–900 Tremor, dysarthria, dizziness, 
gastrointestinal disturbance, 
hypotension, sinus bradycardia.
VT, LQT3 Sinus node dysfunction (unless a pacemaker is present); severe AV
conduction disturbances (unless a pacemaker is present); severe HF;
reduced LVEF; inherited LQTS (other than LQTS3); concomitant
treatments associated with QT-interval prolongation.
Procainamide (IA) 1000–4000 Rash, myalgia, vasculitis, 
hypotension, lupus, agranulocytosis, 
bradycardia, QT prolongation, TdP.
VT Severe sinus node disease (unless a pacemaker is present); severe
AV conduction disturbances (unless a pacemaker is present); severe
intraventricular conduction disturbances; previous myocardial 
infarction; CAD; HF; reduced LVEF; hypotension; reduced LVEF, 
Brugada syndrome.
Propafenone (IC) 450–900 Negative inotrope, gastrointestinal 
disturbance, QRS prolongation, 
AV block, sinus bradycardia, 
pro-arrhythmia (atrial  
monomorphic VT, occasional TdP).
PVC, VT Severe sinus bradycardia and sinus node dysfunction (unless a
pacemaker is present);  (without the concomitant use of
AV-blocking agents); severe AV-conduction disturbances (unless
a pacemaker is present); severe intraventricular conduction 
disturbances; previous myocardial infarction; CAD; HF; reduced 
LVEF; haemodynamically  valvular heart disease; Brugada
syndrome; inherited LQTS (other than LQTS3); concomitant
treatments associated with QT interval prolongation.
Quinidine 600–1600 Nausea, diarrhoea, auditory and 
visual disturbance, confusion, 
hypotension, thrombocytopenia, 
haemolytic anaemia, anaphylaxis, 
QRS and QT prolongation, TdP.
VT, VF, SQTS, 
Brugada 
syndrome
Severe sinus node disease (unless a pacemaker is present); severe
AV conduction disturbances (unless a pacemaker is present); severe
intraventricular conduction disturbances; previous myocardial infarction; 
CAD; HF; reduced LVEF; hypotension; inherited Long QT Syndrome; 
concomitant treatments associated with QT interval prolongation.
Ranolazine (IB) 750 –2000 Dizziness, nausea, constipation, 
hypotension, gastrointestinal 
disturbance, headache, rash, sinus 
bradycardia, QT prolongation.
LQTS3b Severe sinus bradycardia and sinus node disease; severe HF; 
inherited Long QT Syndrome (other than LQTS3); concomitant
treatments associated with QT interval prolongation.
Sotalol (III) 160–320 As for other beta-blockers and 
TdP.
VT, (ARVC)c Severe sinus bradycardia and sinus node disease (unless a pacemaker
is present); AV conduction disturbances (unless a pacemaker
is present); severe HF; Prinzmetal’s angina; inherited LQTS; 
concomitant treatments associated with QT interval prolongation.
Verapamil (IV) 120–480 Negative inotrope (especially 
in patients with reduced LVEF), 
rash, gastrointestinal disturbance, 




Severe sinus bradycardia and sinus node disease (unless a pacemaker
is present); severe AV conduction disturbances (unless a pacemaker
is present); acute phase of myocardial infarction (avoid if bradycardia,
hypotension, left ventricular failure); HF;  reduced LVEF;
atrial  or  associated with accessory conducting
pathways (e.g. WPW syndrome).
AF ¼ atrial fibrillation; ARVC ¼ arrhythmogenic right ventricular cardiomyopathy; AV ¼ atrio-ventricular; CAD ¼ coronary artery disease; HF ¼ heart failure; LQTS3 ¼ long QT
syndrome type 3; LQTS ¼ long QT syndrome; LV ¼ left ventricle/ventricular; LVEF ¼ left ventricular ejection fraction; PVC ¼ premature ventricular complex; SQTS ¼ short QT
syndrome; TdP ¼ Torsade de Pointes; VF ¼ ventricular fibrillation; VT ¼ ventricular tachycardia; WPW ¼Wolff–Parkinson–White.
aAdult drug doses are quoted in this table.
bRanolazine is only approved for the treatment of chronic stable angina. Note that other doses may apply in special conditions.
cSotalol has been indicated for ARVC but its use has been questioned.
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A meta-analysis including 8522 patients post–myocardial infarc-
tion or with systolic HF, randomized to amiodarone or placebo/con-
trol, showed that for every 1000 patients treated with amiodarone,
5 all-cause deaths, 24 cardiovascular deaths and 26 sudden deaths
were averted.133 The 1.5% absolute risk reduction of all-cause mor-
tality did not reach statistical significance.
Chronic administration of amiodarone is associated with complex
drug interactions and a host of extracardiac side effects involving the
thyroid, skin and occasionally the lung and liver. Regular monitoring
of lung, liver and thyroid function is needed. As a general rule, the
longer the therapy and the higher the dose of amiodarone, the
greater the likelihood that adverse side effects will require discon-
tinuation of the drug. Compared with placebo, 10% of patients ran-
domized to amiodarone discontinued therapy.133
4.2.2.3 Sotalol/d-sotalol
Racemic sotalol, a rapid delayed rectifier potassium current inhibi-
tor with beta-blocker properties, is effective in suppressing VA.
Sotalol can be used safely in patients with CAD134,135 unless they
have HF. For example, in a study in 146 patients with sustained VAs
and ICD, sotalol significantly reduced the incidence of recurrences
of sustained ventricular tachyarrhythmias in comparison with no anti-
arrhythmic drug treatment, but it did not improve survival.136
Also, a study of d-sotalol, a pure rapid delayed rectifier potassium
current inhibitor, in 3121 patients with LV dysfunction after myo-
cardial infarction was stopped prematurely because of an increased
mortality rate in the d-sotalol-treated group [RR 1.65 (95% CI 1.15,
2.36), P ¼ 0.006], probably because of ventricular pro-arrhythmias,
although very few cases of TdP were documented.137 Thus sotalol
should not be used in such patients unless an ICD has been im-
planted. The use of anti-arrhythmic doses of sotalol requires careful
monitoring using ECG, especially in patients with a low body mass
index or impaired renal function.
4.2.2.4 Combination therapy
There is a paucity of data to guide combination therapy with anti-
arrhythmic drugs, and such combinations should be reserved for pa-
tients in whom other anti-arrhythmic treatments (including
single-agent anti-arrhythmic drug therapy with different agents,
amiodarone therapy and catheter ablation) have been tried without
satisfactory suppression of arrhythmia episodes. In patients with fre-
quent VT, combinations of sodium channel blockers and potassium
channel blockers (e.g. mexiletine and sotalol, or amiodarone and fle-
cainide/propafenone) have been used, usually in patients with fre-
quent VT recurrences who have a defibrillator. Beta-blocker
therapy in combination with amiodarone reduces the number of
ICD shocks; however, side effects may result in drug discontinuation
in a significant number of patients.138 Ranolazine has been combined
with other anti-arrhythmic agents to suppress VT in otherwise
drug-refractory cases.139 Careful monitoring of the ECG and cardiac
function is needed to detect deterioration of LV function and/or
signs of pro-arrhythmia in such patients.
4.2.3 Patients with a cardioverter defibrillator
Many patients fitted with a cardioverter defibrillator are treated
with beta-blockers to minimize both appropriate and inappropriate
ICD interventions. Patients with recurrent cardioverter defibrillator
shocks may benefit by shifting to sotalol to suppress atrial arrhyth-
mia as well as VA.140 However, sotalol should be avoided in patients
with severely depressed LV function. Because many such patients
also have poor renal function, the more effective combination of
amiodarone and beta-blockers may be preferred to sotalol.138
Anti-arrhythmic drug therapy has never been clearly shown to re-
duce sudden arrhythmic death in patients who have already suffered
a life-threatening VA. However, in both post-myocardial infarction
patients and in patients with HF, amiodarone reduces the occur-
rence of such arrhythmias,123,124,133 and it has been assumed that
the drug does offer some protection against serious VA in those
that have already suffered such events. However, reduction of ar-
rhythmic death does not seem to be associated with a reduction
in total mortality, and adverse events associated with amiodarone
further reduce treatment benefit. Nonetheless, in patients fitted
with an ICD, amiodarone, especially in conjunction with beta-
blockers, significantly reduces ICD interventions.138
In patients with an ICD who have paroxysmal or chronic atrial fib-
rillation (AF) with rapid rates and inappropriate cardioverter defib-
rillator shocks, control of the rapid ventricular response to atrial
tachyarrhythmia is essential, and combination therapy with a beta-
blocker and/or a non-dihydropyridine calcium channel blocker can
be used with care. If ineffective, amiodarone may be helpful. Abla-
tion of the AV node may be required if pharmacological therapy
or AF ablation in selected cases is not effective.
4.2.4 Electrolytes
Administration of potassium to restore normal blood levels can fa-
vourably influence the substrate involved in VA. Magnesium admin-
istration can specifically help to suppress TdP arrhythmias.
Electrolyte disturbances are common in patients with HF,
particularly those using high-doses of potassium-sparing diuretics.
Recently a database study including 38 689 patients with acute myo-
cardial infarction showed the lowest risk of VF, cardiac arrest or
death with potassium concentrations of 3.5–4.5 mmol/L.141
4.2.5 Other drug therapy
Adverse remodelling occurs in the ventricle following myocardial in-
farction or in association with non-ischaemic cardiomyopathy. These
structural changes as well as associated ion-channel alterations can
exacerbate the potential for VA. Several drugs, such as angiotensin-
converting enzyme (ACE) inhibitors, angiotensin II receptor blockers
(ARBs) and mineralocorticoid receptor antagonists (MRAs), improve
reverse remodelling and reduce rates of SCD.142,143 Also, anticoagu-
lants and/or antiplatelets may be helpful for reducing the frequency
of coronary thrombotic occlusions in high-risk patients.144 Further-
more, findings indicate that statins may reduce the occurrence of
life-threatening VAs in high-risk patients.145
4.3 Device therapy
4.3.1 Implantable cardioverter defibrillator
Implantable defibrillators have been used in patients for .30 years.
The original ICD was implanted surgically and connected to leads
fixed to the ventricles via a thoracotomy. This is still occasionally ne-
cessary, but the majority of devices use transvenous leads inserted
predominantly into the right heart for both pacing (single or dual
chamber and univentricular or biventricular) and for defibrillation
via an intracavitary right heart coil(s) and/or the can of the implanted
defibrillator. Most clinical trials supporting the use of ICD therapy
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have been conducted with transvenous ICD therapy. The first pa-
tients to receive defibrillators were survivors of VF or aborted car-
diac arrest. Later trials demonstrated a benefit of defibrillator
therapy in patients at risk of sudden death. ICD therapy prevents
sudden death and prolongs life in patients at high risk of sudden ar-
rhythmic death, provided that the patient does not suffer from other
conditions that limit life expectancy to ,1–2 years.146 Long-term
studies have demonstrated the efficacy of ICDs147 and cardiac re-
synchronization therapy defibrillators (CRT-Ds)148 over a mean
follow-up of 8 and 7 years, respectively.
On the other hand, defibrillators may cause complications, includ-
ing inappropriate shocks, which are especially frequent in children.149
A recent study of .3000 patients with an ICD or CRT-D found a
12-year cumulative incidence of adverse events of 20% (95% CI 18,
22) for inappropriate shock, 6% (95% CI 5, 8) for device-related infec-
tion and 17% (95% CI 14, 21) for lead failure.150
Despite the indications for ICD therapy in post-myocardial infarc-
tion patients with reduced ejection fraction, which is strongly sup-
ported by evidence-based data, a clear gap exists between
guidelines and clinical practices in several countries. A limiting factor
in the use of an ICD is its high upfront costs.
4.3.1.1 Secondary prevention of sudden cardiac death an ventricular
tachycardia
ICD for the secondary prevention of sudden cardiac
death and ventricular tachycardia
Recommendations Classa Levelb Ref.c
ICD implantation is recommended in
patients with documented VF or
haemodynamically not tolerated VT in
the absence of reversible causes or
within 48 h after myocardial infarction
who are receiving chronic optimal
medical therapy and have a reasonable
expectation of survival with a good




ICD implantation should be considered
in patients with recurrent sustained VT
(not within 48 h after myocardial
infarction) who are receiving chronic
optimal medical therapy, have a normal
LVEF and have a reasonable expectation






In patients with VF/VT and an indication
for ICD, amiodarone may be considered
when an ICD is not available,
contraindicated for concurrent medical




ICD ¼ implantable cardioverter defibrillator; LVEF ¼ left ventricular
ejection fraction; SCD ¼ sudden cardiac death; VF ¼ ventricular fibrillation;




Three trials [Antiarrhythmic drugs Versus Implantable Defibrilla-
tor (AVID),153 Canadian Implantable Defibrillator Study
(CIDS)151 and Cardiac Arrest Study Hamburg (CASH)152] have
been conducted in patients who had suffered a cardiac arrest or
life-threatening VA (haemodynamically unstable VA or VT with
syncope) in which treatment with an ICD was compared with
anti-arrhythmic drug therapy, predominantly amiodarone. The re-
sults of all three trials were consistent, although only one showed
a statistically significant reduction in the rate of total mortality; the
ICD reduced rates of arrhythmic mortality in both the AVID and
CASH trials. A meta-analysis of the three trials demonstrated
that ICD therapy was associated with a 50% (95% CI 0.37, 0.67;
P ¼ 0.0001) reduction in arrhythmic mortality and a 28% (95%
CI 0.60, 0.87; P ¼ 0.006) reduction in total mortality (Web
Table 5).154 An analysis of the AVID trial results clearly demon-
strated that the benefit was confined primarily to patients with
an LVEF between 20 and 34%.153 The therapy is moderately
cost effective and guidelines for use of ICDs for secondary pre-
vention have been generally accepted for some years. No recent
trial evidence suggests that previous recommendations should be
substantially changed.
4.3.2 Subcutaneous implantable cardioverter
defibrillator
Subcutaneous implantable cardioverter defibrillator
Recommendations Classa Levelb Ref.c
Subcutaneous defibrillators should
be considered as an alternative to
transvenous defibrillators in patients
with an indication for an ICD when
pacing therapy for bradycardia
support, cardiac resynchronization





The subcutaneous ICD may be
considered as a useful alternative
to the transvenous ICD system when
venous access is difficult, after the
removal of a transvenous ICD for
infections or in young patients










Problems with access to the heart via the vascular system and
recurring problems with transvenous leads prompted the de-
velopment of a subcutaneous defibrillator with an electrode sys-
tem that is placed entirely subcutaneously, outside the thoracic
cavity. The system consists of three electrodes: the ICD can, a
distal electrode on the defibrillator lead and a proximal electrode
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located approximately 8 cm from the tip of the lead. Between
the tip and proximal electrode is a coil for defibrillation against
the defibrillator can. The electrode is positioned so that the
distal part of the lead is placed at the left parasternal edge
and the device is placed over the fifth intercostal space between
the left anterior and mid-axillary line. The precise electrode con-
figuration used for sensing can be configured by programming.
The device is capable of defibrillating most patients with an out-
put of 80 J.159
The available data suggest that subcutaneous defibrillators are
effective in preventing sudden death. Data on the long-term toler-
ability and safety of the treatment are currently lacking but are
being collected. In one of the largest trials, 330 patients, 304 of
whom were successfully implanted, underwent appropriate defib-
rillation testing and were successfully followed for a mean of 11
months.157 There were no lead failures or complications asso-
ciated with lead placement. All induced episodes were successful-
ly terminated and 118 of the 119 spontaneous ventricular
tachyarrhythmias occurring in 21 subjects were terminated by
the device and one episode subsided spontaneously during device
charging. Thirteen per cent of patients received an inappropriate
shock due largely to supraventricular tachycardia or to T-wave
oversensing, which has also been described in younger patient
groups.160 A recently reported ‘real-world’ registry of 472 pa-
tients recorded 317 spontaneous episodes in 85 patients during
a mean follow-up of 18 months. Of these, 169 (53%) received
therapy for VT or VF and only one patient died of recurrent VF
and severe bradycardia.161 Trials of the subcutaneous ICD are
summarized in Web Table 6.157 – 165
The subcutaneous device is not suitable for patients who re-
quire bradycardia pacing unless this need is confined to the
period immediately following delivery of a shock (transcutane-
ous pacing can be delivered by the device for 30 seconds after
the shock). Patients who need cardiac resynchronization ther-
apy (CRT) are also unsuitable for treatment with the subcuta-
neous ICD. Similarly, the subcutaneous ICD is not
appropriate for patients who suffer from tachyarrhythmia that
can be easily terminated by antitachycardia pacing. The device
may be useful when venous access is difficult, in young patients
facing a lifetime of device therapy and in patients at particular
risk of bacteraemia (e.g. with a current or recent transvenous
ICD system). Although the general category of primary preven-
tion of SCD should be suitable for subcutaneous ICD therapy,
no long-term large-scale trials have been conducted in this
population and the long-term performance of the device is
not yet fully understood. For example, individual studies have
presented a higher than average rate of inappropriate shocks
and complications requiring reintervention:160 whether these
results belong to a learning curve or to a higher risk of inappro-
priate shocks in selected populations remains to be determined.
A recent meta-analysis of 852 patients demonstrated that there
were no electrode failures, devices were replaced because of a
need for RV pacing in only 3 patients and inappropriate pacing
was ,5% in the latest quartile of enrolment.166 Prospective
randomized trials comparing the efficacy and complications of
subcutaneous ICD with conventional ICD are currently
ongoing.158
4.3.3 Wearable cardioverter defibrillator
Wearable cardioverter defibrillator
Recommendation Classa Levelb Ref.c
The WCD may be considered
for adult patients with poor LV systolic
function who are at risk of sudden
arrhythmic death for a limited period,
but are not candidates for an
implantable defibrillator (e.g. bridge to
transplant, bridge to transvenous
implant, peripartum cardiomyopathy,
active myocarditis and arrhythmias in









An external defibrillator (plus leads and electrode pads) attached to a
wearable vest has been shown to successfully identify and interrupt
VT and VF.168 No prospective RCTs evaluating this device have
been reported, but there are many case reports, case series and regis-
tries (held by the manufacturer or independently) that have reported
the successful use of the wearable cardioverter defibrillator (WCD) in
a relatively small proportion of patients at risk of potentially fatal VAs.
For example, Chung et al.169 found that 80 sustained VT or VF events
occurred in 59 of 3569 (1.7%) patients wearing the WCD. The first
shock was successful in 76 of 76 (100%) patients with unconscious
VT or VF and 79 of 80 (99%) with any VT or VF. More recently, Ep-
stein et al.170 reported that 133 of 8453 (1.6%) patients received 309
appropriate shocks and 91% were resuscitated from a VA. Thus this
device can save lives in vulnerable patients, but its efficacy has not
been validated. In patients with transient impaired LVEF, the WCD
may be used until LV function has recovered sufficiently, following in-
sults such as myocardial infarction, post-partum cardiomyopathy,
myocarditis or interventions such as revascularization associated
with transient LV dysfunction.171 Similarly, patients with a history or
at risk of life-threatening VAs or who are scheduled for cardiac trans-
plantation may be temporarily protected with the WCD.172
4.3.4 Public access defibrillation
Public access defibrillation
Recommendations Classa Levelb Ref.c
It is recommended that public access
defibrillation be established at sites
where cardiac arrest is relatively
common and suitable storage is available
(e.g. schools, sports stadiums, large
stations, casinos, etc.) or at sites where
no other access to defibrillation is
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It may be considered to teach basic life










Most cardiac arrests occur out of hospital.175 Prompt de-
fibrillation is much more likely than deferred defibrillation to re-
store an organized rhythm and stable cardiac output. Public
access defibrillation linked with cardiopulmonary resuscitation
has been shown to be more effective than cardiopulmonary resus-
citation alone,173 and public access defibrillation is now well estab-
lished, especially in locations where crowds and stress are
common, and particularly where trained volunteers can be readily
available (e.g. casinos, airports, sports stadiums), even when train-
ing does not extend to cardiopulmonary resuscitation.174 Out-of-
hospital cardiac arrests occur most commonly (70%) in the
home, even in younger patients,176 but these are infrequently wit-
nessed and therefore cannot be prevented by home-based
defibrillators.177
Implementation of automatic external defibrillator programmes
reduces mortality in public places where cardiac arrests are usually
witnessed.178 Basic and advanced life support activities have led to
the generation of protocols to guide responders. These documents,
published by the European Resuscitation Council and the Inter-
national Consensus on Cardiopulmonary Resuscitation and Emer-
gency Cardiovascular Care,179 cover the broad expanse of clinical
circumstances and considerations of mechanisms. They provide
clear management information, and the reader is referred to the
source documents for details. As management guidelines, these
documents are classified as level of evidence C, but they are derived
from a combination of varied studies and opinions that range from
level of evidence A to B or C.
4.4 Acute treatment of sustained
ventricular arrhythmias
Cardioversion or defibrillation and acute treatment of
sustained ventricular arrhythmias
Recommendations Classa Levelb Ref.c
Direct current cardioversion is
recommended for patients presenting
with sustained VT and haemodynamic
instability.
I C 180
In patients presenting with sustained
haemodynamically tolerated VT in
the absence of structural heart disease
(e.g. idiopathic RVOT), i.v. flecainide
or a conventional beta-blocker,
verapamil or amiodarone may be
considered.
IIb C
i.v. ¼ intravenous; RVOT ¼ right ventricular outflow tract;




The most common electrical mechanisms for cardiac arrest are
VF or VT, bradyarrhythmias, asystole and electromechanical dis-
sociation (pulseless electrical activity). Overall, survival is better
for patients presenting with ventricular tachyarrhythmias com-
pared with asystole. In 2010, International Liaison Committee
on Resuscitation (ILCOR) member councils updated the conclu-
sions and recommendations derived from an international con-
sensus conference held in Dallas, Texas, in 2010. In the case
of cardiac arrest, the universal algorithm should be applied
(Figure 2).
Whether cardiopulmonary resuscitation before defibrillation
should be performed is still debatable. In cases of out-of-hospital
cardiac arrest, cardiopulmonary resuscitation with chest compres-
sion should be performed immediately until defibrillation is
possible. In cases of in-hospital cardiac arrest, immediate defibrilla-
tion should be attempted because, in this case, the likelihood that
cardiac arrest is due to sustained ventricular tachyarrhythmia is
greater. It is advised to start defibrillation at the maximum output.
Semi-automated defibrillators provide an excellent technology to
spread defibrillation capability within hospitals. In patients with an
ICD, the defibrillator patches should be placed on the chest wall
ideally at least 8 cm from the generator position. Intravenous amio-
darone may facilitate defibrillation and/or prevent VT or VF recur-
rences in an acute situation. Advanced life-support activities other
than those related to electrical measures for termination of ven-
tricular tachyarrhythmias are summarized in the 2010 ILCOR
document.181
Patients presenting with sustained VT should be treated ac-
cording to symptoms and tolerance of the arrhythmia. Patients pre-
senting with monomorphic VT and haemodynamic instability
(syncopal VT) should undergo direct cardioversion. In patients
who are hypotensive and yet conscious, immediate sedation should
be given before undergoing cardioversion. In patients with wide
complex tachycardia who are haemodynamically stable, electrical
cardioversion should be the first-line approach. Intravenous procai-
namide or flecainide may be considered for those who do not pre-
sent with severe HF or acute myocardial infarction. Intravenous
amiodarone may be considered in patients with HF or suspected is-
chaemia. Intravenous lidocaine is only moderately effective in
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patients presenting with monomorphic VT. As a general rule, a
12-lead ECG should be recorded for all patients with sustained
VT who present in a haemodynamically stable condition.
Intravenous verapamil or beta-blockers should be given in pa-
tients presenting with LV fascicular VT [right bundle branch block
(RBBB) morphology and left axis deviation].182
Unresponsive
Not breathing or only occasional gasps
Start CPR
Minimize interruptions in chest compressions















• Consider advanced airway
• Continuous chest compressions
  after advanced airway in place
• Consider capnography
• Obtain IV/IO access
• Consider vasopressors and
  antiarrhythmics










CPR = cardiopulmonary resuscitation; ECG = electrocardiogram; EMS = emergency medical services; i.v. = intravenous; i.o. = intraosseous; PEA = pulseless electrical activity; 
VF = ventricular  VT = ventricular tachycardia.
Reproduced with permission, from the ILCOR recommendations.181
Figure 2 Universal cardiac arrest algorithm
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4.5 Interventional therapy
4.5.1 Catheter ablation
Catheter ablation for the treatment of sustained
monomorphic ventricular tachycardia
Recommendations Classa Levelb Ref.c
Urgent catheter ablation is
recommended in patients with
scar-related heart disease presenting
with incessant VT or electrical storm.
I B 183
Catheter ablation is recommended in
patients with ischaemic heart disease





Catheter ablation should be considered
after a first episode of sustained VT in









4.5.1.1 Patients with scar-related heart disease
Catheter ablation has evolved into an important treatment option
for patients with scar-related heart disease presenting with VT or
VF. Data from two prospective randomized multicentre trials on
outcome in patients with ischaemic heart disease demonstrated
that catheter ablation for VT decreases the likelihood of subsequent
ICD shocks and prevents recurrent episodes of VT.187,188 More-
over, catheter ablation is often used to control incessant VT or
electrical storms (i.e. recurrent VT/VF with frequent appropriate
ICD firing) and to reduce or prevent recurrent episodes of
sustained VT.183,184,187,188
While ICDs can effectively terminate VT in patients with ischae-
mic or non-ischaemic cardiomyopathy, they may not prevent ar-
rhythmia recurrence. Several studies have shown that ICD shocks
are associated with higher mortality and impaired quality of
life.189,190 Beta-blocker therapy in combination with amiodarone re-
duces the number of ICD shocks; however, side effects may result in
drug discontinuation.156 Generally, scar tissue is the underlying sub-
strate in patients presenting with VT.191 Catheter ablation targets
the isthmus of slow conduction (critical isthmus) within the VT re-
entry circuit. The re-entry circuit may span several centimetres and
involve the endo-, mid-, or epicardium within a complex three-
dimensional structure.192,193 Scar-related VT is typically mono-
morphic and multiple VT morphologies may be induced in the
same patient. The QRS morphology is determined by the exit site
where the re-entry wavefronts propagate away from the scar to de-
polarize the ventricular myocardium. Hence, a 12-lead surface ECG
recording of the clinical VT can aid in the mapping and ablation pro-
cedure. In patients with non-ischaemic cardiomyopathy, the QRS
morphology can identify those patients in whom an epicardial abla-
tion is likely to be required.194 – 197 Furthermore, pre-procedural
CMR imaging may facilitate non-invasive identification of the
arrhythmic substrate in patients with a history of myocardial infarc-
tion198 or in patients presenting with epicardial VT.199
Polymorphic VT is defined as a continually changing QRS morph-
ology often associated with acute myocardial ischaemia, acquired
or inheritable channelopathies or ventricular hypertrophy. In
some of these patients who are refractory to drug treatment,
Purkinje-fibre triggered polymorphic VT may be amenable to cath-
eter ablation.200,201
Non-invasive imaging of cardiac structure, best done by magnetic
resonance imaging, can be used to plan and guide ablation
procedures for VT.198 Mapping and ablation may be performed
during ongoing VT (activation mapping). A three-dimensional
electro-anatomical mapping system may aid in localization of abnor-
mal ventricular tissue and permits catheter ablation in sinus rhythm
(substrate ablation) without induction of VT that may prove
haemodynamically unstable. A non-contact mapping system may
be utilized in patients with haemodynamically unstable VT. Several
techniques, including point-by-point ablation at the exit site of the
re-entry circuit (scar dechanneling), deployment of linear lesion
sets or ablation of local abnormal ventricular activity to scar hom-
ogenization, can be used.202 – 205 Epicardial mapping and ablation are
more often required in patients with dilated cardiomyopathy
(DCM)206 or ARVC207 undergoing VT ablation. Potential complica-
tions of epicardial puncture and ablation are damage to the coron-
ary vasculature or inadvertent puncture of surrounding organs, left
phrenic nerve palsy or significant bleeding resulting in pericardial
tamponade.
Patients with VT related to post-myocardial scar tend to have a
better outcome following catheter ablation than patients with VT
due to non-ischaemic cardiomyopathy.208 Five prospective multi-
centre studies have evaluated the role of catheter ablation in the
treatment of sustained VT.184 – 188 Approximately 50% of patients
enrolled in these studies had favourable outcomes (i.e. no further
clinical VT recurrences during the trial follow-up period), with cath-
eter ablation being more effective than anti-arrhythmic drug
therapy.
In an individual, the success rate of catheter ablation for VT is de-
termined by the amount of infarct-related scar burden, represented
as low-voltage areas on electro-anatomic mapping systems,209 while
dedicated units for the treatment of patients undergoing catheter
ablation of VT may positively affect outcome.210 Furthermore, the
experience of the team and centre will influence outcomes, and
all published data stem from experienced centres.
Possible complications related to catheter ablation of VT in
patients with heart disease include stroke, valve damage, cardiac
tamponade or AV block. Procedure-related mortality ranges from
0 to 3% and most commonly is due to uncontrollable VT when
the procedure fails.183– 185,187,211 While catheter ablation is an ac-
cepted treatment option for a wide range of VT substrates, there
is a lack of evidence from prospective, randomized trials that cath-
eter ablation reduces mortality.
4.5.1.2 Patients without overt structural heart disease
VT in patients without overt structural heart disease most com-
monly emanates from the RV or LV outflow tracts (OTs). The
12-lead surface ECG demonstrates a left bundle branch block
(LBBB) inferior axis morphology if VT arises from the RV OT or a
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left or RBBB inferior axis morphology if arising from the LVOT. Trig-
gered activity is the most common underlying pathophysiological
mechanism and targeting the earliest site of activation during cath-
eter ablation results in a high rate of procedural success, while the
rate of SCD in this patient population is generally low. Infrequently
patients may present with idiopathic left VT involving the distal Pur-
kinje network. Catheter ablation is curative in most affected patients
and procedural complications are rare.
4.5.2 Anti-arrhythmic surgery
Surgical ablation of ventricular tachycardia
Recommendations Classa Levelb Ref.c
Surgical ablation guided by
preoperative and intraoperative
electrophysiological mapping
performed at an experienced centre is
recommended in patients with VT
refractory to anti-arrhythmic drug






Surgical ablation at the time of cardiac
surgery (bypass or valve surgery) may be
considered in patients with clinically









In the era of transvascular catheter ablation for the treatment of
VA, the requirement for surgical ablation has become a rarity.
Anatomically guided LV aneurysmectomy was first described
.50 years ago. Large aneurysms may be accompanied by VAs,
and map-guided resection of the aneurysm not only improves
LV function, but also eliminates VAs. Sub-endocardial resection
for the management of VAs was first described by Josephson
et al.218 This technique was associated with significant periproce-
dural morbidity and mortality (10%) and was therefore performed
only in very specialized surgical centres.212 – 214,216 – 219 If patients
survived the initial postoperative phase, their long-term outcome
was excellent. More recent studies have demonstrated that peri-
surgical EPS after subtotal endocardiectomy and cryoablation has
a VT recurrence rate of approximately 10–20%, predominantly
within the first 90 days.213 Therefore early ICD implantation is re-
commended in patients with VT inducibility post-
surgery.213,215,220,221 Most of the surgical techniques have become
the basis for catheter ablation techniques, including a recent tech-
nique of substrate encircling.222
In summary, surgical ablation should be performed in experi-
enced centres with preoperative and intraoperative electrophysio-
logical mapping. Patients with VT refractory to anti-arrhythmic drug
therapy and/or after failed catheter ablation in a highly experienced
ablation centre may be considered for arrhythmia surgery, particu-
larly if an LV aneurysm secondary to myocardial infarction is present
and revascularization is required.216 –219
4.6 Psychosocial impact of implantable
cardioverter defibrillator treatment
Psychosocial management after cardioverter
defibrillator implantation
Recommendations Classa Levelb Ref.c
Assessment of psychological status and
treatment of distress are recommended





Discussion of quality-of-life issues is
recommended before ICD implantation









Controlled defibrillator trials demonstrated preserved or improved
quality of life in recipients of a defibrillator compared with that
in controls.223,224 Nonetheless, anxiety (8–63%) and depression
(5–41%) are common in defibrillator patients228 and are most pro-
nounced in patients experiencing inappropriate and/or frequent
shocks (e.g. more than five shocks).223 – 225,229 These problems fre-
quently go unrecognized and untreated in clinical practice.230,231
While immediate management should isolate the cause of the de-
vice firing, treating psychological distress is an important adjunct.229
The levels of distress vary, but patients can present with more se-
vere forms, such as post-traumatic stress disorder,232,233 which is
associated with prior shock therapy and pre-implantation dis-
tress.234 ICD patients with recent tachyarrhythmia can also display
anticipatory shock anxiety.235 Patients with high levels of pre-
implantation ICD-related concerns are more prone to develop
post-implant problems, and depression may be particularly malig-
nant in this population.236,237 Thus, adequate assessment and treat-
ment of psychological distress should be integral to clinical
management. All ICD patients, in particular those exhibiting distress,
require support on how to live with their device in order to improve
outcomes.238
ICD implantation can affect many areas of life, including the ability
to drive,239,240 intimate relations,241,242 sleep quality,226 body image
concerns (particularly in younger women)227 and participation in
organized sports (particularly in children and adolescents).243 Sup-
port from healthcare professionals mitigates these concerns, but
further research is required to optimize the progression of care
and develop evidence-based interventions.233
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5. Management of ventricular
arrhythmias and prevention of
sudden cardiac death in coronary
artery disease
5.1 Acute coronary syndromes
5.1.1 Ventricular arrhythmias associated with acute
coronary syndromes
Despite the clear reduction in rates of SCD through better revas-
cularization and prevention of CAD through smoking cessation
and statin treatment, acute coronary syndrome (ACS) and late ar-
rhythmias after acute myocardial infarction remain a common
cause of SCD (see section 3.1). A significant number of SCD
events occur in the pre-hospital phase of ACS, underlining the crit-
ical role of screening programmes to identify patients at risk. The
incidence of VA in the hospital phase of ACS has declined in re-
cent decades, mainly due to early and intense revascularization
strategies and the early introduction of adequate pharmacological
treatment. However, up to 6% of patients with ACS develop VT
or VF within the first 48 hours after the onset of symptoms,
most often before or during reperfusion. In addition to quick
and complete coronary revascularization, non-pharmacological in-
terventions (cardioversion, defibrillation, pacing and catheter abla-
tion) as well as pharmacological treatment (non–anti-arrhythmic
and anti-arrhythmic drugs) may be necessary to control VAs in
this situation.
Diagnostic workup in patients with sustained VAs in the context
of an ACS is represented in Figure 3.
5.1.2 Prevention and management of sudden cardiac
death associated with acute coronary syndromes:
pre-hospital phase
Prevention of sudden cardiac death associated with
acute coronary syndromes: pre-hospital phase
Recommendations Classa Levelb Ref.c
In patients with chest pain, it is
recommended to reduce delays both
from symptom onset to first medical
contact and from first medical contact to
reperfusion.
I A 244
It is recommended that ambulance
teams are trained and equipped to
identify ACS (with the use of ECG
recorders and telemetry as necessary)
and treat cardiac arrest by performing
basic life support and defibrillation.
I B 178
It is recommended that basic and
advanced life support are performed
following the algorithm protocols
defined by the European




It is recommended that
post-resuscitation care is performed
in high-volume expert centres capable
of offering multidisciplinary intensive
care treatment, including primary
coronary interventions,
electrophysiology, cardiac assist





The creation of regional networks for the
treatment of cardiac arrest should be
considered to improve outcomes.
IIa B 245




Although in-hospital mortality from ST-segment elevation
myocardial infarction (STEMI) has been reduced substantially
through the use of modern reperfusion therapy, the overall short-
term mortality is still of concern. Infarction presenting as sudden
death during the first few hours after the onset of symptoms is
currently a major cause of mortality in acute myocardial
infarction.
5.1.3 Prevention of sudden cardiac death associated with
acute coronary syndromes: in-hospital phase
Prevention and management of sudden cardiac death
associated with acute coronary syndromes: in hospital
phase. Indications for revascularization
Recommendations Classa Levelb Ref.c






recommended in patients with NSTEMI
or unstable angina according to the ESC
NSTEMI guidelines.
I C 13,250
A coronary angiogram followed, if
necessary, by coronary angioplasty
within 2 h of hospital admission is
recommended in patients with high-risk
NSTEMI, which also includes
life-threatening VA.
I C 13,250
Prompt and complete coronary
revascularization is recommended to
treat myocardial ischaemia that may be





Prompt opening of the infarct vessels
is recommended to reverse
new-onset ischaemic AV conduction
disturbances. This is especially true for
AV block due to inferior infarction,
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Direct admission to the catheterization
laboratory is recommended in comatose
survivors of out-of-hospital cardiac
arrest with electrocardiographic criteria





An intensive care unit stop should
be considered in comatose survivors
of out-of-hospital cardiac arrest
without electrocardiographic criteria
for ST-segment elevation on the
post-resuscitation ECG to exclude
non-coronary causes and, in the
absence of an obvious non-coronary
cause, a coronary angiogram should
be considered as soon as possible












Implantation of an LV assist device
or extracorporeal life support
should be considered in
haemodynamically unstable patients
with recurrent VT or VF despite
optimal therapy.
IIa B 254
Cardiac assist support and
revascularization in specialized centres





ACS ¼ acute coronary syndromes; AV ¼ atrio-ventricular;
ECG ¼ electrocardiogram; ESC ¼ European Society of Cardiology;
LV ¼ left ventricular; NSTEMI ¼ non–ST-segment elevation myocardial
infarction; SCD ¼ sudden cardiac death; STEMI ¼ ST-segment elevation
myocardial infarction; VA ¼ ventricular arrhythmia; VF ¼ ventricular fibrillation;




Prevention and management of sudden cardiac death
associated with acute coronary syndromes: in-hospital
phase. Defibrillation/cardioversion/drugs/catheter
ablation






recommended for the treatment of
polymorphic VT.
I C 258
Immediate electrical cardioversion or
defibrillation is recommended in
patients with sustained VT or VF.
I C 180
Urgent coronary angiography followed,
when indicated, by revascularization is
recommended in patients with
recurrent VT or VF when myocardial




Correction of electrolyte imbalances is
recommended in patients with
recurrent VT or VF.
I C 179
Oral treatment with beta-blockers
should be considered during the
hospital stay and continued thereafter







Radiofrequency catheter ablation at a
specialized ablation centre followed by
the implantation of an ICD should be
considered in patients with recurrent
VT, VF or electrical storms despite






stimulation should be considered if VT is
frequently recurrent despite use of
anti-arrhythmic drugs and catheter
ablation is not possible.
IIa C
Intravenous lidocaine may be considered
for the treatment of recurrent sustained
VT or VF not responding to
beta-blockers or amiodarone or in the




anti-arrhythmic drugs (other than




ACS ¼ acute coronary syndromes; ICD ¼ implantable cardioverter defibrillator;





Prevention and management of sudden cardiac death
associated with acute coronary syndromes: in-hospital
phase. Pacing/implantable cardioverter defibrillator
Recommendations Classa Levelb Ref.c
Temporary transvenous pacing is
recommended in patients symptomatic
for sinus bradycardia despite treatment
with positive chronotropic medication.
I C 271
Temporary transvenous pacing is
recommended in patients with
symptomatic high-degree AV block
without stable escape rhythm.
I C 271
Urgent angiography is recommended
in patients symptomatic for high-degree
AV block who have not received
reperfusion.
I C 271
Reprogramming a previously implanted
ICD is recommended for patients with




by University of Liege user
on 20 August 2018
Reprogramming a previously implanted
ICD should be considered to avoid
unnecessary ICD shocks.
IIa C 272
ICD implantation or temporary use of a
WCD may be considered ,40 days after
myocardial infarction in selected patients
(incomplete revascularization,d
pre-existing LVEF dysfunction, occurrence
of arrhythmias .48 h after the onset of




ICD implantation for the primary
prevention of SCD is generally not





ACS ¼ acute coronary syndrome; AV ¼ atrio-ventricular; ICD ¼ implantable
cardioverter defibrillator; LVEF ¼ left ventricular ejection fraction; SCD ¼
sudden cardiac death; VF ¼ ventricular fibrillation; VT ¼ ventricular tachycardia;




dIncomplete revascularization refers to a failure to treat the culprit lesion or the
presence of non-culprit lesions, which cannot be treated.
ESC Guidelines for the treatment of ACS with or without
ST-segment elevation and coronary revascularization have been
published and all information relevant to the diagnosis of ACS,
NSTEMI or STEMI and treatment recommendations are provided
in detail.13,250,271 This section focuses on the specific role of reper-
fusion and/or revascularization for the prevention and treatment of
VT or VF in patients with ACS.
Owing to the implementation of public awareness programmes on
SCD, an increasing number of survivors of out-of-hospital cardiac
arrest are being admitted to hospital. If ST-segment elevation on
pre-resuscitation or early post-resuscitation ECG is present, urgent
angiography and revascularization is recommended as in all patients
with STEMI.251 However, the absence of ST-segment elevation
does not exclude obstructive or even thrombotic coronary ‘culprit’
lesions, which may be present in 25–58% of cases.251,252 Given the
high prevalence of coronary occlusions and potential difficulties in in-
terpreting the ECG in patients after cardiac arrest, a coronary angio-
gram should be considered in survivors of out-of-hospital cardiac
arrest after an emergency department or intensive care unit stop
to exclude the presence of non-cardiac causes of arrest.276
In the setting of ACS and recurrent sustained and/or haemo-
dynamically relevant VT or VF, successful prompt revascularization
is key to further arrhythmia prevention and should be attempted
immediately.13,250,271
5.1.3.1 Ventricular arrhythmias in acute coronary syndromes
Acute ischaemia causes electrical instability, provoking VA in ACS
patients.266 Early use of beta-blockers in the setting of ACS reduces
VT/VF and is therefore recommended.257,269 Correction of hypo-
magnesaemia and hypokalaemia may help in selected patients. Statin
therapy reduces mortality in patients with CAD, mostly through
prevention of recurrent coronary events, and is therefore part of
the recommended routine medication.250,271
5.1.3.2 Use of anti-arrhythmic drugs in acute coronary
syndromes—general considerations
Electrical cardioversion or defibrillation is the intervention of choice
to acutely terminate VAs in ACS patients.1,271 Early (possibly i.v.)
administration of beta-blockers can help prevent recurrent arrhyth-
mias.257,269,271 Anti-arrhythmic drug treatment with amiodarone
should be considered only if episodes of VT or VF are frequent
and can no longer be controlled by successive electrical cardiover-
sion or defibrillation.1,271 Intravenous lidocaine may be considered
for recurrent sustained VT or VF not responding to beta-blockers
or amiodarone or in the case of contraindications to amiodarone.
In patients with recurrent VT or VF triggered by premature ven-
tricular complex (PVC) arising from partially injured Purkinje fibres,
catheter ablation is very effective and should be considered261 –265
(see section 6.3.2).
5.1.3.3 Patients with acute coronary syndromes and no ventricular
arrhythmias
Beta-blocker treatment is recommended to prevent VA.257,271 Prophy-
lactic treatment with anti-arrhythmic drugs has not proven beneficial
and may even be harmful and is not therefore indicated.257,269
5.1.3.4 Premature ventricular complexes
PVCs and non-sustained ventricular tachycardia (NSVT) occur
frequently in patients with ACS, especially during primary percutan-
eous coronary intervention for STEMI (known as reperfusion ar-
rhythmias). They are very rarely of haemodynamic relevance and
do not require specific treatment. Prolonged and frequent ventricu-
lar ectopy can be a sign that further revascularization (e.g. a repeat
angiogram/percutaneous coronary intervention) is needed.250,271
In haemodynamically relevant NSVT, amiodarone (300 mg i.v. bo-
lus) should be considered.1,271
5.1.3.5 Sustained VT and VF
Recurrent sustained VT, especially when polymorphic, or recurrent
VF may be an indicator of incomplete reperfusion or recurrence of
acute ischaemia. Immediate coronary angiography should therefore
be considered.250,271 Recurrent polymorphic VT degenerating into
VF may respond to beta-blockers. In addition, deep sedation may be
helpful to reduce episodes of VT or VF. Amiodarone (150–300 mg
i.v. bolus) should be considered to acutely suppress recurrent
haemodynamically relevant VAs. The use of other anti-arrhythmic
drugs in ACS (e.g. procainamide, propafenone, ajmaline, flecainide)
is not recommended.1,269,271
5.1.3.6 Catheter ablation of recurrent sustained ventricular tachycardia,
recurrent ventricular fibrillation and electrical storm
In patients with recurrent VT or VF despite complete revasculariza-
tion and optimal medical treatment, radiofrequency catheter abla-
tion should be considered. Recurrent VF episodes may be
triggered by PVCs arising from partially injured Purkinje fibres or
ventricular myocardium injured by ischaemia and/or reperfusion.
In almost all cases the substrate can be accessed from the endocar-
dium. Precise catheter mapping and successful ablation of triggers
for VT or VF, or myocardial substrate sustaining VT or VF, is a com-
plex and demanding procedure. Thus early referral of patients pre-
senting with VT or VF storms to specialized ablation centres should
be considered.261 – 265
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5.1.3.7 Extracorporeal support devices
In selected cases with recurrent VT or VF that cannot be managed
with the treatment recommendations given above, implantation of
LV assist devices or extracorporeal life support should be considered
for haemodynamic stabilization. Such interventions may also generate
time windows allowing coronary interventions in cardiogenic shock
due to recurrent VT or VF. Although haemodynamic stabilization
can be achieved with ventricular assist devices, the likelihood of VT
or VF recurrence is high and interventional treatment is difficult.254
5.1.3.8 Bradycardia and heart block
Bradycardia and heart block can occur and are associated with in-
creased hospital mortality. AV block is most often due to proximal oc-
clusion of the right coronary artery or a dominant circumflex artery.
Prompt coronary revascularization most often resolves conduction.253
When bradycardia results in severe haemodynamic compromise (usu-
ally with advanced or complete heart block in the absence of stable
junctional escape rhythm) or when it persists despite coronary revas-
cularization, transient ventricular pacing with a pacing lead placed per-
cutaneously to the right ventricle may be necessary.271 In persistent
bradycardia or heart block, permanent pacing may be necessary and
should be performed according to current pacing guidelines.10
5.1.4 The prognostic role of early ventricular fibrillation
Early VF (i.e. occurring within 48 h) during ACS is associated with an
up to five-fold increase in hospital mortality277 and probably identi-
fies a risk for longer-term mortality. Not all of the later deaths are
sudden, and the decision for defibrillator therapy needs to be based
on the presence of additional risk factors in addition to VF or VT in
the setting of ACS.278,279
5.2 Early after myocardial infarction
5.2.1 Risk stratification for sudden cardiac death
Risk stratification for sudden cardiac death early
(within 10 days) after myocardial infarction
Recommendations Classa Levelb Ref.c
PVS may be considered early after
myocardial infarction in patients with





Non-invasive tests (e.g. microvolt
T-wave alternans, tests for autonomic
dysfunction or SA-ECG) are not
recommended for risk stratification in





LVEF ¼ left ventricular ejection fraction; PVS ¼ programmed ventricular




SCD is an important cause of death after acute myocardial infarc-
tion and is often due to recurrent infarction. Nonetheless, early
defibrillator implantation after an infarction does not improve
prognosis, probably due to competing causes of death.274,275 Op-
timal revascularization and medical therapy (including beta-
blockers, dual antiplatelet therapy and statins) and prevention
and treatment of HF are recommended and are the mainstays of
prevention of sudden death in this patient group. While several
non-invasive risk markers for sudden death have been tested and
abandoned in this cohort, some data support the use of an early
programmed stimulation in acute myocardial infarction survivors
with a reduced LVEF, as those without inducible monomorphic
VT have a low risk of subsequent sudden death.285 Randomized
trials are necessary to conclusively define the role of programmed
stimulation for risk stratification early after acute myocardial
infarction.
5.2.2 Timing of implantable cardioverter defibrillator
placement after myocardial infarction—assessment
of left ventricular dysfunction before and after
discharge
Timing of implantable cardioverter defibrillator
placement after myocardial infarction. Assessment of
left ventricular ejection fraction
Recommendations Classa Levelb Ref.c
Early (before discharge) assessment of
LVEF is recommended in all patients




Re-evaluation of LVEF 6–12 weeks
after myocardial infarction is
recommended to assess the potential










Early (,40 days) ICD implantation or the temporary (,40
days) use of a WCD may be considered in the presence of specific
conditions such as pre-existing LVEF impairment, incomplete re-
vascularization and arrhythmia occurring .48 h after the onset
of ACS. The type of VA must be assessed (monomorphic, poly-
morphic, pleomorphic VT or VF) as well as the VT cycle length
(non-sustained short runs or non-sustained long runs). If pro-
grammed stimulation was performed, inducibility and the type of
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LVEF should be assessed 6–12 weeks after myocardial infarction
in stable patients and in those on optimized HF medication to assess
a potential indication for a primary preventive defibrillator implant-
ation. This evaluation should be structured and offered to all
patients.271,286 –288
5.3 Stable coronary artery disease after
myocardial infarction with preserved
ejection fraction
Modern revascularization and secondary prevention therapy allows
preservation of LVEF in most patients presenting early with an acute
myocardial infarction. Although the risk for SCD in these patients is
substantially lower compared with patients with severely
impaired LVEF, the absolute number of SCD victims with preserved
LVEF is high. Improved SCD risk-detection strategies in the
intermediate-risk population are needed.
5.3.1 Risk stratification
Risk stratification in patients with stable coronary
artery disease after myocardial infarction with
preserved ejection fraction
Recommendations Classa Levelb Ref.c
PVS should be considered in survivors of
a myocardial infarction with preserved









Most studies that have evaluated the usefulness of non-invasive risk
stratification have been performed in patients with severely im-
paired LVEF (,40%) or in mixed populations. In these studies, ei-
ther the outcome in the subgroup of patients with LVEF .40%
has not been reported or the subgroups were too small to allow
analysis and interpretation of the data. To date, in patients with re-
mote myocardial infarction and preserved LVEF, no non-invasive
risk stratification technique has demonstrated sufficient specificity
and sensitivity.
There is limited evidence from subgroups of large-scale studies
that programmed ventricular stimulation is helpful for risk stratifica-
tion in patients after myocardial infarction with intermediate LVEF
values or with an LVEF .40%.280 – 282 This question is currently
being addressed in the ongoing Risk Stratification in Patients
With Preserved Ejection Fraction (PRESERVE-EF) trial
(NCT02124018).
5.3.2 Recommendations for optimal strategy
Revascularization in patients with stable coronary
artery disease after myocardial infarction with
preserved ejection fraction
Recommendations Classa Levelb Ref.c
Coronary revascularization is
recommended to reduce the risk of
SCD in patients with VF when acute









Guidelines for coronary revascularization have been published re-
cently.13 They provide clear management information and the read-
er is referred to the source documents for details.
In patients with CAD and VAs, assessment of obstructive coronary
disease and ischaemia is essential. Surgical revascularization may in-
crease survival and prevent SCD. Implantation of an epicardial ICD
lead at the time of coronary artery bypass grafting is not associated
with an overall mortality benefit. Percutaneous coronary intervention
is also associated with a marked decline in cardiac mortality driven by
fewer deaths from myocardial infarction or sudden death.
Revascularization may be associated with an increase in LVEF of
≥5–6% in 15–65% of stable patients. This is particularly true for
those with evidence of ischaemic or hibernating myocardium on
preoperative imaging studies.291,292 The majority of patients with se-
verely depressed LVEF immediately after STEMI show significantly
improved systolic function after 3 months.286 LVEF should be re-
evaluated 6–12 weeks after coronary revascularization to assess
potential indications for primary prevention ICD implantation.
In patients who survive SCD, revascularization can reduce the re-
currence of life-threatening arrhythmias and SCD and also improve
patient outcomes, particularly if there is evidence of ischaemia pre-
ceding SCD. Sustained monomorphic VT in patients with previous
myocardial infarction is less likely to be affected by revascularization.
Myocardial revascularization is unlikely to prevent recurrent SCD in
patients with extensive myocardial scarring and markedly depressed
LVEF.
5.3.3 Use of anti-arrhythmic drugs
Use of anti-arrhythmic drugs
Recommendations Classa Levelb Ref.c
Amiodarone may be considered for
relief of symptoms from VAs in survivors
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Therapy with sodium channel blockers
(class IC) is not recommended to
prevent sudden death in patients with
CAD or who survived myocardial
infarction.
III B 131




The role of anti-arrhythmic drugs in the prevention of SCD in post-
myocardial infarction patients with preserved ejection fraction is
limited. Most of the data come from the CAST study,129 which
showed that sodium channel blockers (class IA and IC agents)
increase mortality after myocardial infarction. Class II drugs
(beta-blockers) have an established role in reducing mortality in
post-myocardial infarction patients with reduced LVEF and this
protective role may also persist in patients with preserved LVEF,
but their effect on SCD is unproven. Finally, the class III agent amio-
darone has not been shown to reduce SCD in post-myocardial
infarction patients with preserved LVEF. However, it may have a
role in the relief of symptoms and the reduction of arrhythmic
episodes in this group of patients.
For symptomatic but not life-threatening arrhythmias (PVCs or
short and slow NSVT), amiodarone is the drug of choice since it
suppresses arrhythmias without worsening prognosis.293,294
5.3.4 Catheter ablation
VT occurs in 1–2% of patients late after myocardial infarction, often
after an interval of several years. Recurrent VT can be treated effect-
ively with catheter ablation, which dramatically reduces VT recur-
rence in small patient series treated in specialized centres.
Whether primary ablation of well-tolerated sustained monomorph-
ic VT in patients with an LVEF .40% without a backup ICD is bene-
ficial deserves further study. Until then, ICD implantation should be
considered in survivors of a myocardial infarction suffering from sus-
tained VT or VF in the absence of acute ischaemia, even after suc-
cessful catheter ablation.261 – 265
6. Therapies for patients with
left ventricular dysfunction
with or without heart failure
VAs are present in most patients with HF, and sudden death is com-
mon in this population.1,8,295,296 The presence and severity of VAs
increase along with the severity of HF, but their value to predict
sudden death is unclear.297 – 300 Indeed, identification of increased
risk of sudden death in HF patients has been notoriously difficult,
and the only consistent—and independent—association has been
reported with the severity of LV dysfunction or LVEF.
6.1 Primary prevention of sudden cardiac
death
6.1.1 Drugs
Use of drugs in patients with left ventricular
dysfunction
Recommendations Classa Levelb Ref.c
Optimal pharmacological therapy with
ACE inhibitors (or, when intolerant,
ARBs), beta-blockers and MRAs is
recommended in patients with HF
with systolic dysfunction (LVEF ≤35–





ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin II receptor
blocker; HF ¼ heart failure; LVEF ¼ left ventricular ejection fraction;




ACE inhibitors, beta-blockers and MRAs are recommended in
patients with HF with systolic dysfunction (LVEF ≤35–40%) since
they reduce all-cause mortality and sudden death8 (see section 5).
ACE inhibitors reduce all-cause mortality by 15–25% and are re-





(e.g. 5 mg metoprolol i.v.)






Amiodarone 300 mg i.v.
Lidocaine
Consider need for further
revascularization






referral to specialist center
ACS = acute coronary syndromes; i.v. = intravenous; K+ = potassium;
LV = left ventricular; Mg2+ = magnesium; VF = ventricular 
VT = ventricular tachycardia.
Figure 3 Diagnostic workup in patients with sustained ventricu-
lar arrhythmias and ACS.
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reduce mortality by 35% and have anti-ischaemic properties,
which lead to specific anti-arrhythmic effects, and these agents spe-
cifically reduce the incidence of sudden death.8 Recent data from
the Beta-Blockers in Heart Failure Collaborative Group have chal-
lenged the clinical assumption that beta-blockers improve the prog-
nosis in patients with HF and AF and they advocate that clinicians
should choose therapy for this subgroup of patients with HF accord-
ingly.306 To further explore this provocative observation, the
authors stated that ‘trial data specifically in patients with HF and
AF are urgently needed and eagerly anticipated’.307
MRAs reduce mortality and reduce rates of sudden death in
patients with HF who are already receiving ACE inhibitors and beta-
blocker therapy.143,308,309 In the most recent trial involving eplere-
none, 20% of patients also had an implanted device (ICD or CRT),
but the drug was equally effective in patients with as in those without
device therapy.309 This beneficial effect of MRAs on the incidence of
SCD in patients with LV systolic dysfunction was confirmed by a
meta-analysis of six studies showing patients treated with MRAs
had 23% lower odds of experiencing SCD compared with controls
[OR 0.77 (95% CI 0.66, 0.89), P ¼ 0.001].310 Diuretics and digoxin
are still used by many patients with HF, but they do not reduce rates
of all-cause mortality or sudden death. Angiotensin receptor blockers
and ivabradine are only recommended in subgroups of patients with
HF.8 Amiodarone does not affect outcome in patients with HF,132 and
given its high incidence of drug toxicity,8 it is not recommended for
general use in these patients. However, in cases of symptomatic ven-
tricular (tachy-)arrhythmias in patients with HF (e.g. those suffering
from defibrillator shocks or from non-sustained VAs causing symp-
toms), amiodarone is the anti-arrhythmic agent of choice because it
does not worsen outcome.132 Other anti-arrhythmic drugs are not
recommended in patients with HF because of safety concerns.8
In the past 10 years there has been increased awareness that
many patients who have signs and symptoms of HF have a normal
or preserved ejection fraction (HFpEF).8,311 Many of the therapies
that improve survival in HF with reduced ejection fraction (HFrEF)
are less effective in HFpEF. A relatively high proportion of these pa-
tients have non-cardiovascular co-morbidities, and although sudden
death is common,312 there have been no well-powered studies with
ICDs or CRT. Most large-scale drug trials in HF were conducted be-
fore the positive results from landmark trials with ICDs63,64 and
CRT313,314 became available (in 2005); the evidence from these
trials led to a powerful recommendation in the HF guidelines and
an enormous increase in their use.7,315
6.1.2 Implantable cardioverter defibrillators
Implantable cardioverter defibrillator in patients with
left ventricular dysfunction
Recommendations Classa Levelb Ref.c
ICD therapy is recommended to reduce
SCD in patients with symptomatic HF
(NYHA class II– III) and LVEF ≤35%
after ≥3 months of optimal medical
therapy who are expected to survive for
at least 1 year with good functional
status:







HF ¼ heart failure; ICD ¼ implantable cardioverter defibrillator; LVEF ¼ left
ventricular ejection fraction; NYHA ¼ New York Heart Association;




Early studies regarding the value of ICDs in LV dysfunction were
conducted in patients with a previous cardiac arrest (i.e. secondary
prevention) or in whom additional electrophysiological criteria
were required.1 Two large trials have provided data on the primary
prevention of SCD by an ICD in patients with HF and reduced LVEF:
the SCD-HeFT trial64 and the Multicenter Automatic Defibrillator
Implantation Trial II (MADIT-II).63,318 In the SCD-HeFT, use of an
ICD was associated with a 23% decreased risk of death [hazard ratio
(HR) 0.77 (95% CI 0.62, 0.96), P ¼ 0.007] and an absolute decrease
in mortality of 7% after 5 years (from 29 to 22%). There was a 60%
reduction in sudden death in the ICD arm.319 The effect on all-cause
mortality did not vary according to ischaemic or non-ischaemic
causes of HF, but there was a difference according to NYHA class:
ICDs were very effective in class II patients but had no apparent ef-
fect on mortality in class III. In MADIT-II, patients in the ICD group
had a decrease of 31% in all-cause mortality [HR 0.69 (95% CI 0.51,
0.93), P ¼ 0.016], and a later analysis from this study showed that
the benefit of ICDs in this population was time dependent,318
with a larger benefit in patients whose index myocardial infarction
was more remote from randomization.
While there are more data to support the use of ICDs in survivors
of a myocardial infarction (i.e. ischaemic aetiology), in HFrEF patients
with non-ischaemic aetiologies a reduction in all-cause mortality and
arrhythmic mortality is supported as well. In the DEFibrillator In Non-
Ischemic cardiomyopathy treatment Evaluation (DEFINITE) trial,316 a
trend in mortality reduction was observed in the ICD group [HR 0.65
(95% CI 0.40, 1.06), P ¼ 0.08], while sudden cardiac death was signifi-
cantly reduced [HR 0.20 (95% CI 0.06, 0.71), P ¼ 0.006]. In the
SCD-HeFT trial,63 a trend in reduction of all-cause death [HR 0.73
(95% CI 0.50, 1.07), P ¼ 0.06] was observed in patients without a pre-
vious infarction (and non-ischaemic HF). In the same trial also for
patients with ischaemic aetiology, there was only a trend in the re-
duction of all-cause death [HR 0.79 (95% CI 0.60, 1.04), P ¼ 0.05],
suggesting that the two subgroups were probably too small to reach
statistical significance.63 Accordingly, a meta-analysis by Desai et al.317
of five primary prevention trials enrolling 1854 patients with non-
ischaemic HF, use of an ICD was associated with a significant 31% re-
duction in total mortality [HR 0.69 (95% CI 0.55, 0.87), P ¼ 0.002].
ICD therapy is not recommended in patients with end-stage
(NYHA class IV) HF and in other patients who have an estimated
life expectancy of ,1 year.
Currently there are no RCTs demonstrating the value of an ICD in
asymptomatic patients (NYHA class I) with systolic dysfunction (LVEF
≤35–40%) or in patients with HF and preserved LVEF.40–45%, so
ICDs are not recommended for primary prevention in these patients.
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6.1.3 Implantable cardioverter defibrillators in patients
with New York Heart Association class IV listed for heart
transplantation
Implantable cardioverter defibrillators in patients with
New York Heart Association class IV listed for heart
transplantation
Recommendation Classa Levelb Ref.c
ICD implantation should be considered
for primary and secondary prevention of









There are no randomized trial data regarding the value of ICDs in pa-
tients with NYHA class IV. It is generally accepted that ICD therapy is
not recommended in patients with severe, drug-refractory symptoms
who are not candidates for CRT, a ventricular assist device or heart
transplantation.8,11 However, the situation for ambulatory class IV pa-
tients who are listed for heart transplantation may be different. These
patients often have to wait at least 1 year and their risk of sudden
death is high. Data from two observational studies that together ex-
amined almost 2000 patients, one of them recent320 and the other
older (in which the use of beta-blockers was low),321 have suggested
a survival benefit in patients with an ICD.
6.1.4 Cardiac resynchronization therapy
6.1.4.1 Heart failure with reduced left ventricular ejection fraction and
New York Heart Association class III/ambulatory class IV
Table A. Cardiac resynchronization therapy in the
primary prevention of sudden death in patients in sinus
rhythm and New York Heart Association functional
class III/ambulatory class IV
Recommendations Classa Levelb Ref.c
CRT is recommended to reduce
all-cause mortality in patients with an
LVEF ≤35% and LBBB despite at least 3
months of optimal pharmacological
therapy who are expected to survive at
least 1 year with good functional status:
322–
326










CRT should or may be considered to
reduce all-cause mortality in patients with
an LVEF ≤35% without LBBB despite at
least 3 months of optimal pharmacological
therapy who are expected to survive at












CRT ¼ cardiac resynchronization therapy; LBBB ¼ left bundle branch block;




Table B. Cardiac resynchronization therapy in the
primary prevention of sudden death in patients with
permanent atrial fibrillation in New York Heart
Association functional class III/ambulatory class IV
Recommendations Classa Levelb Ref.c
CRT should be considered to reduce
all-cause mortality in patients with
chronic HF, QRS ≥120 ms and LVEF
≤35% who remain in NYHA functional
class III/ambulatory class IV despite at
least 3 months of optimal
pharmacological therapy who are
expected to survive at least 1 year with
good functional status, provided that
biventricular pacing as close as possible




AV junction ablation should be





AV ¼ atrio-ventricular; CRT ¼ cardiac resynchronization therapy; HF ¼ heart
failure; LVEF ¼ left ventricular ejection fraction; ms ¼ milliseconds; NYHA ¼




For patients in sinus rhythm, recommendations are provided in
relation to LBBB vs. non-LBBB morphology and also regarding
QRS duration (120–150 ms vs..150 ms)10 (Table A in this section).
For patients with AF, recommendations are provided in Table B in
this section.
Two large RCTs [the Comparison of Medical Therapy, Pacing,
and Defibrillation in Heart failure (COMPANION) Trial313 and
the Cardiac Resynchronization – Heart Failure (CARE-HF) Trial314]
in patients with moderate to severe (class III– IV) HF and in sinus
rhythm have shown that CRT reduces morbidity and mortality in
this population.
COMPANION enrolled HFrEF patients with a QRS duration
≥120 ms. When compared with patients on optimal medical ther-
apy alone, a trend in the reduction of all-cause mortality was
observed with a CRT pacemaker (CRT-P) [HR 0.76 (95% CI 0.58,
1.01), P ¼ 0.059] and a 36% reduction was seen with a CRT-D
[HR 0.64 (95% CI 0.48, 0.86), P ¼ 0.003]. CRT-D, but not CRT-P,
reduced the rate of SCD in this study.
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While the criterion for QRS duration was also ≥120 ms in
CARE-HF, additional criteria for dyssynchrony had to be met
in patients with a QRS interval of 120–149 ms. CRT-P reduced
all-cause mortality by 36% [HR 0.64 (95% CI 0.48, 0.85),
P , 0.002].64 In an extended report from the CARE-HF trial
(mean follow-up 37 months), CRT-P also reduced sudden death
by 46% [HR 0.54 (95% CI 0.35, 0.84), P ¼ 0.005], with a reduction
in total mortality at that time of 40% [HR 0.60 (95% CI 0.47, 0.77),
P, 0.001].335
COMPANION and CARE-HF together provide strong evi-
dence favouring the use of CRT (CRT-P or CRT-D) in HFrEF pa-
tients with moderate to severe symptoms who have a prolonged
QRS duration, especially in those with LBBB morphology. Several
other studies, registries and a meta-analysis have addressed the
issue of the response to CRT based on QRS morphology and
the majority supported the view that QRS morphology with
LBBB identifies a subgroup of patients with increased benefit; a
short outline of key studies, registries, and meta-analysis is re-
ported here.
Data from the Medicare ICD Registry,326 which included 14 946
patients, showed that CRT-D was not effective in patients with
RBBB, as shown by the increased mortality at 3 years of RBBB as
compared to LBBB [HR 1.37 (95% CI 1.26, 1.49), P, 0.001]. The
REsynchronization reVErses Remodeling in Systolic left vEntricular
dysfunction (REVERSE) study336 confirmed the reduction in the
composite clinical endpoint only in patients with LBBB (OR 0.53,
P, 0.0032) and showed no benefit in patients with non-LBBB (OR
0.74, P ¼ 0.21). Similarly, analysis of QRS morphology in the
MADIT-CRT322 study showed a reduction in the primary endpoint
in patients with LBBB QRS morphology (HR 0.47, P, 0.001) but
not in patients with non-LBBB QRS morphology (HR 1.24, P ¼
0.257). Also of interest, the risks of VT, VF and death were signifi-
cantly reduced only in patients with LBBB. A long-term analysis in-
volving patients in MADIT-CRT has been published recently,148
confirming that after 7 years of follow-up the survival benefit of
CRT-D was observed in patients with LBBB QRS morphology
[HR 0.59 (95% CI 0.43, 0.80), P , 0.001] while patients with
non-LBBB morphology showed no effect and possibly harm re-
lated to CRT-D [HR 1.57 (95% CI 1.03, 2.39) P ¼ 0.04]. When
data from the Resynchronization–Defibrillation for Ambulatory
Heart Failure Trial (RAFT) were analysed, on the basis of QRS
morphology data, CRT therapy showed a greater benefit in pa-
tients with LBBB vs. non-LBBB morphology.323 Interestingly pa-
tients with non-LBBB QRS morphology with a QRS .160 ms
experienced a modest reduction in the primary outcome [HR
0.52 (95% CI 0.29, 096), P ¼ 0.033]. Despite the fact that only
53 patients were present in this group, the potential benefit of
CRT in non-LBBB QRS morphology in the presence of a marked
QRS prolongation (QRS ≥160 ms) is worth exploring. This obser-
vation is supported by the results of the meta-analysis by Cleland
et al.,334 involving data from CARE-HF, Multicenter InSync Rando-
mized Clinical Evaluation (MIRACLE), REVERSE, Multicenter In-
Sync ICD Randomized Clinical Evaluation (MIRACLE ICD) and
RAFT. Despite an apparent benefit of CRT in patients with LBBB
in univariate analysis, the results in the multivariable model sug-
gested that only QRS duration predicted the magnitude of the ef-
fect of CRT on outcomes. Nery et al.324 reported a meta-analysis
of CRT clinical trials targeted to 485 patients with RBBB QRS
morphology and showed no benefit of resynchronization therapy
[HR 2.04 (95% CI 1.32, 3.15), P ¼ 0.001]; unfortunately no data on
QRS duration were provided.
Sipahi et al.325 performed a meta-analysis in which they exam-
ined 33 clinical trials investigating the effect of QRS morphology
on CRT, but only four (COMPANION, CARE-HF, MADIT-CRT
and RAFT) included outcomes according to QRS morphology.
When they evaluated the effect of CRT on composite adverse clin-
ical events in 3349 patients with LBBB at baseline, they observed a
36% reduction in risk with the use of CRT [RR 0.64 (95% CI 0.52,
0.77), P, 0.00001]. However, such benefit was not observed in
patients with non-LBBB conduction abnormalities [RR 0.97 (95%
CI 0.82, 1.15), P ¼ 0.75].325 Interestingly, when the analysis was
limited to trials without ICD (CARE-HF and COMPANION), the
benefit of CRT was still observed only in patients with LBBB (P,
0.000001).
In a recent large meta-analysis of six RCTs (COMPANION,
CARE-HF, MADIT-CRT, MIRACLE, RAFT and REVERSE),337 includ-
ing 6914 participants (1683 with non-LBBB QRS morphology), CRT
was not associated with a reduction in death and/or HF hospitaliza-
tion in patients with non-LBBB QRS morphology [HR 1.09 (95% CI
0.85, 1.39)].337
Therefore wide QRS with non-LBBB morphology still remains an
area of uncertainty for CRT. Based on these data, despite the fact
that most patients in Europe receive a CRT-D,314 our recommenda-
tions are expressed in general for CRT.
Discrepancies exist in previous documents [American College of
Cardiology Foundation/AHA guidelines and the consensus docu-
ment on pacing from the European Heart Rhythm Association
(EHRA)/ESC] about the class of recommendation for CRT in pa-
tients with QRS between 120 and 150 ms. Based on a meta-analysis
by Sipahi et al.,328 CRT significantly reduced all-cause mortality or
hospitalization in patients with a QRS duration ≥150 ms [RR 0.60
(95% CI 0.53, 0.67), P, 0.001], but not in patients with a QRS dur-
ation of 120–150 ms [RR 0.95 (95% CI 0.82, 1.10), P ¼ 0.49]. How-
ever, methodological concerns due to the multiplicity of analysis in
the study by Sipahi et al. have been pointed out,338 and therefore the
conclusion that CRT is effective only for patients with a QRS
≥150 ms should at this time be regarded as exploratory only.338
CRT is not recommended in HF patients with a QRS duration
,120 ms.339
In patients with AF, CRT should be considered in those with
markedly reduced LVEF, but this has not been shown to reduce
mortality or sudden death in these patients.8,340 In the RAFT trial,
229 (or 13% of the total population of 1798) patients had AF or
flutter at baseline.327 Although there was formally no significant
interaction between baseline rhythm and treatment effect (ICD
vs. CRT-D, P ¼ 0.14), the number of patients in this study was small
and the effect in patients with AF or atrial flutter appeared less than
in those in sinus rhythm. Success of CRT in patients with AF is, for
the most part, determined by the degree of biventricular pacing, and
this can be achieved only by means of AV junction ablation in many
patients.10
Although the decision to perform AV junction ablation in these
patients is still a matter of some debate, recent data suggest that
long-term survival after CRT among patients with AF who have
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undergone AV junction ablation is similar to that observed in pa-
tients in sinus rhythm.333 In summary, CRT can be considered in pa-
tients with HF, permanent AF and LVEF ≤35% if (i) ventricular
pacing is required or the patient otherwise meets CRT criteria
and (ii) near 100% ventricular pacing is achieved with CRT with
AV junction ablation or pharmacological rate control (class 2A–B
level of recommendation).
6.1.4.2 Heart failure with reduced left ventricular ejection fraction but
mild symptoms (New York Heart Association class II)
Table C. Cardiac resynchronization therapy
defibrillatora in the primary prevention of sudden
death in patients in sinus rhythm with mild (New York
Heart Association class II) heart failure
Recommendations Classb Levelc Ref.d
CRT-D is recommended to reduce
all-cause mortality in patients with a
QRS duration ≥130 ms, with an LVEF
≤30% and with LBBB despite at least
3 months of optimal pharmacological
therapy who are expected to survive









CRT-D may be considered to prevent
hospitalization for HF in patients with a
QRS duration ≥150 ms, irrespective of
QRS morphology, and an LVEF ≤35%
despite at least 3 months of optimal
pharmacological therapy who are







CRT-D ¼ cardiac resynchronization therapy defibrillator; HF ¼ heart failure;
LBBB ¼ left bundle branch block; LVEF ¼ left ventricular ejection fraction; ms ¼
milliseconds.
aThese recommendations refer specifically to CRT-D, since studies on the effect




Two controlled trials randomized 3618 patients with mild HF to op-
timal pharmacological therapy plus an ICD or optimal pharmaco-
logical treatment plus CRT-D.327,329
The MADIT-CRT study329 enrolled 1820 patients who were mildly
symptomatic (NYHA class I or II) and who had an LVEF ≤30% with a
QRS duration≥130 ms. The initial report showed a 34% reduction in
the primary endpoint of all-cause death or HF events [25.3% vs. 17.2%
for ICD vs. CRT-D; HR 0.66 (95% CI 0.52, 0.84), P ¼ 0.001]. In a long-
term follow-up report from MADIT-CRT (mean follow-up of 7
years),148 CRT-D significantly reduced mortality [HR 0.59 (95% CI
0.43, 0.80), P, 0.001] compared with ICD only, which, however,
was confined to patients with LBBB at baseline, while no beneficial ef-
fect was observed in those without LBBB (P, 0.001 for interaction)
(Table C in this section).
The RAFT trial327 enrolled 1798 patients with mild to moderate HF
(NYHA class II or III), LVEF ≤30% and a QRS duration ≥120 ms (or a
paced QRS duration ≥200 ms). Compared with patients with an ICD
alone, the CRT-D group showed a 25% RR reduction in all-cause mor-
tality [HR 0.75 (95% CI 0.62, 0.91), P ¼ 0.003], substantiating the sys-
tematic use of CRT therapy in HFrEF patients with mild symptoms.
6.2 Premature ventricular complexes in
patients with structural heart disease/left
ventricular dysfunction
Treatment of patients with left ventricular dysfunction
and premature ventricular complex
Recommendations Classa Levelb Ref.c
In patients with frequent symptomatic
PVC or NSVT:
– Amiodarone should be considered. IIa B 64





Catheter ablation should be considered










PVCs and runs of NSVT are common in patients with LV dysfunction
and may be the consequence or cause of LV dysfunction. PVCs and
runs of NSVT in subjects with structural heart disease contribute to
an increased mortality risk, and .10 PVCs per hour or runs of
NSVT are an acceptable marker of increased risk.344 If patients
are symptomatic due to PVCs or NSVTs, or if PVCs or NSVTs con-
tribute to reduced LVEF (‘tachycardia-induced cardiomyopathy’),
amiodarone or catheter ablation should be considered.
A high PVC burden (.24%) in patients with LV dysfunction and a
rather short coupling interval of the PVCs (,300 ms) suggest
PVC-induced cardiomyopathy.342 In such patients, catheter ablation
can suppress PVCs and restore LV function.341
6.3 Sustained ventricular tachycardia
6.3.1 Drug therapy
Treatment of patients with left ventricular dysfunction
and sustained recurrent monomorphic ventricular
tachycardia
Recommendations Classa Levelb Ref.c
Optimization of HF medication
according to current HF guidelines is
recommended in patients with LV
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Amiodarone treatment should be
considered to prevent VT in patients
with or without an ICD.
IIa C 64
HF ¼ heart failure; LV ¼ left ventricular; ICD ¼ implantable cardioverter




Patients with LV dysfunction with or without HF presenting with sus-
tained VT should be treated according to recently published HF
guidelines, similar to patients with LV dysfunction without VT.8 In add-
ition, medical drug therapy for sustained VT should target maximal
sympathetic blockade. In the MADIT-II study, patients with ICD trea-
ted with the highest doses of beta-blockers experienced a significant
reduction in recurrent episodes of VT or VF necessitating ICD inter-
vention compared with patients not taking beta-blockers [HR 0.48
(95% CI 0.26, 0.89), P ¼ 0.02].8 The Optimal Pharmacological Ther-
apy in Cardioverter Defibrillator Patients (OPTIC) study compared
the use of beta-blockers, sotalol and beta-blockers plus amiodarone
for the prevention of ICD shocks.156 Amiodarone plus beta-blocker
therapy significantly reduced the risk of shock compared with beta-
blocker treatment alone [HR 0.27 (95% CI 0.14, 0.52), P, 0.001]
and sotalol [HR 0.43 (95% CI 0.22, 0.85), P ¼ 0.02]. However, drug
discontinuation was more frequent in patients taking sotalol or a com-
bination of amiodarone and a beta-blocker. The rates of study drug
discontinuation at 1 year were 18.2% for amiodarone, 23.5% for so-
talol and 5.3% for beta-blocker alone.
In the SCD-HeFT trial, patients with LV dysfunction and NYHA
class II or III HF received conventional HF therapy, conventional
therapy plus amiodarone or conventional therapy and a single-
chamber ICD.64 Compared with conventional HF therapy, the add-
ition of amiodarone did not increase mortality.
6.3.2 Catheter ablation
Prevention of ventricular tachycardia recurrences in
patients with left ventricular dysfunction and sustained
ventricular tachycardia
Recommendations Classa Levelb Ref.c
Urgent catheter ablation in specialized
or experienced centres is recommended
in patients presenting with incessant VT
or electrical storm resulting in ICD
shocks.
I B 183
Amiodarone or catheter ablation is
recommended in patients with






ICD implantation is recommended in
patients undergoing catheter ablation






Amiodarone or catheter ablation should
be considered after a first episode of









Depending on the underlying substrate, catheter ablation for sus-
tained VT may result in acute termination and reduction of recur-
rent VT episodes in patients with structural heart disease.
6.3.2.1 Patients with left ventricular dysfunction
In patients with LV dysfunction and sustained VT, scar-mediated re-
entry is the common pathophysiological mechanism and ablation
targets the critical isthmus within the re-entry circuit. VT is mostly
monomorphic. If a 12-lead ECG of the clinical VT is not available in
ICD patients, the cycle length of the stored ICD electrograms during
VT may facilitate identification of the clinical VT during the electro-
physiology study. Irrigated ablation catheters are commonly used,
which facilitate deeper lesion formation and reduce the risk of
char formation during energy delivery.
At present, the best ablative strategy is unknown. There is a
lack of RCTs comparing catheter ablation during VT with a
substrate-based approach. In addition, there is no consensus with
respect to the ideal procedural endpoint. While elimination of all
clinical VTs should be attempted, non-inducibility of any VT after ab-
lation may be the preferred procedural endpoint.
Patients may present with electrical storms. Catheter ablation can
acutely terminate this potentially life-threating event and has been
shown to decrease the rate of recurrent electrical storm episodes
when compared with medical treatment only.183 Patients with VT
related to post-myocardial scar tend to have a better outcome fol-
lowing catheter ablation than patients with VT due to non-ischaemic
cardiomyopathy. Five prospective studies have evaluated the role of
catheter ablation in the treatment of sustained VT.184 –188 The Mul-
ticenter Thermocool study reported an acute success rate, defined
as abolishment of all inducible VTs, of 49% and a mid-term freedom
from VT of 53% over 6 months of follow-up.185 In the Cooled RF
Multi Center Investigators Group study, acute success, defined as
elimination of all inducible VTs, was achieved in 41% of patients.184
Freedom from recurrent VA was noted in 46% of patients during
8+ 5 months of follow-up. In the prospective Euro-VT study, abla-
tion was acutely successful in 81% of patients and freedom from re-
current VT was achieved in 51% of patients.186 The Substrate
Mapping and Ablation in Sinus Rhythm to Halt Ventricular Tachycar-
dia Trial (SMASH-VT) evaluated the role of catheter ablation in pa-
tients with previous myocardial infarction and reduced LVEF.187
Patients underwent ICD implantation for VF, haemodynamically un-
stable VT or syncope with inducible VT during invasive electrophysi-
ology testing. The control arm underwent ICD implantation only.
None of the patients received anti-arrhythmic drugs. Catheter abla-
tion was performed using a substrate-guided approach targeting ab-
normal ventricular potentials during sinus rhythm without the need
for VT induction. During a mean follow-up of 23+6 months there
was a significant reduction in the incidence of VT episodes, from
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33% in the control group to 12% in the ablation arm. Furthermore,
the rate of appropriate ICD shocks decreased from 31% to 9% fol-
lowing catheter ablation.
The Ventricular Tachycardia Ablation in Coronary Heart Disease
(VTACH) study prospectively randomized patients with previous
myocardial infarction, reduced ejection fraction (≤50%) and
haemodynamically stable VT to catheter ablation or no additional
therapy, apart from subsequent ICD.188 The primary endpoint
was time to first recurrence of VT or VF. The rate of survival free
from recurrent VT over 24 months was higher in the ablation group
compared with the control arm [47% vs. 29%, HR 0.61 (95% CI 0.37,
0.99), P ¼ 0.045]. The mean number of appropriate ICD shocks per
patient per year decreased from 3.4+9.2 to 0.6+ 2.1 in patients
undergoing catheter ablation (P ¼ 0.018). Catheter ablation did
not affect mortality.
Overall, the success rate of catheter ablation for VT is deter-
mined by the amount of infarct-related scar burden, represented
as low-voltage areas on electro-anatomic mapping systems,209 while
dedicated units for the treatment of patients undergoing catheter
ablation of VT may positively impact outcome.210
6.3.2.2 Bundle branch re-entrant tachycardia
Prevention of ventricular tachycardia recurrences in
patients with bundle branch re-entrant tachycardia
Recommendation Classa Levelb Ref.c
Catheter ablation as first-line therapy is
recommended in patients presenting








Bundle branch tachycardia is a rare macro-re-entry tachycardia that
typically involves the right bundle branch as the anterograde and the
left bundle branch as the retrograde limb. On the 12-lead surface
ECG, LBBB morphology with left-axis deviation is seen. Bundle
branch re-entry is often associated with cardiomyopathy.347 Cath-
eter ablation of one of the bundle branches is curative, although
the right bundle branch is the preferred target, as it is more easily
accessible for ablation.347 As the underlying structural abnormality
remains unchanged, concomitant placement of an ICD should be
strongly considered.347
6.3.3 Implantable cardioverter defibrillator
Implantation of an ICD in patients with sustained VT increases sur-
vival compared with anti-arrhythmic drug therapy. To date, no trial
has been conducted comparing catheter ablation for sustained VT
without ICD implantation and ICD placement only. In view of the
scarcity of data and the rather high rate of recurrence following
catheter ablation for sustained VT, ICD implantation should be con-
sidered in all patients with LV dysfunction (ejection fraction ,45%)
and sustained VT.
7. Cardiomyopathies
Cardiomyopathies are myocardial disorders defined by structural
and functional abnormalities of the ventricular myocardium that
are not solely explained by flow-limiting coronary artery stenosis
or abnormal loading conditions.348 They are grouped according to
morphological and functional characteristics and subclassified into
familial and non-familial forms. Nearly all cardiomyopathies can be
associated with VA and an increased risk of SCD that varies with
the aetiology and the severity of the disease.
7.1 Dilated cardiomyopathy
7.1.1 Definitions, epidemiology and survival data
DCM is defined as LV dilatation and systolic dysfunction in the
absence of abnormal loading conditions or CAD sufficient to
cause global systolic impairment.348 Some genetic defects that
cause DCM can also cause systolic dysfunction without LV dilata-
tion or result in myocardial scarring that is only detectable on
CMR.
DCM presents in people of all ages and ethnicities. In adults, it is
more common in men than in women, with an overall prevalence of
1 in 2500 individuals and a conservative estimated annual incidence
of 7 per 100 000.349 In children, the yearly incidence is 0.57 cases per
100 000.350
Potentially pathogenic genetic mutations are found in at least
20% of adults with DCM and between 10 and 20% of relatives
have evidence for disease on clinical screening.351 Sarcomere
and desmosomal protein gene mutations are the most common,
but mutations in lamin A/C (LMNA) and desmin are frequent in pa-
tients with conduction diseases.352,353 A small number of patients
have an X-linked disease caused by mutations in the dystrophin
gene. A large spectrum of acquired conditions can cause DCM, in-
cluding inflammatory, infective and systemic diseases, as well as
various drugs and toxins. In some cases, patients are genetically
predisposed to the development of DCM following exposure to
exogenous triggers such as infection, cytotoxic drugs, alcohol
and pregnancy.
7.1.2 Approach to risk stratification and management
Risk stratification and management of patients with
dilated cardiomyopathy
Recommendations Classa Levelb Ref.c
Optimal medical therapy (ACE
inhibitors, beta-blockers and MRA) is
recommended in patients with DCM to
reduce the risk of sudden death and
progressive HF.
I A 8
Prompt identification and treatment of
arrhythmogenic factors (e.g.
pro-arrhythmic drugs, hypokalaemia)
and co-morbidities (e.g. thyroid disease)
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A coronary angiography is
recommended in stable DCM patients
with an intermediate risk of CAD and
new onset VA.
I B 8
An ICD is recommended in patients with
DCM and haemodynamically not
tolerated VT/VF, who are expected to





An ICD is recommended in patients
with DCM, symptomatic HF (NYHA
class II– III) and an ejection fraction
≤35% despite ≥3 months of
treatment with optimal pharmacological
therapy who are expected to survive








Catheter ablation is recommended in
patients with DCM and bundle branch
re-entry ventricular tachycardia





An ICD should be considered in patients
with DCM and a confirmed
disease-causing LMNA mutation and
clinical risk factors.d
IIa B 71
Amiodarone should be considered in
patients with an ICD that experience
recurrent appropriate shocks in spite of
optimal device programming.
IIa C 229
Catheter ablation may be considered in
patients with DCM and VA not caused




Invasive EPS with PVS may be
considered for risk stratification
of SCD.
IIb B 115
Amiodarone is not recommended for





Use of sodium channel blockers and
dronedarone to treat VA is not





ACE ¼ angiotensin-converting enzyme; CAD ¼ coronary artery disease;
DCM ¼ dilated cardiomyopathy; EPS ¼ electrophysiological study;
HF ¼ heart failure; ICD ¼ implantable cardioverter defibrillator; LMNA ¼ lamin
A/C; LVEF ¼ left ventricular ejection fraction; MRA ¼ mineralocorticoid
receptor antagonists; NSVT ¼ non-sustained ventricular tachycardia;
NYHA ¼ New York Heart Association; PVS ¼ programmed ventricular
stimulation; SCD ¼ sudden cardiac death; VA ¼ ventricular arrhythmia;




dRisk factors in patients with a confirmed LMNA mutation: NSVT during
ambulatory electrocardiogram monitoring, LVEF ,45% at first evaluation, male
sex and non-missense mutations (insertion, deletion, truncations or mutations
affecting splicing).
All-cause mortality in unselected adult patients with DCM has de-
creased substantially with the use of neurohormonal antagonists
and device therapy.358 Mortality in children with DCM is relatively
high in the first year of life but thereafter many children recover
function or remain clinically stable.359 The major causes of cardio-
vascular death in DCM are progressive HF and SCD secondary to
VA or, less commonly, bradyarrhythmias. Many non-invasive vari-
ables have been suggested as predictors of sudden death, but in a
recent meta-analysis of 45 studies enrolling 6088 patients, functional
and electrocardiographic variables provided only modest discrimin-
ation between high- and low-risk patients. The highest OR was for
fragmented QRS and T-wave alternans; none of the autonomic tests
were significant predictors.115 The role of CMR imaging has been
evaluated in a meta-analysis of nine studies in patients with non-
ischaemic cardiomyopathy360 and suggests that late gadolinium en-
hancement in patients is associated with increased risk of all-cause
mortality, HF hospitalization and SCD. The incremental value of late
gadolinium enhancement over other prognostic markers needs to
be determined.
Invasive EPS with PVS might play a role in patients with DCM.115
7.1.2.1 Trials of implantable cardioverter defibrillator therapy
in dilated cardiomyopathy
A number of trials have compared ICD therapy alone or in combin-
ation with CRT against placebo or amiodarone in patients with
DCM.64,151–154,313,316,317,354 Most were conducted in an era when
best medical therapy evolved to include ACE inhibitors, beta-blockers
and MRAs.358 The first RCTs of ICD therapy were underpowered to
detect clinically meaningful differences in survival, and in some cases
(e.g. DEFINITE) the overall mortality rate was lower than anticipated
before enrolment. Follow-up was relatively short in some studies and,
as in other settings, the relation of appropriate shocks to prognosis is
still uncertain. No study has prospectively investigated the benefit of
ICDs in specific aetiological subgroups of DCM.
7.1.2.2 Primary prophylaxis
Four randomized trials [CArdiomyopathy Trial (CAT),361 AMIO-
darone Versus Implantable cardioverter-defibrillator: Randomized
Trial in patients with non-ischaemic dilated cardiomyopathy and
asymptomatic non-sustained ventricular tachycardia (AMIO-
VIRT),354 DEFINITE316 and SCD-HeFT64] examined the effect of
ICD therapy alone for primary prevention of SCD. A further study,
COMPANION,313 compared CRT-D, CRT-P and amiodarone ther-
apy in patients with advanced HF (NYHA class III or IV) and a QRS
interval .120 ms. The studies differ in design: CAT, AMIOVIRT and
DEFINITE enrolled only patients with non-ischaemic DCM, where-
as SCD-HeFT and COMPANION included patients with ischaemic
and non-ischaemic LV dysfunction. Only COMPANION demon-
strated a statistically significant reduction in sudden death with
ICDs compared with optimal medical therapy. All-cause mortality
was lower in the CRT-D group than in the pharmacological therapy
group [HR 0.50 (95% CI 0.29, 0.88), P ¼ 0.015], but was associated
with a significantly higher risk of moderate or severe adverse events
from any cause (69% vs. 61% in the medical therapy arm, P ¼ 0.03).
Pooled analysis of the five primary prevention trials (1854 patients
with non-ischaemic DCM) demonstrated a statistically significant
31% reduction in all-cause mortality for ICD relative to medical
therapy [RR 0.69 (95% CI 0.55, 0.87), P ¼ 0.002].317 This effect per-
sisted when COMPANION was excluded [RR 0.74 (95% CI 0.58,
0.96), P ¼ 0.02].317 Recommendations for ICD therapy in this guide-
line are based on these analyses.
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7.1.2.3 Secondary prophylaxis
Three trials (AVID,153 CASH152 and CIDS;151 see Web Table 5) ex-
amined ICD therapy for secondary prevention in patients with a his-
tory of aborted cardiac arrest or symptomatic VT. In the CASH
study, patients were initially randomized to receive an ICD or one
of three drugs: amiodarone, metoprolol or propafenone, but the
propafenone arm was terminated early due to increased mortality.
The final analysis pooled data from the amiodarone and metoprolol
arms. The three trials enrolled a total of 1963 patients, of whom
only 292 (14.8%) had non-ischaemic cardiomyopathy. Neither
AVID nor CIDS reported a significant reduction in all-cause mortal-
ity with ICD therapy in the subgroup of patients with non-ischaemic
cardiomyopathy; outcomes for this subgroup were not reported in
CASH. The CASH trial also differed from AVID and CIDS in that the
mean LVEF was higher and .50% of patients received epicardial
ICD systems. In a subsequent meta-analysis in which data from
AVID and CIDS were pooled, there was a non-significant 31% re-
duction in all-cause mortality relative to medical therapy.154
7.1.2.4 Cause-specific mortality
Few studies have examined prognosis or treatment in specific DCM
subtypes. The best-characterized are the approximately 5–10% of
patients who have disease caused by mutations in the LMNA
gene.71,352 LMNA-related cardiac disease shows age-related pene-
trance with early onset atrial arrhythmias followed by development
of a conduction disease and a high risk of sudden death, often with
only mild LV dilatation and systolic impairment. In a multicentre
registry of 269 LMNA mutation carriers, multivariable analysis de-
monstrated that NSVT during ambulatory ECG monitoring, LVEF
,45% at first evaluation, male sex and non-missense mutations
(insertion-deletion/truncating or mutations affecting splicing) were
independent risk factors for malignant VA.71 Malignant VA occurred
only in persons with at least two of these risk factors and there was a
cumulative risk for each additional risk factor.
7.1.2.5 Management of ventricular arrhythmia in dilated
cardiomyopathy
Patients with DCM and recurrent VA should receive optimal med-
ical therapy with ACE inhibitors, beta-blockers and MRAs in accord-
ance with the ESC guidelines for chronic HF.8 Obvious precipitating
factors for VA (e.g. pro-arrhythmic drugs, hypokalaemia) or co-
morbidities (e.g. thyroid disease) for VA should be sought and trea-
ted when possible. In previously stable patients with new-onset VA,
coronary angiography should be considered in patients with an
intermediate to high risk of CAD. Amiodarone should be consid-
ered in patients with an ICD that experience recurrent appropriate
shocks in spite of optimal device programming,229 but should not be
used to treat asymptomatic episodes of NSVT. The use of sodium
channel blockers and dronedarone is not recommended in patients
with impaired LV function because of their potential pro-arrhythmic
effects.129,152,357,362,363
7.1.2.6 Ablation of ventricular tachycardia
The substrate for VT in DCM is highly complex, reflecting the mul-
tiple causes of the disease. Studies evaluating different ablation
strategies in DCM report, at best, modest success that is not im-
proved when epicardial and endocardial mapping is performed. In
a recent registry study comparing 63 patients with non-ischaemic
cardiomyopathy and 164 with ischaemic LV dysfunction,208 abla-
tion of the clinical VT only was achieved in 18.3% of non-ischaemic
cardiomyopathy. Thus catheter ablation of VT in DCM patients
should be reserved for patients presenting with a clear VT mech-
anism (e.g. bundle branch re-entry) and performed in experienced
centres.
7.2 Hypertrophic cardiomyopathy
7.2.1 Definitions, epidemiology and survival data
HCM is characterized by increased LV wall thickness that is not sole-
ly explained by abnormal LV loading conditions.116 This definition
applies to children and adults and makes no assumptions about
the aetiology, but for the purposes of this guideline, recommenda-
tions on the prevention of SCD apply to patients without metabolic,
infiltrative or other diseases that have very distinct natural histories
and treatment.
Studies in North America, Europe, Asia and Africa report a preva-
lence of unexplained LV hypertrophy in the range of 0.02–0.23% in
adults, with much lower rates in patients,25 years of age.116 While
HCM is most frequently transmitted as an autosomal dominant gen-
etic trait, most studies report a small male preponderance, and the
frequency of HCM in different racial groups is similar.116
Overall annual cardiovascular mortality and the rate of death or
appropriate ICD discharge for VT/VF in unselected adults with
HCM is 1–2 and 0.81%, respectively.364,365 Other major causes of
cardiovascular death are HF, thromboembolism and AV block.
7.2.2 Approach to risk stratification and management
Prevention of sudden cardiac death in patients with
hypertrophic cardiomyopathy
Recommendations Classa Levelb Ref.c
Avoidance of competitive sportsd
is recommended in patients with
HCM.
I C 366
ICD implantation is recommended in
patients who have survived a cardiac
arrest due to VT or VF or who have
spontaneous sustained VT causing
syncope or haemodynamic compromise





Risk stratification with the HCM
Risk-SCD calculator is recommended to
estimate the risk of sudden death at 5
years in patients ≥16 years of age
without a history of resuscitated VT or






It is recommended that the 5-year risk of
SCD is assessed at first evaluation and at
1- to 2-year intervals, or when there is a
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ICD implantation should be considered
in patients with an estimated 5-year risk
of sudden death ≥6% and a life
expectancy .1 year following detailed
clinical assessment that takes into
account the lifelong risk of complications
and the impact of an ICD on lifestyle,





ICD implantation may be considered in
individual patients with an estimated
5-year risk of SCD of ≥4 to ,6% and a
life expectancy .1 year following
detailed clinical assessment that takes
into account the lifelong risk of
complications and the impact of an ICD






ICD implantation may be considered
in individual patients with an estimated
5-year risk of SCD ,4% when they
have clinical features that are of
proven prognostic importance and
when an assessment of the lifelong
risk of complications and the impact
of an ICD on lifestyle, socioeconomic
status and psychological health






Invasive EPS with PVS is not
recommended for stratification of SCD
risk.
III C 116
ESC ¼ European Society of Cardiology; EPS ¼ electrophysiological study; HCM
¼ hypertrophic cardiomyopathy; ICD ¼ implantable cardioverter defibrillator;
PVS ¼ programmed ventricular stimulation; SCD ¼ sudden cardiac death; VF ¼




dESC guidelines define competitive sport as amateur or professional engagement
in exercise training on a regular basis and participation in official competitions
(see relevant ESC guidelines for more detail).
7.2.3 Ventricular arrhythmias in hypertrophic
cardiomyopathy
NSVT occurs in 25% of patients during ambulatory ECG monitor-
ing.373,374 Its prevalence increases with age and correlates with LV
wall thickness and late gadolinium enhancement on CMR.375
NSVT during ambulatory monitoring is associated with an increased
risk of SCD.373 Documented NSVT during or immediately following
exercise is very rare, but may be associated with a higher risk of
SCD.376
Documented sustained monomorphic VT (≥30 s) is uncommon,
but may be more frequent in patients with apical LV aneurysms. The
presence of CAD should be excluded in patients with prolonged or
symptomatic episodes if risk factors for coronary atherosclerosis
are present.377 Patients with poorly tolerated sustained VT should
be considered for ICD therapy and treatment with beta-blockers
or amiodarone to suppress further episodes. In patients with evi-
dence for a focal origin of their VT, EPS and ablation may be
considered.
7.2.4 Approach to risk stratification and management in
adults patients
Historically the risk of SCD in patients with HCM has been esti-
mated using a simple score based on a number of selected clinical
parameters.367,378,379 Other clinical features, such as myocardial fi-
brosis (determined by contrast-enhanced CMR), LV apical aneur-
ysms and multiple sarcomere protein gene mutations, have been
suggested as features that can be used to guide ICD therapy in indi-
viduals who are at intermediate risk, with few supportive data. ESC
guidelines on HCM recommend the use of a calculator (HCM
Risk-SCD) that estimates 5-year risk.116
The predictor variables used in the model are all associated with
an increased risk of SCD in at least one published multivariable ana-
lysis (http://doc2do.com/hcm/webHCM.html). The calculator is de-
signed specifically for use in patients ≥16 years of age and is not
intended for use in elite athletes or in individuals with metabolic
or infiltrative diseases (e.g. Anderson–Fabry disease) and syn-
dromes (e.g. Noonan syndrome). The model does not use
exercise-induced LVOT gradients and has not been validated before
and after myectomy or alcohol septal ablation.
Invasive EPS with PVS does not contribute to SCD risk stratifica-
tion in HCM and its routine use in patients with syncope or symp-
toms suggestive of arrhythmia is not recommended.116
In contrast with the recently released HCM guidelines,116 we
have not incorporated a class III recommendation for patients
with an estimated risk ,4% at 5 years, in consideration of the de-
gree of uncertainty in estimating risk that calls for caution when ex-
cluding a category of patients from the use of ICD.
7.2.5 Approach to risk stratification and management in
paediatric patients
In patients ,16 years of age, implantation of an ICD (epicardial if
necessary) is recommended after a life-threatening VA. Few data
are available on the use of clinical risk markers to guide primary
prophylaxis, particularly in very young children (,8 years of age).
Current ESC guidelines recommend that severe LV hypertrophy
(defined as a maximum LV wall thickness ≥30 mm or a Z-score
≥6), unexplained syncope, NSVT and a family history of sudden
death should be considered as major risk factors for SCD in chil-
dren.116 Implantation of an ICD should be considered in children
who have two or more of these major risk factors. In individual pa-
tients with a single risk factor, ICD implantation may be considered
after careful consideration of the risks and benefits to the child.
Single-chamber defibrillators suffice in the majority of cases and re-
duce the likelihood of complications.116
7.2.6 Prevention of sudden cardiac death
7.2.6.1 Drugs and lifestyle advice
Patients with HCM should be advised against participation in com-
petitive sports and discouraged from intense physical activity, espe-
cially when they have recognized risk factors for SCD or an LVOT
gradient. There are no RCTs of anti-arrhythmics in HCM. Amiodar-
one possibly reduces the incidence of SCD in patients with NSVT
during ambulatory ECG monitoring but often failed to prevent
SCD in many studies.380,381 Disopyramide and beta-blockers are
used to treat LVOT obstruction, but there is no evidence that
they reduce the risk of SCD.116 Similarly, current ESC guidelines
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on HCM do not recommend surgical myectomy or alcohol ablation
to reduce risk of SCD in patients with LVOT obstruction.116
7.2.6.2 Implantable cardioverter defibrillators
Secondary prophylaxis. While there are no trials of ICD therapy in
HCM, observational cohort studies and meta-analyses show that
aborted cardiac arrest or sustained VT are associated with a high
risk of subsequent lethal cardiac arrhythmias.368 For this reason,
ICDs are recommended in this small group of patients.116
Primary prophylaxis. It is recommended that patients with HCM
undergo a standardized clinical evaluation in line with the ESC guide-
lines on HCM.116 This should include a clinical and family history,
48-h ambulatory ECG, transthoracic echocardiography (or CMR
in the case of inadequate echo windows) and a symptom-limited ex-
ercise test. Recommendations for ICD therapy are based on the
5-year SCD risk calculated using the HCM Risk-SCD model and tak-
ing into account the age and general health of the patient.
7.3 Arrhythmogenic right ventricular
cardiomyopathy
7.3.1 Definitions, epidemiology and survival
ARVC (or arrhythmogenic cardiomyopathy) is a progressive heart
muscle disorder characterized by VA, HF and SCD.382 The histological
hallmark of the disease is replacement of cardiomyocytes by adipose
and fibrous tissue.382,383 Clinically, ARVC is defined by structural and
functional abnormalities of the right ventricle, but LV involvement oc-
curs in.50% of patients.384 Current task force criteria use histologic-
al, genetic, electrocardiographic and imaging parameters to classify
patients into definite, borderline and possible diagnostic categories.382
In most cases ARVC is inherited as an autosomal dominant gen-
etic trait caused by mutations in genes encoding for desmosomal
proteins (plakoglobin), desmoplakin, plakophilin-2, desmoglein-2
and desmocollin-2. A minority of cases are caused by mutations in
non-desmosomal genes and rare recessive forms (e.g. Carvajal syn-
drome and Naxos disease) associated with a cutaneous phenotype
of palmar and plantar hyperkeratosis.52
ARVC has an estimated prevalence of 1 in 1000 to 1 in 5000 of
the general population and is an important cause of SCD in athletes
and young adults.385,386 Clinical manifestations, including palpita-
tions, syncope, VT and SCD, usually develop between the second
and fourth decade of life. Disease progression may result in right
or biventricular HF. The annual mortality rate reported in different
studies varies considerably, depending on the characteristics of re-
ported cohorts. Data from one meta-analysis reported an annual-
ized rate for cardiac mortality, non-cardiac mortality and heart
transplantation of 0.9, 0.8 and 0.9%, respectively.387
7.3.2 Approach to risk stratification and management
Risk stratification and management of patients with
arrhythmogenic right ventricular cardiomyopathy
Recommendations Classa Levelb Ref.c
Avoidance of competitive sportsd
is recommended in patients with
ARVC.
I C 388
Beta-blockers titrated to the maximally
tolerated dose are recommended as
the first-line therapy to improve






ICD implantation is recommended in
patients with a history of aborted SCD
and haemodynamically poorly tolerated
VT.
I C 389
Amiodarone should be considered to
improve symptoms in patients with
frequent PVC or NSVT who are





Catheter ablation, performed in
experienced centres, should be
considered in patients with frequent
symptomatic PVC or VT unresponsive
to medical therapy to improve








ICD implantation should be considered
in ARVC patients who have
haemodynamically well-tolerated
sustained VT, balancing the risk of ICD
therapy, including long-term






ICD implantation may be considered in
patients with one or more recognized
risk factors for VA in adult patients with a
life expectancy .1 year following
detailed clinical assessment that takes
into account the lifelong risk of
complications and the impact of an ICD






Invasive EPS with PVS may be




ARVC ¼ arrhythmogenic right ventricular cardiomyopathy; EPS ¼
electrophysiological study; ESC ¼ European Society of Cardiology; ICD ¼
implantable cardioverter defibrillator; NSVT ¼ non-sustained ventricular
tachycardia; PVC ¼ premature ventricular complexes; VA ¼ ventricular




dESC guidelines define competitive sport as amateur or professional engagement
in exercise training on a regular basis and participation in official competitions
(see relevant ESC guidelines for more detail).
7.3.3 Ventricular arrhythmias in arrhythmogenic right
ventricular cardiomyopathy
Up to two-thirds of patients have VAs on resting or ambulatory ECG
monitoring and exercise testing.396–399 These VAs are usually of RV
origin (i.e. show a left bundle branch morphology), but the QRS axis
during VT usually differs from the QRS axis in RVOT,400 and many pa-
tients have multiple QRS morphologies. In a recent prospective regis-
try of patients predominantly treated with an ICD, most appropriate
therapies were for sustained monomorphic VT.401
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7.3.3.1 Treatment of ventricular arrhythmia
Few systematic data are available on the efficacy of anti-arrhythmic
drugs in ARVC and the impact of medical therapy on mortality is
unknown. Based largely on serial PVS testing, beta-blockers—
in particular sotalol—are conventionally recommended as
the first approach in patients with frequent ventricular ectopy
or NSVA.391 However, in a recent observational registry
neither beta-blockers nor sotalol seemed to reduce VA;390 amio-
darone was superior in preventing VA in a small cohort of
patients.390
Invasive electrophysiological testing with voltage mapping can be
used to identify regions of fibro-fatty replacement and to guide cath-
eter ablation of VA.202,207,392,402 Acute suppression of VT is more
often successful in patients presenting with a single or only a few se-
lected dominant VT morphologies and epicardial ablation may in-
crease success rates. As neither anti-arrhythmic drugs nor
catheter ablation provides sufficient protection against SCD, abla-
tion should be used to reduce the frequency of arrhythmia episodes
rather than to improve prognosis.
7.3.3.2 Exercise restriction
Endurance training at a competitive level probably exacerbates the
phenotype of ARVC.81,403 Therefore, while there are no controlled
trials demonstrating a beneficial effect, avoidance of high-level en-
durance training is recommended.
7.3.3.3 Implantable cardioverter defibrillators
Most studies on risk stratification and ICD therapy are retrospective
and of selected and relatively small high-risk cohorts recruited from
single centres. Many also provide little information on the indication
for an ICD. In a recent systematic review (24 studies) and
meta-analysis (18 studies) of 610 patients followed for a mean per-
iod of 3.8 years,387 the annualized appropriate ICD intervention rate
was 9.5%. Difficult ICD lead placement was reported in 18.4% of
cases, with lead malfunction, infection and displacement occurring
in 9.8, 1.4 and 3.3% of cases, respectively. The annual rate of in-
appropriate ICD intervention was 3.7%.
Patients with a history of aborted SCD, poorly tolerated VT and
syncope have the greatest risk of SCD (up to 10% per annum) and
ICD therapy is recommended in this group.387 Other risk factors for
SCD or appropriate ICD discharge reported in different cohorts in-
clude documented sustained VT, unexplained syncope, frequent
NSVT, a family history of premature sudden death, extensive RV dis-
ease, marked QRS prolongation, late gadolinium enhancement on
CMR (including LV involvement), LV dysfunction and VT induction
during EPS.113,114,387,389,395,404– 406 Compound or digenic heterozy-
gosity occurs in .10% of carriers of the ARVC-causing desmo-
somal gene mutation and may be a risk factor for major
arrhythmic events and SCD.407 As the studies examining outcomes
in ARVC are so diverse, recommendations on ICD therapy for pri-
mary prophylaxis are challenging. Based on available data, the con-
sensus is that patients with unexplained syncope should be
considered for an ICD. For patients without syncope, an ICD may
be considered following detailed clinical assessment that takes
into account family history, severity of RV and LV function, lifelong
risk of complications and impact of an ICD on lifestyle, socio-




Recommendation Classa Levelb Ref.c
An ICD should be considered in patients
with light-chain amyloidosis or hereditary
transthyretin associated cardiac
amyloidosis and VA causing haemodynamic
instability who are expected to survive .1








The two main types of cardiac amyloidosis are light-chain amyloid-
osis, caused by deposition of monoclonal light chains, and hereditary
transthyretin-associated amyloidosis, in which normal (wild-type)
or mutant transthyretin is deposited in the myocardium.413,414 Until
quite recently, cardiac amyloidosis was associated with a very poor
prognosis, with a median survival of ,1 year after the onset of HF
symptoms, but advances in therapy for light-chain amyloidosis have
improved survival.415
Up to half of all patients with cardiac amyloidosis die suddenly.413,416
Death is often attributed to electromechanical dissociation, but case re-
ports describe successful termination of sustained VA with ICDs.408 VAs
during ambulatory monitoring are reported in .25% of patients with
cardiac amyloidosis,409–411 but their presence does not seem to predict
SCD. Elevated levels of cardiac troponins and N-terminal pro-B-type
natriuretic peptide are sensitive markers of cardiac involvement and pre-
dict adverse outcome in patients with light-chain amyloidosis, but there
are no data to suggest that these biomarkers can be used to identify pa-
tients who might benefit from an ICD. Based on such limited data, ICDs
should be considered in patients with light-chain amyloidosis or heredi-
tary transthyretin-associated amyloidosis that experience sustained VA
and have a life expectancy .1 year. There are insufficient data to pro-
vide recommendations on primary prophylaxis.
7.5 Restrictive cardiomyopathy
Restrictive cardiomyopathy
Recommendations Classa Levelb Ref.c
An ICD is recommended in patients with
restrictive cardiomyopathy and
sustained VA causing haemodynamic
instability who are expected to survive
.1 year with good functional status to





ICD ¼ implantable cardioverter defibrillator; SCD ¼ sudden cardiac death;
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The term restrictive cardiomyopathy refers to hearts in which
there is restrictive physiology, normal or reduced diastolic vo-
lumes of one or both ventricles, normal or reduced systolic vo-
lumes and normal ventricular wall thickness. Restrictive
cardiomyopathy is the least common of all the cardiomyopathies
and is caused by a number of genetic and acquired disorders.412
In western societies, the most common cause in adults is amyloid-
osis followed by mutations in sarcomeric protein genes and meta-
bolic disorders.421
Patients with restrictive cardiomyopathy typically present with
signs and symptoms of biventricular HF and are diagnosed by char-
acteristic features on non-invasive cardiac imaging and cardiac cath-
eterization. Restrictive cardiomyopathy is associated with poor
long-term prognosis. In children, freedom from death at 1, 2 and
5 years is 82, 80 and 68%, respectively;417 –420 the corresponding va-
lues for transplant-free survival are 48, 34 and 22%, respectively.
There are fewer data in adults, but reported survival rates are similar
at 5 years. Risk factors for all-cause death include NYHA functional
class, left atrial size and male sex.417 –420 In children, the risk of sud-
den death may be higher, particularly in those with ECG evidence of
myocardial ischaemia.
The treatment of restrictive cardiomyopathy is mostly palliative.
HF symptoms are treated with diuretics and heart rate control to
optimize LV filling. Anticoagulation should be used in all patients
with AF. There are no prospective data on prophylactic implantation
of ICDs in restrictive cardiomyopathy, so for patients with symp-
tomatic sustained VA, indications for ICD should be similar to those
for other heart muscle disease, taking into account the short-term
prognosis related to HF. Primary prophylaxis should be determined




Non-compaction refers to the presence of prominent ventricular
trabeculations and deep intertrabecular recesses in the left and/or
right ventricle, which are often associated with a thin compacted
epicardial myocardial layer.422 In some patients, non-compaction
is associated with ventricular dilatation and systolic dysfunction.
LV non-compaction occurs in association with congenital cardiac
disorders and in an isolated form. Familial disease occurs in 18–
50% of adults with isolated LV non-compaction, mostly with an
autosomal dominant pattern of inheritance. Numerous mutations
in genes encoding sarcomere proteins, calcium-handling proteins
and other cardiomyopathy-related genes such as LMNA, LDB3
and Taffazin are reported.423
Many patients with LV non-compaction are completely asymp-
tomatic, but some present with HF, thromboembolism, arrhythmias
or SCD. Increased age, LV end diastolic diameter at presentation,
symptomatic HF, permanent or persistent AF, bundle branch block
and associated neuromuscular disease are reported predictors for
increased mortality, but there are few data to suggest that LV non-
compaction by itself is an indication for an ICD.422 – 425 The need for
an ICD should be guided by the severity of LV systolic dysfunction




Recommendations Classa Levelb Ref.c
An ICD should be considered in patients
with Chagas cardiomyopathy and an
LVEF ,40% when they are expected to










Chagas disease is a myocardial disease caused by the parasite Trypa-
nosoma cruzi. Worldwide, 8–10 million people are currently
estimated to be infected and 20–40% will develop chronic myocar-
dial disease, sometimes many decades after the initial infection. Con-
duction system abnormalities, including RBBB and left anterior
fascicular block, are often the earliest manifestations, followed by
segmental LV wall-motion abnormalities, complex VA, sinus node
dysfunction and more advanced conduction abnormalities. In the la-
ter stages of the disease there is progressive LV dilatation and systol-
ic dysfunction.426– 430
Reported annual mortality rates for patients with Chagas disease
vary from 0.2 to 19.2%, reflecting the characteristics of the different
study populations. The most consistent independent predictors of
death are LV dysfunction, NYHA functional class and NSVT. The
risk associated with the combination of NSVT and LV dysfunction
may be as high as 15-fold.
Primarily thanks to the study by Gali et al.,430 examining the effect
of ICDs in patients with Chagas disease, evidence has been obtained
that the greatest benefit is in patients with an LVEF,40%, although
most patients with an ICD received appropriate therapies regard-
less of their LV systolic function.
8. Inherited primary arrhythmia
syndromes
8.1 Long QT Syndrome
8.1.1 Definitions and epidemiology
Diagnosis of Long QT Syndrome (in the absence of
secondary causes for QT prolongation)
Recommendations Classa Levelb Ref.c
LQTS is diagnosed with either
– QTc ≥480 ms in repeated 12-lead
ECGs or
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LQTS is diagnosed in the presence of a
confirmed pathogenic LQTS mutation,





ECG diagnosis of LQTS should be
considered in the presence of a QTc
≥460 ms in repeated 12-lead ECGs in
patients with an unexplained syncopal
episode in the absence of secondary









This panel has modified the diagnostic criteria for LQTS proposed in
the EHRA/Heart Rhythm Society consensus document.14 Specifically,
it was felt that a QTc .500 ms—suggested as the threshold for diag-
nosis of LQTS in asymptomatic patients without a family history of the
disease—is very conservative and is identical to the QT duration as-
sociated with a high risk for arrhythmic events in SCD.1,67 According-
ly, we have used a corrected QT (QTc) ≥480 ms or a score .3431
for clinical diagnosis. In the presence of unexplained syncope, how-
ever, a QTc ≥460 ms is sufficient to make a diagnosis.
LQTS is characterized by a prolonged QT interval and VAs mainly
triggered by adrenergic activation. The mean age at presentation is
14 years. The annual rate of SCD in patients with untreated LQTS is
estimated to be between 0.3367 and 0.9%,432 whereas that for syn-
cope is estimated to be 5%.432
Mutations in 13 genes have been associated with LQTS, most en-
coding for subunits of potassium, sodium or calcium voltage-
dependent ion channels. Genetic screening identifies a disease-causing
mutation in 75% of LQTS cases and three main genes (KCNQ1, KCNH2
and SCN5A) account for 90% of positively genotyped cases.52
The subtypes of LQTS may be grouped into the following three
categories:
† Autosomal dominant LQTS (Romano–Ward syndrome; preva-
lence 1 in 2500), which includes LQT1–6 and LQT9–13 and is
characterized by an isolated prolongation of the QT interval;
† Autosomal dominant LQTS with extracardiac manifestation,
comprising
– LQT7 (Andersen–Tawil syndrome), which shows a pro-
longed QT interval with prominent U wave, polymorphic
or bidirectional VT, facial dysmorphisms and hyper-/hypo-
kalaemic periodic paralysis433 and
– LQT8 (Timothy syndrome), characterized by prolonged QT,
syndactyly, cardiac malformations, autism spectrum disorder
and dysmorphisms;
† Autosomal recessive LQTS (Jervell and Lange–Nielsen syn-
drome), which combines an extremely prolonged QT interval
with congenital deafness.
8.1.2 Approach to risk stratification and management
Risk stratification and management in Long QT
Syndrome
Recommendations Classa Levelb Ref.c
The following lifestyle changes are
recommended in all patients with a
diagnosis of LQTS:
(a) Avoidance of QT-prolonging drugs
(http://www.crediblemeds.org).
(b) Correction of electrolyte
abnormalities (hypokalaemia,
hypomagnesaemia, hypocalcaemia)
that may occur during
diarrhoea, vomiting or metabolic
conditions.
(c) Avoidance of genotype-specific
triggers for arrhythmias (strenuous
swimming, especially in LQTS1, and
exposure to loud noises in LQTS2
patients).
I B 434
Beta-blockers are recommended in
patients with a clinical diagnosis of LQTS.
I B 435
ICD implantation with the use of beta-
blockers is recommended in LQTS




Beta-blockers should be considered in
carriers of a causative LQTS mutation
and normal QT interval.
IIa B 67
ICD implantation in addition to
beta-blockers should be considered in
LQTS patients who experienced
syncope and/or VT while receiving an
adequate dose of beta-blockers.
IIa B 439
Left cardiac sympathetic denervation
should be considered in patients with
symptomatic LQTS when
(a) Beta-blockers are either not
effective, not tolerated or
contraindicated;
(b) ICD therapy is contraindicated or
refused;
(c) Patients on beta-blockers with an
ICD experience multiple shocks.
IIa C 440
Sodium channel blockers (mexiletine,
flecainide or ranolazine) may be
considered as add-on therapy to shorten





Implant of an ICD may be considered in
addition to beta-blocker therapy in
asymptomatic carriers of a pathogenic
mutation in KCNH2 or SCN5A when
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Invasive EPS with PVS is not
recommended for SCD risk
stratification.
III C 117
EPS ¼ electrophysiological study; ICD ¼ implantable cardioverter defibrillator;
LQTS ¼ long QT syndrome; LQTS1 ¼ long QT syndrome type 1; LQTS2 ¼
long QT syndrome type 2; LQTS3 ¼ long QT syndrome type 3; PVS ¼
programmed ventricular stimulation; QTc ¼ corrected QT; VT ¼ ventricular




Clinical, electrocardiographic and genetic parameters should be con-
sidered for the stratification of individual risk.67 Survivors of a cardiac
arrest have a high risk of recurrence, even when receiving beta-
blockers (14% within 5 years on therapy): this evidence supports the
use of ICDs in survivors of cardiac arrest.436 The occurrence of synco-
pal events is associated with an increased risk of cardiac arrest.439,444
Women with LQTS have an increased risk during the 9-month post-
partum period (especially women with the LQT2 genotype).445 In
LQT1 and LQT2 patients, the location and type of mutation may be
associated with different risks of cardiac events. However, these find-
ings require further study before application in clinical practice.14 Silent
carriers of pathogenic mutations present a modest risk of cardiac
events estimated at 10% between birth and age 40 years; the use
of beta-blockers should be considered in this group of patients.446
Prophylactic ICD therapy may be considered, on an individual
basis, in high-risk patients such as women with LQT2 and QTc
.500 ms, patients with QTc .500 ms and signs of electrical in-
stability and patients with high-risk genetic profiles (carriers of
two mutations, including Jervell and Lange–Nielsen syndrome or
Timothy syndrome).
There are no data supporting any prognostic value for invasive
EPS with PVS in patients with LQTS.117
8.2 Short QT syndrome
8.2.1 Definitions and epidemiology
Diagnosis of Short QT Syndrome
Recommendations Classa Levelb Ref.c
SQTS is diagnosed in the presence of a




SQTS should be considered in the
presence of a QTc ≤360 ms and one or
more of the following:
(a) A confirmed pathogenic mutation
(b) A family history of SQTS
(c) A family history of sudden death at
age ,40 years
(d) Survival from a VT/VF episode in the





QTc ¼ corrected QT; SQTS ¼ short QT syndrome; VF ¼ ventricular




SQTS is characterized by a reduced duration of cardiac repolariza-
tion, which constitutes the substrate for the development of life-
threatening arrhythmias. Five genes have been linked to SQTS
(KCNH2, KCNQ1, KCNJ2, CACNA1C and CACNB2b), but the yield
of genetic screening remains low (20% overall).119
The disease appears to be highly lethal in all age groups, including
children in their first months of life, and the probability of a first car-
diac arrest by the age of 40 years is.40%.119,447 Given the small size
of the populations reported so far, the high lethality may partially re-
flect a reporting bias related to the underdetection of SQTS in
asymptomatic patients.
8.2.2 Approach to risk stratification and management
Risk stratification and management in Short QT
Syndrome
Short QT Syndrome
Recommendations Classa Levelb Ref.c
ICD implantation is recommended
in patients with a diagnosis of SQTS
who
(a) Are survivors of an aborted cardiac
arrest, and/or





Quinidine or sotalol may be considered
in patients with a diagnosis of SQTS
who qualify for an ICD but present a





Quinidine or sotalol may be considered
in asymptomatic patients with a





Invasive EPS with PVS is not





EPS ¼ electrophysiological study; ICD ¼ implantable cardioverter defibrillator;
PVS ¼ programmed ventricular stimulation; SCD ¼ sudden cardiac death; SQTS




SQTS patients who survive a previous cardiac arrest should receive
an ICD for secondary prevention, because the rate of recurrence of
cardiac arrest has been estimated at 10% per year.119
The optimal strategy for primary prevention of cardiac arrest in
SQTS is unclear, given the lack of independent risk factors for car-
diac arrest, including syncope.119 No data are available to quantify
the risk of arrhythmic events during competitive physical activity
in SQTS patients.
An ICD might be considered on a case-by-case basis in patients
with SQTS with a strong family history of SCD and evidence for ab-
breviated QTc in at least some of the patients, but there are not en-
ough data to make generalized recommendations.14
Reports on small cohorts of patients suggest that quinidine therapy
can prolong the QTc interval and possibly reduce arrhythmic events.
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Patients on quinidine should be carefully monitored for QT prolonga-
tion and possible pro-arrhythmic events.118,448 The use of quinidine
may be considered in survivors of cardiac arrest who qualify for an
ICD but present a contraindication to the ICD or refuse it.118,448
So far there are no data supporting the role of PVS for predicting
arrhythmic events.
8.3 Brugada syndrome
8.3.1 Definitions and epidemiology
Diagnosis of Brugada Syndrome
Recommendations Classa Levelb Ref.c
Brugada syndrome is diagnosed in
patients with ST-segment elevation with
type 1 morphology ≥2 mm in one or
more leads among the right precordial
leads V1 and/or V2 positioned in the
second, third, or fourth intercostal
space, occurring either spontaneously or
after provocative drug test with
intravenous administration of sodium
channel blockers (such as ajmaline,








The prevalence of Brugada syndrome seems to be higher in South-
east Asia than in western countries; the prevalence ranges from 1 in
1000 to 1 in 10 000.449
Brugada syndrome is inherited as a dominant trait and shows age-
and sex-related penetrance: clinical manifestations of the disease are
more frequent in adults and they are eightfold more frequent in men
than in women.450 VF occurs at a mean age of 41+ 15 years but it
may manifest at any age, usually during rest or sleep.451 Fever, exces-
sive alcohol intake and large meals are triggers that unmask a type I
ECG pattern and predispose to VF.
In a recent meta-analysis, the incidence of arrhythmic events (sus-
tained VT or VF or appropriate ICD therapy or sudden death) in pa-
tients with Brugada syndrome was 13.5% per year in patients with a
history of sudden cardiac arrest, 3.2% per year in patients with syn-
cope and 1% per year in asymptomatic patients.452
At least 12 genes have been associated with Brugada syndrome,
but only two (SCN5A and CACN1Ac) individually account for.5% of
positively genotyped patients.52 Results of genetic screening do not
currently influence prognosis or treatment.
8.3.2 Approach to risk stratification and management
Risk stratification and management in Brugada
Syndrome
Recommendations Classa Levelb Ref.c
The following lifestyle changes are
recommended in all patients with a
diagnosis of Brugada syndrome:
(a) Avoidance of drugs that may induce
ST-segment elevation in right
precordial leads (http://
www.brugadadrugs.org)
(b) Avoidance of excessive alcohol intake
and large meals






ICD implantation is recommended in
patients with a diagnosis of Brugada
syndrome who
(a) Are survivors of an aborted cardiac
arrest and/or
(b) Have documented spontaneous
sustained VT.
I C 451
ICD implantation should be considered
in patients with a spontaneous diagnostic
type I ECG pattern and history of
syncope.
IIa C 451
Quinidine or isoproterenol should be
considered in patients with Brugada
syndrome to treat electrical storms.
IIa C 453
Quinidine should be considered in
patients who qualify for an ICD but
present a contraindication or refuse it
and in patients who require treatment
for supraventricular arrhythmias.
IIa C 454
ICD implantation may be considered in
patients with a diagnosis of Brugada
syndrome who develop VF during PVS
with two or three extrastimuli at two
sites.
IIb C 120
Catheter ablation may be considered in
patients with a history of electrical





ECG ¼ electrocardiogram; ICD ¼ implantable cardioverter defibrillator; PVS ¼
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The only treatment able to reduce the risk of SCD in Brugada syn-
drome is the ICD, therefore the device is recommended in patients
with documented VT or VF and in patients presenting with a spon-
taneous type 1 ECG and a history of syncope.14,451 The prognostic
value of PVS has been debated and most clinical studies have not
confirmed either a positive or a negative predictive value for the
occurrence of cardiac events at follow-up.14,456 Quinidine has
been proposed as preventive therapy in patients with Brugada syn-
drome, based on data showing that it reduces VF inducibility during
PVS; however, there are no data confirming its ability to reduce the
risk of SCD. Recently it has been suggested that epicardial catheter
ablation over the anterior RVOT may prevent electrical storms in
patients with recurring episodes, but the data require confirmation
before entering general clinical practice.455
8.4 Catecholaminergic polymorphic
ventricular tachycardia
8.4.1 Definitions and epidemiology
Diagnosis of catecholaminergic polymorphic
ventricular tachycardia
Recommendations Classa Levelb Ref.c
CPVT is diagnosed in the presence of a
structurally normal heart, normal ECG
and exercise- or emotion-induced




CPVT is diagnosed in patients who are
carriers of a pathogenic mutation(s) in
the genes RyR2 or CASQ2.
I C 14,52
CPVT ¼ catecholaminergic polymorphic VT; ECG ¼ electrocardiogram;




CPVT is a rare inheritable arrhythmogenic disorder characterized
by adrenergic-induced bidirectional and polymorphic VT. The dis-
ease has an estimated prevalence of 1 in 10 000.14
Two genetic types of CPVT have been identified: a dominant
variant due to mutations in the gene encoding for the cardiac ryano-
dine receptor gene (RyR2) and a rare recessive variant caused by
mutation in the cardiac calsequestrin gene (CASQ2).52 Mutations
in other genes such as KCNJ2, Ank2, TRDN and CALM1 have been
identified in patients with clinical features similar to CPVT. How-
ever, at the present time it is not clear whether they are pheno-
copies of CPVT.14
The clinical manifestations of CPVT usually occur in the first dec-
ade of life and are prompted by physical activity or emotional
stress.458 Diagnosis is challenging because patients with CPVT
have a normal ECG and echocardiogram, therefore an exercise
stress test that elicits atrial arrhythmias and VA (bidirectional or
polymorphic VT) is recommended to establish the diagnosis.14
The use of catecholamine infusion has also been suggested, but its
sensitivity is not clearly defined,14,459 therefore we have not estab-
lished a recommendation on this specific issue.
8.4.2 Approach to risk stratification and management
Risk stratification and management in
Catecholaminergic Polymorphic Ventricular
Tachycardia
Recommendations Classa Levelb Ref.c
The following lifestyle changes are
recommended in all patients with a
diagnosis of CPVT: avoidance of






Beta-blockers are recommended in all
patients with a clinical diagnosis of






ICD implantation in addition to
beta-blockers with or without flecainide
is recommended in patients with a
diagnosis of CPVT who experience






Therapy with beta-blockers should be
considered for genetically positive family





Flecainide should be considered in
addition to beta-blockers in patients
with a diagnosis of CPVT who
experience recurrent syncope or
polymorphic/bidirectional VT while on
beta-blockers, when there are risks/
contraindications for an ICD or an ICD
is not available or rejected by the
patient.
IIa C 463
Flecainide should be considered in
addition to beta-blockers in patients
with a diagnosis of CPVT and carriers of
an ICD to reduce appropriate ICD
shocks.
IIa C 463
Left cardiac sympathetic denervation
may be considered in patients with a
diagnosis of CPVT who experience
recurrent syncope or polymorphic/
bidirectional VT/several appropriate
ICD shocks while on beta-blockers or
beta-blockers plus flecainide and in





Invasive EPS with PVS is not
recommended for stratification of
SCD risk.
III C 14
CPVT ¼ catecholaminergic polymorphic ventricular tachycardia;
EPS ¼ electrophysiological study; ICD ¼ implantable cardioverter defibrillator;
PVS ¼ programmed ventricular stimulation; SCD ¼ sudden cardiac death;
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Diagnosis in childhood, the lack of beta-blocker therapy and the persist-
enceof complex arrhythmiasduring theexercise stress testona full dose
of beta-blockers are independent predictors for arrhythmic events.461
Most referral centres treat patients with nadolol, even though
comparative data on different types of beta-blockers are not available.
Exercise restriction and beta-blockers without intrinsic sympatho-
mimetic activity are the first-line therapy for patients with CPVT.14
Preliminary data suggest that flecainide significantly reduces the
VA burden in a limited number of patients with CPVT and should
be considered as the first addition to beta-blockers when control
of arrhythmias is incomplete.462,463 Left cardiac sympathetic denerv-
ation seems to have some degree of efficacy in the management of
patients with CPVT intolerant to beta-blockers, but more data and
longer follow-up are needed to quantify its efficacy.464,465 Survivors
of cardiac arrest should receive beta-blockers and an ICD; flecainide
should also be considered if arrhythmic control in the exercise
stress test is incomplete.14 An ICD should also be considered in pa-
tients with CPVT who do not respond to beta-blockers and flecai-
nide.14 The ICD should be programmed with long delays before
shock delivery, because painful shocks can increase the sympathetic
tone and trigger further arrhythmias, leading to a malignant cycle of
ICD shocks and even death.466
PVS has no diagnostic or prognostic value in CPVT, as neither bi-
directional nor polymorphic VT is inducible.14
8.5 Early repolarization syndrome
8.5.1 Definitions and epidemiology
The presence of an early repolarization pattern in the inferior
and/or lateral leads has been associated with idiopathic VF in
case–control studies.467,468 Owing to the high incidence of the early
repolarization pattern in the general population, it seems reasonable
to diagnose an ‘early repolarization syndrome’ only in patients with a
pattern who are resuscitated from a documented episode of idio-
pathic VF and/or polymorphic VT.
The genetics of early repolarization are probable polygenic in
many instances. No clear evidence of familial transmission of the
early repolarization syndrome exists.
Given the uncertainties in the interpretation of the early
repolarization pattern as a predictor of SCD, this panel of experts
has decided that there is insufficient evidence to make recommen-
dations for management of this condition at this time.
9. Paediatric arrhythmias and
congenital heart disease
9.1 Management of ventricular
arrhythmias in children with a structurally
normal heart
Management of ventricular arrhythmias in children
with a structurally normal heart
Recommendations Classa Levelb Ref.c
It is recommended that asymptomatic
children with frequent isolated PVCs or
an accelerated ventricular rhythm
and normal ventricular function




Medical therapy or catheter ablation is
recommended in children with frequent






Catheter ablation should be considered
when medical therapy is either not
effective or undesired in symptomatic
children with idiopathic RVOT VT/





Catheter ablation by experienced
operators should be considered after
failure of medical therapy or as an
alternative to chronic medical therapy in
symptomatic children with idiopathic





Sodium channel blockers (class IC
agents) should be considered as an
alternative to beta-blockers or
verapamil in children with outflow
tract VT.
IIa C 471
Catheter ablation is not recommended
in children ,5 years of age except
when previous medical therapy fails or
when VT is not haemodynamically
tolerated.
III B 475
The use of verapamil is not
recommended in children ,1 year
of age.
III C 476
LVOT ¼ left ventricular outflow tract; PVC ¼ premature ventricular complex;
RVOT ¼ right ventricular outflow tract; VA ¼ ventricular arrhythmia;




In children, VAs may occur in congenital heart diseases (CHDs), in-
heritable channelopathies or cardiomyopathies, myocarditis and
cardiac tumours (neonatal rhabdomyomas), as well as in structurally
normal hearts. In otherwise healthy children, isolated monomorphic
PVCs are very common, particularly in infants (20%) and teenagers
(20–35%), originating primarily from the RVOT. When PVCs occur
frequently (5–10% of all beats) or are more complex, cardiac evalu-
ation including CMR and family history taking is recommended to
exclude inheritable channelopathies or cardiomyopathies. Follow-
up is recommended to identify the development of LV dysfunction,
(non-)sustained VT or cardiomyopathies, which seldom occur.
Medical treatment or catheter ablation is rarely indicated since
most children remain asymptomatic and PVCs often resolve in
time.469,470,477 – 480 Accelerated idioventricular rhythm can be found
in otherwise healthy newborns and infants, usually as a coincidental
finding. It is a benign arrhythmia and, similar to PVCs in infants, gen-
erally disappears without treatment in the first year of life.481 The
reported incidence of sustained VT in the general paediatric popu-
lation is 1 per 100 000 children in 10 years. The prevalence of non-
sustained and sustained VT is also low, at 2–8 per 100 000
schoolchildren.482,483
Most idiopathic VTs first present in older children and teenagers,
with similar sites of origin as in adults (RVOT, LVOT or aortic cusps).
Verapamil-sensitive left fascicular VT is less common.471 – 474
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Incessant VT, commonly originating from the LV, is associated with in-
tracardiac hamartomas in infancy. These tachycardias often lead to HF
and have significant mortality despite aggressive drug therapy, cath-
eter ablation and even surgical therapy.484 Polymorphic VT or multi-
form PVC occur infrequently in children with normal hearts and are
usually associated with inheritable channelopathies or cardiomyop-
athies, structural or inflammatory heart disease or metabolic or toxi-
cological abnormalities.
In older children, recommendations regarding treatment of idio-
pathic VTs are similar to those for adults. In young children, studies
on the efficacy and safety of drug treatment of idiopathic VTs are
limited mainly to beta-blockers and verapamil, with less data avail-
able on sodium channel blockers (class IC) and class III drugs.471,472
In infants ,1 year of age, (i.v.) verapamil should be avoided because
it may lead to acute haemodynamic deterioration.476
In young children, complication rates of catheter ablation appear
to be higher and there is concern regarding the growth of
radiofrequency and cryo-energy lesions in the ventricular myocar-
dium.475,485 – 487 Idiopathic VTs and complex PVC in children tend
to resolve spontaneously within months to years.471 Therefore, in
this age group, catheter ablation, including ‘simple’ RVOT–VT abla-
tion, is only indicated as second-line therapy and should be per-
formed in experienced centres.
9.2 Sudden cardiac death and ventricular
arrhythmias in patients with congenital
heart disease
Prevention of sudden cardiac death and management
of ventricular arrhythmias in patients with congenital
heart disease
Recommendations Classa Levelb Ref.c
After evaluation to define the cause of
the event and exclude any reversible
causes, ICD implantation is
recommended for patients with CHD





ICD implantation is recommended for
patients with CHD with symptomatic






Catheter ablation is recommended as
additional therapy or an alternative to
ICD in patients with CHD who have
recurrent monomorphic VT or
appropriate ICD therapies that are not
manageable by device reprogramming or
drug therapy.
I C 492
ICD therapy is recommended in adults
with CHD and a systemic LVEF ,35%,
biventricular physiology, symptomatic
HF despite optimal medical treatment




ICD implantation should be
considered in patients with CHD with
syncope of unknown origin in the
presence of either advanced ventricular
dysfunction or inducible sustained VT





ICD implantation should be considered
in selected patients with tetralogy of
Fallot and multiple risk factors for SCD,
including LV dysfunction, non-sustained
VT, QRS duration .180 ms or inducible





Catheter ablation should be considered
as an alternative to drug therapy
for symptomatic sustained
monomorphic VT in patients with
CHD and an ICD.
IIa B 492
ICD therapy may be considered in
patients with advanced single or
systemic RV dysfunction in the presence
of other risk factors such as
non-sustained VT, NYHA functional






PVS may be considered for risk
stratification of SCD in patients with
tetralogy of Fallot who have one or
more risk factors among LV dysfunction,
non-sustained VT and QRS duration
.180 ms.
IIb B 496
PVS may be considered in patients with
CHD and non-sustained VT to





Surgical ablation guided by
electrophysiological mapping may be
considered in patients with CHD
undergoing cardiac surgery, with clinical
sustained VT and with inducible






Catheter ablation or prophylactic
anti-arrhythmic therapy is not
recommended for asymptomatic
infrequent PVC in patients with CHD





PVS is not recommended to stratify the
risk in patients with CHD in the absence
of other risk factors or symptoms.
III B 496
AV ¼ atrio-ventricular; CHD ¼ congenital heart disease; HF ¼ heart failure;
ICD ¼ implantable cardioverter defibrillator; LV ¼ left ventricular; LVEF ¼ left
ventricular ejection fraction; PVS ¼ programmed ventricular stimulation; PVC ¼
premature ventricular complex; NYHA ¼ New York Heart Association; RV ¼
right ventricular; SCD ¼ sudden cardiac death; VA ¼ ventricular arrhythmia; VF




CHD is the most common birth defect, with an incidence of
700–800 per 100 000 live births.499 Patients with CHD represent
a heterogeneous group whose life expectancy has improved
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dramatically following advances in diagnosis and surgical techni-
ques. The majority of patients with CHD will live to adulthood.500
Despite these successes, the repair of CHD in childhood is often
followed by the development of HF and arrhythmias, which may
cause late cardiac mortality in young adulthood.
The incidence of SCD in the total CHD population is low (0.09%
per year) but is higher than in age-matched controls.501 The risk of
SCD is time dependent and progressively increases after the second
decade of life. Thus far, no RCTs have been performed to delineate
risk factors for SCD or the benefit of primary prevention therapies.
Retrospective studies have demonstrated that SCD accounts for
14–26% of all deaths after initial repair.497,501 – 503 In a large study
of adults with a range of CHDs, SCD related to arrhythmias oc-
curred in 14%. SCD occurred mostly at rest and was not limited
to patients with severe defects. In this study, risk factors for SCD
were similar to those in ischaemic cardiomyopathy, including supra-
ventricular tachycardia, systemic or pulmonary ventricular dysfunc-
tion and prolonged QRS duration.497
The congenital heart defects with the highest risk of SCD are tet-
ralogy of Fallot, (congenitally corrected) transposition of the great
arteries, left heart obstructed lesions and univentricular
hearts.497,501 – 503 Most studies on risk assessment have been per-
formed in patients with tetralogy of Fallot, showing a risk of SCD
of 2–3% per decade, increasing late after operative correc-
tion.495,501,504 Although many risk factors have been identified, the
strongest risk factors for SCD are a QRS duration.180 ms, RV vol-
ume overload, LV dysfunction or clinical or inducible sustained
VT.494 – 496 PVS is reported to be useful for risk assessment.496
Retrospective studies on ICD therapy in tetralogy of Fallot have re-
ported high appropriate shock rates of 8–10% per year for primary
and secondary prevention.488
In patients with transposition of the great arteries after
the atrial switch operation (Mustard or Senning), the risk of
SCD is 5% per decade.501,505 The presence of atrial tachyar-
rhythmia and systemic RV failure are important risk factors for
SCD.498 Underlying mechanisms for SCD are atrial tachyarrhyth-
mia with rapid 1 : 1 AV conduction deteriorating to VF, as well as
primary VA. Currently catheter ablation of atrial tachycardia is an
effective therapy and relevant for lowering the risk of SCD in this
group of patients. PVS does not seem useful for general risk
stratification. ICDs for secondary prevention appear to be effect-
ive, whereas primary prevention ICD therapy for patients with
ventricular dysfunction seems less useful, with a shock rate of
0.5% per year.489 Nowadays, atrial switch is not used and conse-
quently this population of patients is gradually declining in
number.
Adequate repair of congenital aortic stenosis (including
the bicuspid valves) substantially reduces the native risk of SCD, of-
ten obviating the need for specific anti-arrhythmic therapy.501,506
In patients with univentricular hearts after the Fontan
operation, long-term morbidity is characterized by complex
atrial tachycardia and the development of HF, progressively
increasing with age. Arrhythmia-related SCD is not rare in
Fontan patients, with a reported incidence of 9% during a mean
follow-up of 12 years, but no risk factors have yet been identified.507
Data on the efficacy of ICD therapy in Fontan patients remain
scarce.
In general, ICD therapy in patients with CHD has shifted
from secondary to primary prevention in the last two dec-
ades.490,491 Retrospective cohort studies have shown that in
addition to VA, an impaired ventricular function, either left or
right, has become a consistent risk factor for SCD in patients
with different types of CHD.493 – 495,497,498 This emphasizes
the importance of effectively treating ventricular dysfunction
by surgical interventions of residual defects, optimizing medica-
tion and, if applicable, CRT. In general, patients with CHD with
syncope or non-sustained VT should undergo haemodynamic
and electrophysiological evaluation. PVS can be useful to iden-
tify patients at risk for SCD. Catheter ablation and surgical ther-
apies should be considered as an alternative or in addition to an
ICD in patients with recurrent sustained VT after surgical repair
of CHD.492
9.3 Implantable cardioverter defibrillator
therapy in paediatric patients
Implantable cardioverter defibrillator in paediatric
patients
Recommendations Classa Levelb Ref.c
ICD implantation is recommended for
paediatric patients who are survivors of






ICD implantation in combination with
medical therapy is recommended for







Periodic defibrillation threshold testing
of non-transvenous ICD systems should
be considered during growth in young
children.
IIa C 512




SCD is a rare phenomenon in paediatric patients and the use of
ICDs is therefore uncommon, with an annual implantation rate of
,1 per million508,513 for primary or secondary prevention.490,509
Paediatric patients at risk of SCD form a heterogeneous group
with a wide variety of underlying cardiac diseases, including inherit-
able channelopathies or cardiomyopathies, and the broad spectrum
of CHD.490,509 Current indications for ICD therapy in adults are
being applied to paediatric patients. Most recommendations for
cardiac diseases relevant for the paediatric population have a level
of evidence of B or C.
In contrast to adult guidelines, ICDs are not used routinely in
paediatric patients with DCM and advanced LV dysfunction because
of the low incidence of SCD in this age group.514,515 Interpretation
and comparison of results of paediatric ICD series remain difficult
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because ICD therapy is often evaluated for a variety of conditions
and often includes adults with CHD. Several paediatric ICD series
have reported appropriate shocks for secondary prevention in
40–67% of patients. When ICD therapy was used for primary pre-
vention, the appropriate shock rates ranged from 10 to 26% during a
mean follow-up of 2–4 years.490,508,510,511,516 –519
Lead fractures and insulation breaks, vascular problems, infections
and late increases in the defibrillation threshold are more common in
the paediatric population than in adults, likely due to their higher ac-
tivity levels, smaller body size and growth.520 Large studies have re-
ported annual rates of lead fracture of 5.3 and 6.5%, with age ,8
years and the Fidelisw lead as independent risk factors.521,522 In
most paediatric series, the reported incidence of inappropriate
shocks is remarkably high, ranging from 17 to 30%.490,508,511,516–519
Inappropriate shocks due to sinus tachycardia, supraventricular ar-
rhythmias and T-wave oversensing are common and can be reduced
by individual programming, in particular using higher detection rates. In
older paediatric patients, as in adults, transvenous dual-chamber ICD
systems are mostly used. In younger patients, single-chamber systems
are commonly used to avoid venous obstruction, leaving a loop of the
ICD lead in the right atrium to allow for growth. In infants and small
children, alternative non-transvenous ICD systems seem safe and ef-
fective.512 These systems are constructed by the insertion of the gen-
erator into the abdomen, a subcutaneous array in the left thorax and
placement of the ventricular lead epicardially.508,512 Other variants
have also been reported.508 Late increases in the defibrillation thresh-
old occur more frequently with the use of these alternative systems,
and periodic defibrillation threshold testing should be considered.512
CRT has become an important adjunct to the treatment of HF in
paediatric patients, most commonly when there is an indication for
antibradycardia pacing.523,524 CRT-D therapy may be beneficial in
selected patients, in particular in the postoperative CHD popula-
tion, but data supporting its use are scarce.
10. Ventricular tachycardias
and ventricular fibrillation in
structurally normal hearts
10.1 Outflow tract ventricular
tachycardia
Treatment of outflow tract ventricular tachycardia
Recommendations Classa Levelb Ref.c
Catheter ablation of RVOT VT/PVC is
recommended in symptomatic patients
and/or in patients with a failure of
anti-arrhythmic drug therapy (e.g.
beta-blocker) or in patients with a





Treatment with sodium channel blockers






Catheter ablation of LVOT/aortic cusp/
epicardial VT/PVC by experienced
operators after failure of one or more
sodium channel blockers (class IC
agents) or in patients not wanting
long-term anti-arrhythmic drug therapy






LV ¼ left ventricular; LVOT ¼ left ventricular outflow tract; PVC ¼ premature





The ventricular OTs are the most common origins of idiopathic VT/
PVC.525,534 – 536 Approximately 70% originate from the RVOT.536
Other origins include the aortic sinuses of Valsalva,537 – 540
LVOT,539 – 541 great cardiac veins,195,539,541 epicardial myocar-
dium,195,539,541,542 aorta-mitral continuity529,543 and rarely the pul-
monary artery.544 – 546 Idiopathic focal OT–VT usually occurs in
patients without structural heart disease, however, subtle wall ab-
normalities have been demonstrated on CMR imaging in some pa-
tients.547,548 They have a focal mechanism secondary to
automaticity, micro-re-entry or triggered activity.549 – 552 Idiopathic
RVOT–VT typically presents between the ages of 20 and 50 years
and more frequently in women.553 There are two typical forms: ex-
ercise/stress-induced VT and repetitive monomorphic VT occurring
at rest. Repetitive NSVT occurs in 60–92% of cases while incessant
VT occurs only occasionally.549 –552
Paroxysmal sustained VT separated by long periods of infrequent
PVCs is less common. Episodes increase in frequency and duration
during exercise and/or emotional stress; exercise tests may provoke
focal OT–VT during the exercise or recovery phases. Typical QRS
morphology is an inferior axis with dominant LBBB morph-
ology.525,534– 541 PVCs or the first beat of VT generally have relative-
ly long coupling intervals to the preceding QRS complex.553 VT is
monomorphic, however, the QRS morphology may vary slightly.
Multiple distinct VT morphologies are very rare and raise the suspi-
cion for scar-related VT, such as in ARVC.535 Although idiopathic
OT–VT follows a benign course, malignant VT may occasionally oc-
cur.551,553 ECG during sinus rhythm is usually normal, however,
10% have complete or incomplete RBBB.554 Exercise testing
and cardiac imaging should be performed to exclude the presence
of underlying structural heart disease, and cardiac catheterization
may be warranted in some cases.
Treatment is only warranted if patients are symptomatic. It is
worth noting that symptoms may be related to LV dysfunction, con-
sidering that idiopathic VT may be a cause of tachycardia-induced
cardiomyopathy.555 In such patients, treatment with sodium channel
blockers (class IC agents) or catheter ablation should be considered.
In patients with RVOT–VT/PVCs, primary catheter ablation should
be recommended, whereas in patients with LVOT–VT/PVCs, cath-
eter ablation should only be considered after failed anti-arrhythmic
therapy.
The close anatomical proximity of the RVOT, LVOT and
great cardiac veins limits precise localization of the VT origin
based on QRS morphology except for classic RVOT tachycardia.
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Precise localization should be guided by activation mapping and/or
pacemapping during an EPS532,537 – 540 and should begin in
the RVOT (including the pulmonary artery sinus), followed by
the great cardiac veins, aortic cusps and endocardial LVOT.
When ablation at a site with early ventricular activation does
not eliminate the clinical arrhythmia, epicardial mapping may be
considered.
10.1.1 Right ventricular outflow tract tachycardias
Clinically, RVOT–VTs have shorter cycle lengths and are more
likely to be associated with syncope compared with LVOT ar-
rhythmias.550 – 552 The typical RVO–VT/PVC ECG has a later R/S
transition at V4 compared with LVOT–VT/PVC. In published re-
ports, acute RVOT–VT/PVC catheter ablation success rates are
.95% in patients without structural heart disease when per-
formed by experienced operators;525,534 – 540 however, only lim-
ited long-term follow-up data are available.527,528 Reported
complication rates are low, with only very rare cases of RVOT
rupture, particularly at the free wall.525 Therefore, in symptomatic
patients with surface ECGs highly suggestive of RVOT tachyar-
rhythmia, an EPS is recommended and primary catheter ablation
should be performed when the mapping has confirmed an
RVOT–VT/PVC origin.
10.1.2 Left ventricular outflow tract tachycardias
LVOT–VT/PVC ablation requires an in-depth understanding and
careful mapping, including the LVOT, aortic cusps, pulmonary artery
and epicardium.532,556 The septal LVOT, although primarily muscu-
lar, includes the membranous ventricular septum. The posterior
quadrant consists of an extensive fibrous curtain. The lateral and an-
terior LVOT are muscular structures. Epicardially the left anterior
descending and left circumflex coronary arteries lie superior to
the aortic portion of the LVOT and occupy the most superior por-
tion of the LV, termed the LV summit by McAlpine.557 This is a major
source of idiopathic VT/PVCs. Typically LVOT–VT/PVCs have an
inferior axis with early transition at V1/V2 and LBBB or RBBB
(70% and 30%, respectively).195,529,530,532,533,537– 543,558
Complication rates of catheter ablation are not negligible and in-
clude major complications such as myocardial rupture and tampon-
ade, stroke, valvular damage and coronary artery damage. As a
combined transseptal and retrograde approach for complete
mapping and ablation may be required due to anatomical complex-
ity, LVOT ablation should only be performed in highly experienced
ablation centres after use of at east one sodium channel blockers
(class IC agents) has failed.532
10.1.3 Aortic cusp ventricular tachycardias
VT originating within the sinuses of Valsalva accounts for 20% of
idiopathic OT–VTs, most from the left coronary cusp, followed by
the right coronary cusp, right coronary cusp/left coronary cusp
junction and rarely the fibrous non-coronary cusp.195,529,537 – 543
ECGs typically show broad QRS with early transition at V1–
V2.537,538 The main complication from ablation within the aortic
cusps is the acute occlusion of the left main coronary artery. It is
therefore important to identify the coronary ostium of the left
main and/or right coronary artery by angiography, intracardiac
echocardiography or CT before ablation. A margin .6 mm from
the left main coronary artery should be observed, using convention-
al energy with power titration. Aortic valve injury has been rarely
reported.559 So far, complication rates have been low and are likely
to have been underreported, as these arrhythmias are generally per-
formed in highly experienced centres. Therefore ablation should
only be performed after failure of at least one sodium channel block-
er (class IC agents).
10.1.4 Epicardial outflow tract ventricular tachycardias
An epicardial approach should be considered only after unsuccess-
ful endocardial ablation of OT–VT/PVCs.195,530,539 – 541,558 Most
focal epicardial VTs originate adjacent to the great cardiac veins
or coronary arteries,195,539 – 541 and coronary artery injury is a
major concern.531,560 – 562 The overlying left atrial appendage
and epicardial fat pads can also be anatomical obstacles to
ablation.
10.1.5 Others (including pulmonary arteries)
Successful ablation of VT originating from the pulmonary artery has
only been described in case reports and series.544 – 546 However,
there is no myocardium in this region with the exception of
that in the pulmonary sinuses.556 ECG recordings typically show
LBBB with tall R waves in the inferior leads and transition in V4/
V5.544 – 546 Complication rates of catheter ablation, generally per-
formed in highly experienced centres, are unknown due to the small
number of patients concerned.
10.2 Ventricular tachycardias of
miscellaneous origin
Treatment to prevent recurrence of idiopathic
ventricular tachycardia
Recommendations Classa Levelb Ref.c
Catheter ablation by experienced
operators is recommended as a first-line







When catheter ablation is not available
or desired, treatment with
beta-blockers, verapamil or sodium
channel blockers (class IC agents) is
recommended in symptomatic patients






verapamil or sodium channel blockers
(class IC agents) is recommended in







verapamil or sodium channel
blockers (class IC agents) is
recommended in symptomatic patients
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Catheter ablation under echo guidance
by experienced operators after failure of
one or more sodium channel blockers
(class IC agents) or in patients refusing
long-term anti-arrhythmic drug therapy
should be considered in symptomatic





Catheter ablation by experienced
operators after failure of one or more
sodium channel blockers (class IC
agents) or in patients not wanting
long-term anti-arrhythmic drug should
be considered in symptomatic patients










10.2.1 Idiopathic left ventricular tachycardia
Monomorphic and polymorphic idiopathic left VT may occur in pa-
tients with and without underlying structural heart disease. These
may be divided into different entities: verapamil-sensitive left fasci-
cular VT, bundle branch re-entry tachycardia, interfascicular VT
and focal Purkinje VT.582
The most common form is left posterior fascicular VT (.90%),
occurring predominantly in young patients without structural heart
disease. On the surface ECG, left posterior fascicular VT appears
with RBBB morphology, a superior axis and a narrow QRS complex.
Catheter ablation in experienced centres is recommended as a first-
line treatment since left posterior fascicular VT affects mostly young
patients and long-term drug-based treatment with verapamil is not
effective.563 – 567 Recurrence rates after successful ablation range
from 0 to 20%.564,568 –570
Left anterior fascicular VT and left upper septal fascicular VT are
responsible for ,10% and ,1%, respectively, of left fascicular VTs.
On the surface ECG, left anterior fascicular VT is characterized by
RBBB morphology and right-axis deviation, whereas left upper sep-
tal fascicular VT demonstrates a narrow QRS complex and a normal
axis or right-axis deviation. In both types of VT, catheter ablation
is recommended as a first-line treatment in experienced ablation
centres.571 – 573
Bundle branch re-entry tachycardia is usually found in patients
with pre-existing intraventricular conduction defects such as pro-
longed His-ventricular intervals or bundle branch block.346,347,574
Bundle branch re-entry tachycardia is amenable to catheter ablation
either within the left bundle or (more commonly) by right bundle
branch ablation, at least in experienced centres, and commonly re-
sults in non-inducibility and can be considered curative.346,347,575
ICD implantation is generally not indicated in patients with normal
hearts.
10.2.2 Papillary muscle ventricular tachycardia
Idiopathic VTs or PVCs may arise from the RV or LV papillary
muscles in a small number of patients.576 – 578 When originating
from the left posterior papillary muscle, they usually present
with RBBB morphology and a right or left superior QRS axis
and a QRS duration .150 ms.576 In the case of non-
responsiveness to sodium channel blockers (class IC agents)
and/or beta-blockers, catheter ablation of PVCs or VTs arising
from the papillary muscles is an effective treatment option.578
However, catheter stability during mapping and ablation in the re-
gion of the papillary muscles is challenging. A transseptal approach
and guidance by intracardiac echocardiography should be strongly
considered. Mitral regurgitation after successful ablation is a po-
tential but rare complication.
10.2.3 Annular ventricular tachycardia (mitral and
tricuspid)
The mitral annulus is responsible for 5% of all idiopathic PVCs and
VTs.534,579 – 581 The QRS complex usually presents with an RBBB
pattern, a persistent S wave in lead V6 and pre-cordial R-wave tran-
sition in lead V1 or in some cases between leads V1 and V2. The in-
cidence of a tricuspid annulus origin is described with up to 8% of all
idiopathic VTs and PVCs.581 Tachycardia presents usually with LBBB
morphology and left-axis deviation. In the case of an insufficient re-
sponse to class IC anti-arrhythmic drugs and/or beta-blockers, cath-
eter ablation (performed in experienced centres) at the earliest site
of ventricular activation or at a site with a perfect pace map is an ef-
fective treatment option for mitral as well as tricuspid annular
tachycardias.581
10.3 Idiopathic ventricular fibrillation
Treatment of idiopathic ventricular fibrillation
Recommendations Classa Levelb Ref.c
ICD implantation is recommended in




Catheter ablation of PVCs triggering
recurrent VF leading to ICD
interventions is recommended when





Catheter ablation of PVCs leading to
electrical storm is recommended






ICD ¼ implantable cardioverter defibrillator; SCD ¼ sudden cardiac death; PVC




Idiopathic VF is a diagnosis by exclusion, but may change in the fu-
ture due to better diagnostics of underlying structural heart disease
or new evidence of ion channel defects. ICD implantation is strongly
recommended for secondary prevention.
Anti-arrhythmic drug therapy using beta-blockers and/or class III
anti-arrhythmic drugs may potentially reduce, but rarely prevent, re-
current VF episodes.154 In patients with VF and underlying structural
heart disease, as well as in patients with idiopathic VF, PVC originat-
ing from various locations within the Purkinje system or from the
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RVOT can be identified as triggers and potential targets for catheter
ablation.467,584 – 588 Catheter ablation of the PVC triggering recur-
rent VF should be considered in patients with frequent VF episodes,
but relies on the presence of such extrasystolic beats during the
procedure, mostly after a VF episode or VF storm. In patients with-
out spontaneous PVCs, a pre-interventional 12-lead Holter ECG is
recommended to document the morphology of the contractions
and guide ablation.
A long-term success rate of 82%, defined as the absence of
VF, polymorphic VT or SCD, after a follow-up of .5 years
has been reported.586,588 Irrespective of the results of catheter
ablation, all patients with idiopathic VF should undergo ICD
implantation.
10.4 Short-coupled torsade de pointes
Treatment of short-coupled torsade de pointes
Recommendations Classa Levelb Ref.c
ICD is recommended in patients with
conclusive diagnosis of short-coupled
TdP.
I B 589
Intravenous verapamil to acutely
suppress/prevent an electrical storm or





Catheter ablation for long-term
suppression/prevention of an electrical
storm or recurrent ICD discharges
should be considered.
IIa B 586




Short-coupled TdP is a rare variant of polymorphic VT of unknown
aetiology. TdP is characterized by its typical ECG pattern in the form
of non-uniform but organized electrical activity with progressive
changes in its morphology, amplitude and polarity. Short-coupled
TdP is characterized by an extremely short-coupled interval of
the first premature ventricular contraction (,300 ms) initiating
the tachycardia. This predominantly affects young patients who of-
ten present with unclear syncope and a positive family history for
SCD.589 – 591 In most cases, TdP deteriorates into VF. Although
the mechanisms are not yet well understood, there may be a link
to an autonomic nervous system imbalance.592 Intravenous verap-
amil seems to be the only drug that can suppress the arrhythmia,
but it does not reduce the risk of SCD.590,591 Consequently, ICD im-
plantation is strongly recommended.589 In cases of recurrence of VA
triggered by monomorphic premature ventricular contractions des-
pite drug therapy, catheter ablation should be strongly considered.
The ablation target is the PVC initiating TdP.
11. Inflammatory, rheumatic and
valvular heart diseases
Management of ventricular arrhythmias in
inflammatory heart disease
Recommendations Classa Levelb Ref.c
It is recommended that patients with a
life-threatening presentation of
sustained ventricular tachyarrhythmias
in the context of clinically suspected
myocarditis are referred to specialized
centres with the ability to perform
haemodynamic monitoring, cardiac
catheterization and endomyocardial
biopsy and to use mechanical





Temporary pacemaker insertion is
recommended in patients with
bradycardia and/or heart block





Anti-arrhythmic therapy should be
considered in patients with
symptomatic non-sustained or
sustained VT during the acute phase of
myocarditis.
IIa C 594
The implant of an ICD or pacemaker
in patients with inflammatory
heart diseases should be





In patients with haemodynamically
compromising sustained VT occurring
after the resolution of acute episodes,
an ICD implantation should be
considered if the patient is expected to
survive .1 year with good functional
status.
IIa C 8
A wearable defibrillator should be
considered for bridging until full
recovery or ICD implantation in
patients after inflammatory heart
diseases with residual severe LV





ICD implantation may be considered
earlier in patients with giant cell
myocarditis or sarcoidosis who had
haemodynamically compromising
sustained VA or aborted cardiac arrest,
due to adverse prognosis of these
conditions, if survival .1 year with
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Demonstration of persistent myocardial
inflammatory infiltrates by
immunohistological evidence and/or
abnormal localized fibrosis by CMR
after acute myocarditis may be
considered as an additional indicator of
increased risk of SCD in inflammatory
heart disease.
IIb C 601
CMR ¼ cardiac magnetic resonance; ICD ¼ implantable cardioverter
defibrillator; LV ¼ left ventricular; SCD ¼ sudden cardiac death; VA ¼





Myocarditis is the pathological result of myocardial infection and/or
autoimmunity that causes active inflammatory destruction of myo-
cytes. Aetiologically, a wide spectrum of infectious agents, including
viruses, bacteria, chlamydia, rickettsia, fungi and protozoans, as well
as toxic and hypersensitivity reactions might be involved.609 Enter-
oviruses (Coxsackie B), adenoviruses, parvovirus B19 and human
herpes virus type 6 are among the most common causal
agents. Myocarditis can occur also in patients with advanced HIV in-
fections due to cardiotoxicity with cellular apoptosis induced by
viral glycoprotein 120, opportunistic infections, autoimmune
response, drug-related cardiac toxicity and possibly nutritional
deficiencies.609,610
The typical microscopic image required for the diagnosis of myo-
carditis consists of the presence of inflammatory cells together with
necrotic myocytes. According to the World Health Organization
report, myocarditis is defined as inflammatory disease of the myo-
cardium diagnosed by established histological, immunological and
immunohistochemical criteria.611 In the same document, myocardi-
tis associated with cardiac dysfunction is referred to as inflammatory
cardiomyopathy, and both definitions are recommended for use by
the relevant ESC recommendations.593
Thus endomyocardial biopsy remains the gold standard for the
definite diagnosis of myocarditis and should be performed especially
in patients with a life-threatening course of the disease. CMR is be-
coming routine and is a sensitive, non-invasive test for confirmation
of acute myocarditis even before endomyocardial biopsy. Essential
first-line tests to confirm the diagnosis in patients with a clinical
presentation consistent with myocarditis should include 12-lead
ECG, transthoracic echocardiogram and assessment of biomarker
concentrations (including troponins), erythrocyte sedimentation
rate and C-reactive protein. The diagnosis of myocarditis should
be based on the criteria summarized by Caforio et al.593
In the acute stage of disease, myocarditis may be asymptomatic or
present with an unrecognized non-specific course. Considering ma-
lignant arrhythmias associated with myocarditis, two distinct clinical
settings have to be distinguished:
† Acute fulminant myocarditis with refractory malignant ventricu-
lar tachyarrhythmias in the context of severe acute HF, and
adverse short-term prognosis with early death due to multisys-
tem failure.
† Long-term evolution to inflammatory cardiomyopathy with LV
dysfunction and resulting in a high risk of SCD similar to that
for DCM.
11.1.1 Acute and fulminant myocarditis
Management of HF and potentially fatal arrhythmias is the main clin-
ical challenge in acute myocarditis. Patients with fulminant myocar-
ditis have a high acute mortality and a severe risk of life-threatening
refractory ventricular tachyarrhythmias. In patients who initially pre-
sent with an HF syndrome suggestive of first DCM manifestation and
in whom possible or probable acute myocarditis is suspected, sup-
portive measures with a recommendation to avoid exercise and use
of pharmaceutical treatment with neurohormonal blockade with
ACE inhibitors and beta-blockers is recommended. Progressive
wall motion abnormalities with deteriorating LV function on echo-
cardiography, persistent or fluctuating cardiac troponin concentra-
tions, widening of the QRS complex and frequent non-sustained VA
may precede a sustained life-threatening arrhythmia in the setting of
acute myocarditis.594,612
Patients with VA or heart block in the setting of acute myocarditis
need prolonged ECG monitoring and must be admitted to hospital.
Lyme’s disease and diphtheria myocarditis are frequently asso-
ciated with various degrees of heart block, which can also trigger
ventricular tachyarrhythmias. Thus temporary pacemaker insertion
is recommended in patients with acute myocarditis who present
with symptomatic heart block (as with other causes of acute
symptomatic heart block). Pacing is recommended in patients
with symptomatic sinus node dysfunction or AV block following
myocarditis (as with other causes of sinus or AV node dysfunc-
tion). Ventricular tachyarrhythmias triggered by high-degree AV
block require temporary pacemaker insertion. If persistent AV
blocks develop, permanent pacing is recommended. However,
device selection should reflect the presence, extent and prognosis
(progression or regression) of LV dysfunction in order to appro-
priately choose a pacemaker or ICD with or without cardiac re-
synchronization capability. Owing to the adverse prognosis of
patients with giant cell myocarditis or sarcoidosis, the implantation
of an impulse generator may be considered earlier in these
patients.596
Fulminant myocarditis is a distinct clinical entity with an adverse
short-term but a relatively good long-term prognosis. Refractory
sustained arrhythmias are typical for the fulminant form of myocar-
ditis. According to a Japanese registry, the short-term survival rate
of patients with fulminant myocarditis was only 58%.595,613
Ventricular tachycardia was the most common sustained arrhyth-
mia in 2148 children with acute myocarditis, accounting for 76% of
314 cases with arrhythmias during the course of the disease. Patients
with sustained arrhythmias had a very high risk of cardiac arrest,
need for mechanical circulatory support and/or death compared
with patients without arrhythmias [OR 5.4 (95% CI 3.9, 7.4), P ,
0.001].596
Giant cell myocarditis is a severe form of myocarditis with a dra-
matic clinical course, frequently affecting young patients. The diag-
nosis is confirmed by endomyocardial biopsy showing the
presence of typical multinucleated giant cells in inflammatory le-
sions. Patients may develop heart block, requiring placement of tem-
porary or permanent pacemakers. However, refractory electrical
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storms with incessant VT or VF have a particularly adverse progno-
sis despite the use of aggressive anti-arrhythmic drug therapy.
Surprisingly, in a retrospective study among adult patients after
acute myocarditis, those with the fulminant form had a better long-
term prognosis than patients with non-fulminant myocarditis. After
11 years, 93% of patients with fulminant myocarditis were alive with-
out heart transplantation compared with only 45% with the non-
fulminant form.614
Aggressive haemodynamic support using percutaneous cardio-
pulmonary support or an intra-aortic balloon pump in addition to
drug therapy is recommended for patients with acute or fulminant
myocarditis to bridge the dramatic but often curable acute stage of
the disease. Percutaneous cardiopulmonary support should be
initiated if refractory VT or VF does not respond to three to five
defibrillation attempts.594
The important association between undiagnosed myocarditis and
SCD is emphasized by post-mortem data, which have implicated
myocarditis in SCD of young adults at rates of 8.6–44%.615 –618
Data on the causative agents are rare. Chlamydia myocarditis was
implicated in the sudden death of 5 of 15 young Swedish elite ath-
letes (orienteers) following the identification of chlamydial RNA in
their hearts.619
During the acute phase of myocarditis, ICD implantation should
be deferred until resolution of the acute episode. Because myocar-
ditis may heal completely, the indication for ICD implantation and its
timing remain controversial even beyond the acute stage. Bridging
the critical period to full recovery by a WCD vest in patients with
myocarditis and VT or VF appears to be a promising therapeutic op-
tion.598,599 The presence of malignant VA or heart block in giant cell
myocarditis or cardiac sarcoidosis might warrant earlier consider-
ation of an ICD due to the known high risk of arrhythmic death
or need for transplantation.600
11.1.2 Myocarditis leading to inflammatory
cardiomyopathy
Myocarditis has been identified as a cause of DCM in up to 10% of
cases in large prospective series. Importantly, inflammatory cardio-
myopathy is involved in the pathogenesis of DCM, with a poor prog-
nosis. In long-term follow-up studies of patients after acute
myocarditis, DCM developed in 21%.620
On the other hand, a viral genome was identified in the myocar-
dium of two-thirds of patients with ‘idiopathic’ LV dysfunction. Fur-
thermore, persisting cardiac viral infections may constitute a major
cause of progressive LV dysfunction in patients with DCM and with a
suspicion of prior myocarditis.621 However, these observations
were not confirmed by Kindermann et al.,597 who identified immu-
nohistological evidence of inflammatory infiltrates in the myocar-
dium as the primary factor associated with a three-fold or greater
increase in risk of cardiac death or heart transplantation. Over
5 years of follow-up, 61% of patients in NYHA functional class III
or IV with positive immunohistology and not receiving beta-blocker
therapy died or underwent heart transplantation.597
In patients with documented symptomatic sustained VT of un-
clear aetiology, myocarditis should also be suspected and a CMR
scan may reveal abnormal fibrotic myocardial tissue, frequently lo-
cated in subepicardial and intramural regions. In a cohort of 405 pa-
tients with suspected myocarditis, all of the patients who died
suddenly or experienced aborted SCD or ICD discharge had abnor-
mal CMR scans.601 Successful radiofrequency catheter ablation of
epicardial arrhythmogenic foci in myocarditis has been described
recently.622
Drug treatment of arrhythmias in patients with inflammatory
heart disease does not differ from generally accepted clinical princi-
ples. Arrhythmia management outside the acute phase should be in
line with current ESC guidelines on arrhythmia and device implant-
ation in chronic HF management.8 In general, the indications for an
ICD in inflammatory cardiomyopathy are the same as for non-
ischaemic DCM. In secondary prevention of SCD, implantation of
an ICD in patients with myocarditis is recommended after cardiac
arrest due to VF or after symptomatic VT. CRT-D is recommended
for primary prevention in patients with impaired LV function (LVEF
,35%) and LBBB in NYHA functional classes II– IV.8 As LV function
may improve over time in patients with inflammatory cardiomyop-
athy due to the natural course of the disease and/or appropriate HF
therapy, implantation of an ICD/CRT-D should not be indicated
prematurely.
11.2 Endocarditis
VAs in infective endocarditis are predictors of a very poor progno-
sis.623 However, there are no specific recommendations for their
management beyond the general principles. Abscess formation in
the valve annulus (more often aortic than mitral) can result in first-
or second-degree heart block. New-onset heart block in a patient
with endocarditis should raise the clinical suspicion of an abscess.
The acute haemodynamic compromise related to acute aortic re-
gurgitation secondary to endocarditis can result in sustained VT
and is an indication for early surgery.605
11.3 Rheumatic heart disease
Acute rheumatic fever can cause a pancarditis involving the pericar-
dium, myocardium and endocardium. There are no specific data on
VA in rheumatic heart disease and their management should follow
general principles.
Complete AV block during acute rheumatic fever is rare and usu-
ally transient. Temporary pacing should be considered when symp-
tomatic or when serious VAs are triggered.
11.4 Pericarditis
SCD can occur in the course of pericardial disease resulting from a
variety of pathological processes; these include both constrictive
and restrictive processes resulting from trauma, inflammation, neo-
plastic and infectious aetiologies. However, there is no evidence
linking specific VAs with pericardial disease. Furthermore, SCD in
these patients has mostly a haemodynamic and not an arrhythmic
cause.
11.5 Cardiac sarcoidosis
Cardiac sarcoidosis is a rare and difficult-to-diagnose clinical entity
with a wide spectrum of manifestations from subtle asymptomatic
ECG alterations to HF and SCD. Cardiac sarcoidosis is a rare cause
of VT (5% of all non-ischaemic cardiomyopathies referred for VT).
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Studies performed using voltage cardiac mapping have demon-
strated the presence of widespread and confluent RV scarring with
predominant epicardial location. Left ventricular scarring was patchier
in the basal septum, anterior wall and perivalvular regions. Such sub-
strate is capable of sustaining a large number of re-entrant circuits.
Catheter ablation in conjunction with anti-arrhythmic drugs is an
effective palliative therapy for terminating VT storm and eliminating
one or more inducible VTs in the majority of patients, but recur-
rences are common and these patients require ICD backup.624,625
11.6 Valvular heart disease
Management of ventricular arrhythmias in valvular
heart disease
Recommendations Classa Levelb Ref.c
The implantation of an ICD is
recommended in patients with valvular
heart disease who, after surgical repair,
satisfy the criteria for primary and




Surgical treatment of acute aortic
regurgitation due to endocarditis






An EPS with standby catheter ablation
should be considered in patients who
develop VT following valvular surgery in





EPS ¼ electrophysiological study; ICD ¼ implantable cardioverter defibrillator;




Valvular heart disease, both in the preoperative period and after valvu-
lar surgery, predisposes patients to VA. Aetiologically, increased myo-
cardial mass, ventricular dilatation and wall stress and subendocardial
ischaemia in the absence of CAD, together with chronic myocardial
damage and iatrogenic post-surgical fibrosis, may be responsible for
an increased incidence of complex ventricular tachyarrhythmias that
may be associated with sustained VT and SCD.606 Malignant arrhyth-
mogenic substrate may be further enhanced by frequent concomitant
structural heart disease, mainly CAD and HF.
In the past, several investigators described an increased incidence
of NSVT in patients with aortic and mitral valvular heart dis-
ease.626,627 In older studies on the natural history of valvular heart
disease, sudden death occurred in 15–20% of adult patients with
aortic stenosis, at an average age of 60 years. Among symptomatic
non-operated patients, sudden death occurs with a prevalence of up
to 34%.628,629 In one study, 60% of all cardiac deaths occurring dur-
ing non-surgical follow-up in patients with severe mitral regurgita-
tion were sudden.630
A study of 348 patients with mitral regurgitation due to flail leaflet
revealed that sudden death is not rare in conservatively managed
older patients. Since correction of this type of mitral regurgitation
appears to be associated with a reduced incidence of sudden death,
repair should be considered earlier, with a previous, mandatory and
careful search for accompanying CAD.631 After mitral regurgitation
repair, more than two episodes of NSVT during ambulatory moni-
toring were predictive of sudden death during a 9-year follow-up.632
Overall rates of SCD in patients with prosthetic valves vary consid-
erably, ranging from 15 to 30%, with an estimated annual risk of 0.2–
0.9%.633 In a large series of 1533 patients who underwent aortic or
mitral valve replacement, 6% of deaths were caused by arrhyth-
mias.634 In a US cooperative study, sudden death accounted for
23% of deaths for mitral valve replacement and 16% for aortic valve
replacement.635,636
Martinez-Rubio et al.607 demonstrated that inducibility of VT, to-
gether with LV volume overload, is predictive of malignant arrhyth-
mic events in patients presenting with VT, VF or syncope. An EPS is
of considerable clinical importance in patients who develop VT fol-
lowing valvular surgery. In up to 30% of patients, VT (occurring
mostly within 1 month of surgery) was due to bundle branch re-
entry—an arrhythmia that is potentially curable with catheter
ablation.608
Valvular heart disease as the presumably dominant aetiology con-
stituted 7% of patients referred for secondary prevention ICD im-
plantation.602 This single-centre experience has shown that 31
patients with valvular heart disease and malignant ventricular tachyar-
rhythmias protected with ICDs had a favourable outcome. Their sur-
vival was not inferior to patients with CAD and was more favourable
than that in patients with DCM.602 In the experience of Yang et al.,603
patients with valvular heart disease and residual LV dysfunction fol-
lowing valvular surgery who underwent a tailored approach to pri-
mary preventive ICD implantation had similar overall and
arrhythmia-free survival as patients with ischaemic cardiomyopathy.
More recently, it has been demonstrated that patients
with valvular heart disease who undergo ICD implantation
for primary or secondary SCD prevention have similar appropri-
ate ICD discharge rates and mortality as those with CAD or
DCM.604
12. Arrhythmic risk in selected
populations
12.1 Psychiatric patients
Arrhythmic risk in psychiatric patients
Recommendations Classa Levelb Ref.c
Dosage adjustment or interruption of
the offending agent is recommended
when, after treatment with antipsychotic
drugs, the QTc interval reaches a length
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Monitoring of plasma potassium levels to
avoid hypokalaemia is recommended
during treatment with antipsychotic
drugs.
I C 638
Avoidance of treatment with more than





Evaluation of the QT interval before
initiation of treatment and during titration











Patients with schizophrenia, anorexia nervosa and other mental
health disorders have a higher than expected incidence of sudden
death,643 believed to be related to both these diseases and to their
treatment. For instance, patients with schizophrenia have a three-
fold increase in the risk of SCD compared with the general popula-
tion.644 Moreover, a number of antipsychotic and antidepressant
drugs are known to increase the risk of VA and SCD,639 with the
principal mechanism believed to be TdP.645
Ray et al.646 studied the association between the use of anti-
psychotic drugs (mostly conventional antipsychotics) and sudden
death in .480 000 patients and found evidence for a dose-
dependent effect, with a higher risk in patients with cardiovascular
disease. In another recent large study by Ray et al.,647 the association
with sudden death was also demonstrated for atypical antipsycho-
tics, with a dose-dependent effect.
A recent study by Wu et al.639 enrolled 17 718 patients with inci-
dent VA and/or SCD to examine the effects of antipsychotic drugs
on the risk of VA/SCD. Antipsychotic drug use was associated with a
1.53-fold increased risk of VA and/or SCD (95% CI 1.38, 1.70; P,
0.005) and antipsychotics with a high potency of the human
ether-a-go-go-related gene potassium channel blockade had the
highest risk of VA and/or SCD (see Table 6).
12.1.2 Diagnosis
Drugs such as tricyclic antidepressants are associated with a greater
increase in QTc and TdP than selective serotonin reuptake inhibitors.
Severe sodium channel blockade and baseline risk factors, including
previous arrhythmias, impaired LV function, concurrent digoxin ther-
apy and hypokalaemia (diuretics), are frequently involved.638,642,648,649
The association of different drugs must be carefully monitored even if
these drugs are not known to prolong the QT interval.
12.1.3 Treatment
Anassessmentof cardiac riskprofile is recommended, and in thecaseof
positive findings, assessment by a cardiologist. After initiating drugs, a
heart check-up is recommended, and in the event of QTc prolongation
.500 ms or new cardiac symptoms, treatment should be re-
evaluated.641Useofconcomitantdrugs interactingwiththemetabolism
Table 6 Risk of ventricular arrhythmia and/or sudden cardiac death in relation to current antipsychotic use among
17,718 patients. With permission from Wu et al.639
Antipsychotic class and agent  Case period, N Control period, N Crude OR 95% CI Adjusted OR 95% CI
Use of Antipsychotics 5625 5117 1.84 1.67 to 2.03 1.53 1.38 to 1.70
First-generation Antipsychotics 2070 1770 2.02 1.76 to 2.33 1.66 1.43 to 1.91
Chlorpromazine 248 218 1.98 1.28 to 3.05 1.45 0.93 to 2.27
Clopenthixol 30 25 2.66 0.71 to 10.04 2.40 0.46 to 12.48
Clothiapine 135 117 2.68 1.33 to 5.39 2.16 1.03 to 4.53
Flupentixol 400 382 1.28 0.92 to 1.78 1.07 0.77 to 1.51
Haloperidol 833 730 1.83 1.47 to 2.27 1.46 1.17 to 1.83
Loxapine 14 14 1.00 0.14 to 7.10 0.49 0.04 to 5.87
Prochlorperazine 272 172 2.04 1.60 to 2.61 1.69 1.32 to 2.17
Thioridazine 194 173 2.17 1.24 to 3.79 1.78 1.01 to 3.15
87 73 1.88 1.02 to 3.44 1.37 0.73 to 2.57
Second-generation antipsychotics 4017 3736 1.63 1.45 to 1.84 1.36 1.20 to 1.54
Amisulpride 90 88 1.14 0.56 to 2.34 0.94 0.45 to 1.96
Aripriprazole 35 34 1.14 0.41 to 3.15 0.90 0.31 to 2.59
Clozapine 141 130 2.64 1.09 to 6.38 2.03 0.83 to 4.94
Olanzapine 245 221 2.01 1.23 to 3.29 1.64 0.98 to 2.72
Quetiapine 1421 1326 1.51 1.26 to 1.82 1.29 1.07 to 1.56
Risperidone 1163 1066 1.67 1.36 to 2.05 1.39 1.13 to 1.72
Sulpiride 1015 930 1.59 1.29 to 1.95 1.26 1.02 to 1.56
Ziprasidone 27 26 1.20 0.37 to 3.93 0.80 0.24 to 2.67
Zotepine 154 142 1.86 0.97 to 3.56 1.50 0.77 to 2.91
n ¼ number; CI ¼ confidence interval; OR ¼ odds ratio.
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of a QT-prolonging drug should be avoided. It is important to know all
co-medications, including those purchased over the counter.641
12.2 Neurological patients
12.2.1 Sudden unexplained death in epilepsy
Sudden unexplained death in epilepsy (SUDEP) is defined as a non-
accidental death in a person with epilepsy. Most cases occur at night
or during sleep and are not witnessed.650 The greatest risk factor for
SUDEP is frequent seizures, especially generalized tonic–clonic
seizures.651 – 660
Patients with epilepsy should undergo ECG screening to rule out
diseases that mimic epilepsy. Furthermore, epilepsy may also be
due to neurological channelopathy, providing potential inter-
action between ion channel abnormalities in the heart and the
brain.658,661 – 664 The best way to prevent SUDEP is to maximize
seizure control.
12.2.2 Neuromuscular disorders
Arrhythmic risk in patients with neuromuscular
disorders
Recommendations Classa Levelb Ref.c
Annual follow-up is recommended in
patients with muscular dystrophies, even
in the concealed phase of the disease





It is recommended that patients with
neuromuscular disorders who have VAs






Permanent pacemaker implantation is
recommended in patients with
neuromuscular diseases and
third-degree or advanced
second-degree AV block at any
anatomical level.
I B 669
Permanent pacemaker implantation may
be considered in patients with myotonic
dystrophy type 1 (Steinert disease),
Kearns–Sayre syndrome or limb-girdle
muscular dystrophy with any degree of
AV block (including first-degree) in






The use of an ICD may be considered in
myotonic dystrophy type 1 (Steinert
disease), Emery–Dreifuss and
limb-girdle type 1B muscular
dystrophies when there is an indication






AV ¼ atrio-ventricular; ECG ¼ electrocardiogram; ICD ¼ implantable




Muscular dystrophies are a group of inherited diseases affecting skel-
etal and cardiac muscle. Cardiac involvement occurs as a degenera-
tive process with fibrosis and fatty replacement of the
myocardium666 and the most frequent manifestations are dilated
cardiomyopathy and conduction defects, which may coexist. In all
the muscular dystrophies, respiratory muscle involvement can im-
pact quality and quantity of life and needs to be factored in when
considering a prophylactic device.
Cardiac involvement is frequent in most patients with Duchenne
and Becker dystrophies, myotonic dystrophy type 1 (Steinert
disease), Emery–Dreifuss and limb-girdle type 1B dystrophies666
(Table 7). The development of a dilated cardiomyopathy is common
in Duchenne and Becker muscular dystrophies.666 Arrhythmias
(ventricular premature beats and NSVT) and conduction disease
occur after the development of the dilated cardiomyopathy and
therefore arrhythmia management should be aligned with recom-
mendations issued for patients with DCM. In Duchenne muscular
dystrophy, sudden death occurs primarily in patients with both re-
spiratory and cardiac failure. The proportion of deaths due to ar-
rhythmias is uncertain, but VA and sudden death are believed to
play a similar role in these disorders as in other non-ischaemic di-
lated cardiomyopathies. Prophylactic ICD implantation should fol-
low the same criteria as in the other forms of non-ischaemic
dilated cardiomyopathies.666
Myotonic dystrophy type 1 (Steinert dystrophy) presents with
conduction disease often requiring pacing with or without dilated
cardiomyopathy (Table 7); up to one-third of deaths in these pa-
tients are sudden and unexpected.666 In a review of 18 studies
(1828 patients) by Petri et al.,667 first-degree AV block was reported
in almost 30% of patients, QRS duration .120 ms in 20%, frequent
PVCs in 15% and NSVT in 4%. LV systolic dysfunction was reported
in 7.2% of the patients and AF or atrial flutter in 5%. Based on the
high incidence of conduction disease, it has been speculated that
SCD in Steiner disease is primarily caused by progressive conduc-
tion disease; however, evidence of sudden death in patients with
pacemaker673 and spontaneous or inducible VTs suggests that
VAs account of some of the sudden deaths.
Lallemand et al.668 studied patients with Steiner disease and per-
formed serial invasive measurements of HV intervals showing that
the appearance of a new conduction disease is followed within 5
years by lengthening of infra-hissian conduction. Similarly, a study
by Laurent et al.673 suggested that prolongation of the HV interval
.70 ms at invasive EPS is predictive of complete AV block within
6 years. Groh et al.669 investigated 406 adult patients with genet-
ically confirmed myotonic dystrophy type 1, showing that the
severity of AV and/or intraventricular conduction defect and the
presence of atrial arrhythmias were independent risk factors for
sudden death. In a large retrospective observational study by
Wahbi et al.,672 the use of an electrophysiology study followed
by implantation of a pacemaker in patients with an HV interval
.70 ms reduced sudden death compared with patients followed
by ECG assessment.
In patients with Emery–Dreifuss and limb-girdle type 1B muscu-
lar dystrophies associated with lamin A or C mutations, sudden
death is responsible for 30% of all deaths.71
Some series of patients with the two lamin A/C dystrophies sug-
gested that the development of AV block is associated with poor
ESC Guidelines 1657
Downloaded from https://academic.oup.com/europace/article-abstract/17/11/1601/447560
by University of Liege user
on 20 August 2018
outcomes and pacing therapy is insufficient to prevent SCD, thus
supporting the use of prophylactic ICDs rather than pacemakers
when cardiac involvement is present.674 Risk factors for sudden
death and appropriate ICD therapy include non-sustained ventricu-
lar tachycardia, left ventricular ejection fraction,45%, male sex and
lamin A or C non-missense mutations.71 Management of the rare
X-linked recessive Emery–Dreifuss muscular dystrophy associated
with mutations in the emerin gene is complicated by a lack of clinical
data; in the absence of gene-specific information it seems reasonable
to adopt the management strategy used in the dominant form of
Emery–Dreifuss.666,671
12.3 Pregnant patients
12.3.1 Arrhythmias not related to peripartum
cardiomyopathy
Management of arrhythmic risk during pregnancy
Recommendations Classa Levelb Ref.c
Implantation of an ICD is recommended
if an indication emerges during
pregnancy.
I C 675
Beta-blocking agents are recommended
during pregnancy and also





Oral metoprolol, propranolol or
verapamil is recommended for





Immediate electrical cardioversion is






Sotalol or procainamide i.v. should be




Amiodarone i.v. should be considered
for acute conversion of sustained,
monomorphic VT when
haemodynamically unstable, refractory
to electrical cardioversion or not





Catheter ablation may be considered for
management of drug-refractory and
poorly tolerated tachycardias.
IIb C 675
CPVT ¼ catecholaminergic polymorphic ventricular tachycardia; i.v. ¼
intravenous; ICD ¼ implantable cardioverter defibrillator; LQTS ¼ long QT





Pregnancy contributes a significant risk in women with structural
heart disease.675,679 – 681 There is a substantial increase in the risk
of cardiac events in women with the congenital LQTS in the post-
partum period (the 40-week period after delivery), and beta-
blocker therapy should be continued676,682 throughout pregnancy
and post-partum. Women with Brugada syndrome can have a safe
pregnancy and peripartum period.683,684
Table 7 Cardiac involvement in muscular dystrophies. Adapted with permission from Groh et al.666











Duchenne Dystrophin DCM >90% PVC Only at late stage Yes
Becker Dystrophin DCM 60–75%












Conduction disease 10–25% Uncommon Uncommon Yes
Emery-Dreifuss
Emerin, 
lamin A and C
Conduction disease and DCM >90%  VT, ICD indicated
Common, atrial 
standstill
Yes, 30% of death
Limb-girdle type 1B Lamin A and C Conduction disease and DCM >90%  VT, ICD indicated Common Yes, 30% of death








Conduction disease 5–15% Rare VTs Rare No
DCM ¼ dilated cardiomyopathy; ICD ¼ implantable cardioverter defibrillator; PVC ¼ premature ventricular complex; VT ¼ ventricular tachycardia.
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12.3.1.2 Diagnosis
Palpitations may be caused by atrial or ventricular extrasystoles or
even sinus tachycardia, and most are benign.677,685 –688 Symptomatic
exacerbation of paroxysmal supraventricular tachycardia occurs
during pregnancy in many patients. New-onset VT may present dur-
ing pregnancy677,686 – 688 and may be related to elevated catechola-
mines.689 Risk of recurrent VT is higher in patients with previous VT
and structural heart disease.676,690,691
12.3.1.3 Treatment
When benign arrhythmias are found, patients need reassurance and
should avoid stimulants such as caffeine, smoking and alcohol. Symp-
tomatic tachyarrhythmia should be treated by catheter ablation be-
fore pregnancy, if the pregnancy was previously planned. If drug
therapy is recommended, it is advised to begin as late in pregnancy
as possible and to use the lowest effective dose.
Arrhythmias in the absence of structural heart disease during
pregnancy are usually sensitive to beta-blocker therapy.675,692,693
Sotalol or sodium channel blockers (class IC agents) may be consid-
ered in the absence of structural heart disease if beta-blocking
agents are ineffective.
While the first trimester is associated with the greatest terato-
genic risk, drug exposure later in pregnancy may confer adverse ef-
fects on foetal growth and development as well as increase the risk
of pro-arrhythmia. The Food and Drug Administration has defined
five categories for the use of anti-arrhythmic drugs during
pregnancy:694
† A: controlled studies show no risk (no anti-arrhythmic drug)
† B: chance of foetal harm is remote (sotalol, lidocaine)
† C: potential benefits outweigh the risk (quinidine, adenosine,
metoprolol, propranolol, verapamil, diltiazem, digoxin, flecainide,
propafenone)
† D: positive evidence of risk (phenytoin, amiodarone)
† X: contraindicated.
The pharmacological treatment of idiopathic VT from the RVOT is
verapamil or beta-blockers (metoprolol or sotalol) as prophylaxis, if
they are associated with severe symptoms or haemodynamic com-
promise. Idiopathic fascicular left VT usually does not respond to
beta-blockers and may be treated with verapamil; the mechanism
of this tachycardia depends on the slow entry of calcium in partially
depolarized Purkinje fibres.1 Catheter ablation may be necessary in
the case of drug-refractory and poorly tolerated tachycardias.
Patients with ICDs can have a successful pregnancy with no
foetal compromise.695 – 697 If indications for an ICD emerge during
pregnancy, the use of subcutaneous ICD may be considered, to
avoid fluoroscopy, but weighted against the limited experience
available.
12.3.2 Arrhythmias related to peripartum
cardiomyopathy
Management of arrhythmias related to pregnancy-
induced cardiomyopathy
Recommendations Classa Levelb Ref.c
Electrical cardioversion or defibrillation




Standard management of HF with
avoidance of drugs contraindicated in
pregnancy (ACE inhibitors, ARB and





ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin II receptor blocker;




Peripartum cardiomyopathy is defined as HF caused by LV systolic
dysfunction presenting towards the end of pregnancy or in the
months following delivery.700 The cause of peripartum cardiomyop-
athy is uncertain, and infections, inflammation and autoimmune pro-
cesses may play a role.1,701 The incidence has been estimated at 50
in 100 000 live births.702 The estimated mortality rate associated
with peripartum cardiomyopathy in the US ranges from 6 to
10%.703 Recent studies indicate that peripartum cardiomyopathy
can be a manifestation of familial DCM associated with gene
mutations.704
Peripartum cardiomyopathy usually presents with HF secondary
to LV systolic dysfunction towards the end of pregnancy or in the
months following delivery. The LV may not be dilated, but the ejec-
tion fraction is nearly always reduced (,45%).698 With this recent
definition, the time window is not strictly defined.705 Complex VA
and sudden cardiac arrest may occur as a result. Post-partum cardio-
myopathy should be ruled out in women presenting with new-onset
VT during the last 6 weeks of pregnancy or in the early post-partum
period.706
Guidelines for the management of acute HF should be applied.8
During pregnancy, ACE inhibitors, ARBs and renin inhibitors are
contraindicated.699,707 Beta-blocker treatment is recommended
for all patients with HF, if tolerated; beta-blockers with
beta1-adrenoceptor preferential properties (i.e. metoprolol)
should be preferred. Atenolol should not be used.708 MRAs should
be avoided.709 Potentially life-threatening ventricular tachyarrhyth-
mias should be terminated by electrical cardioversion. Implantation
of an ICD in patients with VA or low ejection fraction should follow
ESC Guidelines 1659
Downloaded from https://academic.oup.com/europace/article-abstract/17/11/1601/447560
by University of Liege user
on 20 August 2018
standard guidelines. However, the relatively high rate (50%) of spon-
taneous recovery of dilated cardiomyopathy after delivery must be
considered when decisions are made.710
12.4 Obstructive sleep apnoea
12.4.1 Bradyarrhythmias and tachyarrhythmias
Management of ventricular arrhythmias and
bradyarrhythmias in sleep apnoea
Recommendations Classa Levelb Ref.c
Sleep apnoea syndrome should be
considered in the differential diagnosis of
bradyarrhythmias.
IIa B 711
The presence of sleep apnoea and
reduced oxygen saturation may be
considered as a risk factor for SCD in
subjects with sleep disordered
breathing.
IIb C 712





Data on the prevalence of obstructive sleep apnoea in the
general population are not univocal due to the high heterogeneity
of the populations studied; however, according to a rigorous
population-based study determining the epidemiological features
of obstructive sleep apnoea, the prevalence of the disease in
602 adults between 30 and 60 years of age was 9% for women
and 24% for men.713 The prevalence of arrhythmias largely de-
pends on the co-morbidities present in the different populations.
Data from the Busselton Health Study714 and the Wisconsin Sleep
Cohort715 suggest that obstructive sleep apnoea is associated with
increased mortality. The existence of a link with SCD has been
debated.
Recently Gami et al.712 showed that obstructive sleep apnoea as-
sociated with a reduced mean nocturnal oxygen saturation ,93%
and a lowest nocturnal oxygen saturation ,78% were independent
risk factors for SCD (P, 0.0001). Therefore the presence of ob-
structive sleep apnoea should be included in panels of investigations
for risk stratification for SCD.
The frequency of cardiac arrhythmias, mainly nocturnal, increases
with the increased severity of sleep apnoea–hypopnea
syndrome.716 –718
12.4.1.2 Diagnosis
The most common cardiac rhythm abnormalities seen in patients
with sleep apnoea–hypopnea syndrome are sinus bradycardia, sinus
pause, first-degree and Mobitz I second-degree AV block and an in-
creased rate of PVCs.719 – 724 A circadian pattern of VA712,725 – 729
and a higher rate of SCD during sleep time (midnight to 6 A.M.)
have been demonstrated.
12.4.1.3 Treatment
At the present time there is no evidence suggesting a deviation from
the standard management of VA in patients with sleep apnoea–
hypopnea syndrome; furthermore, the value of continuous positive
airway pressure for the prevention of VA and SCD is still un-
defined.711,730– 733
Whether the appropriate treatment of obstructive sleep apnoea
could modify clinical manifestations and avoid the need for pace-
maker therapy in patients in whom arrhythmias are solely related
to obstructive respiratory events is unknown.733– 739
Newer innovative pacing therapies for the treatment of central
sleep apnoea–hypopnea syndrome using phrenic nerve stimulation
and upper airway stimulation for the obstructive form are under
investigation.740
12.5 Drug-related pro-arrhythmia
Management of drug-related pro-arrhythmia
Recommendations Classa Levelb Ref.c
Withdrawal of offending agents is
recommended whenever drug-induced
arrhythmias are suspected and the
presence of other arrhythmogenic
substrates has been excluded.
I B 362
Despite a possible correctable cause
for VA, the need for prophylactic
ICD implantation should be
considered based on an individual









12.5.1 Drug–substrate interaction due to underlying
disease substrate
When drug-induced arrhythmias are suspected, any offending
drug should be interrupted. In addition, a full assessment to ex-
clude cardiovascular risk factors that could contribute to an ar-
rhythmic episode should be performed. Drug-induced
arrhythmias should be suspected if an inherited or acquired ar-
rhythmogenic substrate has been excluded and the patient is being
treated with agents known to alter the electrical properties of the
heart (e.g. inducing QT prolongation) or causing electrolyte
abnormalities.
In patients with LV hypertrophy, the use of sotalol has been asso-
ciated with pro-arrhythmia.743 Similarly, there is some concern
about using flecainide and propafenone in these patients, particular-
ly when significant hypertrophy (LV wall thickness .1.4 cm) and/or
underlying CAD is present.744
Sodium channel-blocking drugs should not be used in patients
with a history of myocardial infarction129 or sustained VT due to
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structural heart disease. Other drugs with sodium channel-blocking
activity, such as tricyclic antidepressants, should also be avoided in
these circumstances. If ventricular function is abnormal, evaluation
and treatment should be similar to that for patients experiencing
VA in the absence of anti-arrhythmic drugs.
12.5.2 Drug–drug interaction (due to specific drugs and
combinations)
Many non-cardiac medications inhibit potassium channels (http
://www.crediblemeds.org) and are associated with a risk for TdP ta-
chycardias in susceptible patients. Treatment with several antibio-
tics, such as quinolones or azithromycin, significantly increases the
risk of death and cardiac arrhythmia.125,745 – 747 Other macrolide
antibiotics, including erythromycin and clarithromycin (metabolized
also by the cytochrome P450 3A4 enzyme), have been shown to in-
crease the risk of polymorphic VT and cardiac death, especially in
women.748 The combination of inhibitors of the renin–angiotensin
system and antibiotics such as co-trimoxazole with unrecognized
hyperkalaemia has been associated recently with an increased risk
of sudden death.749
Sodium channel-blocking drugs, such as tricyclic antidepressants,
may produce QRS prolongation and the typical Brugada syndrome
ECG.750 Anthracycline cardiotoxicity is dose dependent, with high-
er cumulative doses increasing the risk of cardiomyopathy and lethal
arrhythmias.751,752 5-fluorouracil may cause VF due to coronary
spasm.753 –755 Toad venom may produce clinical toxicity resembling
that of digoxin;756 herbal products such as foxglove tea have been
reported to produce similar effects.757,758 Many others drugs may
produce coronary spasm.759 – 761
Almost independent of the specific drug that caused TdP,
treatment should focus on avoiding drug treatment in high-risk pa-
tients for drug-induced arrhythmia. Intravenous magnesium can
suppress episodes of TdP without necessarily shortening QT,
even when serum magnesium concentration is normal.762 Tem-
porary pacing is highly effective in managing TdP. Isoproterenol
can also be used. Withdrawal of any offending drugs and correc-
tion of electrolyte abnormalities are recommended in these
patients.
12.5.3 Pro-arrhythmic risk of anti-arrhythmic drugs
Anti-arrhythmic drugs have direct effects on cardiac ion channels.
Flecainide, propafenone and quinidine have sodium channel-
blocking effects.763 In large clinical trials such as CAST and CASH,
sodium channel-blocking drugs increased mortality among patients
with previous myocardial infarction.129,764 Similar trends were seen
in earlier trials of mexiletine363 and disopyramide.362 In patients
treated for sustained VT, these agents may provoke more frequent,
and often more difficult to cardiovert, episodes of sustained
VT.765,766
D-sotalol, the QT-prolonging agent (a pure class III anti-
arrhythmic), slightly increased mortality in a large RCT in patients
with remote infarction.137 In the Danish Investigators of Arrhythmia
and Mortality on Dofetilide (DIAMOND) trial, 3.3% of patients with
severe HF had TdP during the first 72 h of dofetilide therapy.767
Amiodarone may cause TdP much less commonly than other
QT-prolonging anti-arrhythmics.768
Bradyarrhythmias are common pharmacological effects of di-
goxin, verapamil, diltiazem and beta-blockers. Some arrhythmias
are typical of digitalis toxicity: enhanced atrial, junctional or ven-
tricular automaticity often combined with AV block.
In most cases, management includes discontinuing the drug, mon-
itoring rhythm and maintaining normal serum potassium. Intraven-
ous magnesium and temporary pacing can be useful.762
Isoproterenol can also be used to increase heart rate and shorten
ventricular action potential duration, to eliminate depolarizations
and TdP.762,769 –771
12.5.4 Pro-arrhythmia due to triggering factors
Several triggering factors, such as hypokalaemia (,3.5 mM), a ra-
pid rise in extracellular potassium and hypomagnesaemia, are asso-
ciated with VA and SCD.772,773 Hypomagnesaemia is classically
associated with polymorphic VT or TdP, which may respond to
i.v. magnesium.774,775 Hypokalaemia with or without hypomagnes-
aemia may be responsible for VAs in subjects with hypertension
and congestive cardiac failure (precipitated by the use of thiazide
and loop diuretics).774 Multiple factors, such as bradycardia, is-
chaemia, coronary spasm, thrombosis, acute starvation776 and
acute alcohol toxicity/withdrawal,777,778 may facilitate develop-
ment of VAs and SCD. ICDs may also cause the appearance of
VA.779 – 781
Withdrawal of any offending drugs and correction of electrolyte
abnormalities are recommended in these patients.
12.6 Sudden cardiac death after heart
transplantation
Many clinical studies have demonstrated that sudden death is fre-
quent after heart transplantation (.10% of cardiac transplant reci-
pients).782 Some patients may have sudden death after a history of
several episodes of severe rejection.
In patients with acute rejection, the conduction system may be
damaged, leading to VA and sudden death. These hearts may be at
increased risk of developing arrhythmias during the haemodynamic
stresses of haemodialysis or plasmapheresis.783 Coronary disease
is found in most of the heart transplant patients with sudden death;
it may be due to hyperkalaemia, haemodialysis or plasmapheresis
as triggers of the event, but it may also be a primary arrhythmic
death.
The use of an ICD after heart transplantation may be appropriate
in selected high-risk patients.784
12.7 Sudden cardiac death in athletes
Prevention of sudden cardiac death in athletes
Recommendations Classa Levelb Ref.c
Careful history taking to uncover
underlying cardiovascular disease,
rhythm disorder, syncopal episodes or
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Upon identification of ECG
abnormalities suggestive of structural
heart disease, echocardiography and/or





Physical examination and resting 12-lead
ECG should be considered for






Middle-aged individuals engaging in
high-intensity exercise should be
screened with history, physical
examination, SCORE and resting
ECG.
IIa C 785
Staff at sporting facilities should be
trained in cardiopulmonary resuscitation





CMR ¼ cardiac magnetic resonance; ECG ¼ electrocardiogram; SCD ¼ sudden




Athletes appear at excessive risk of SCD compared with similar-
aged non-athletes:26 the annual incidence of SCD in young athletes
(,35 years) is estimated to range from 0.7 to 3.0 per 100 000 ath-
letes.788 In older athletes the incidence is higher and is expected to
increase with age.789 The intensity of the activity and the age of the
athlete are core risk factors.
The most frequent causes of sudden death in younger athletes are
inherited arrhythmogenic disorders (cardiomyopathies and channe-
lopathies) and CAD (both congenital and acquired). In the US, the
National Registry of Sudden Death in Athletes was established at the
Minneapolis Heart Institute in the 1980s and has reported on 1866
sudden deaths in individuals ,40 years of age during a 27-year
observational period. Their data show that 36% of all sudden deaths
in this registry are attributed to confirmed cardiovascular causes, of
which the most frequent are HCM (36%), congenital anomalies of
the coronary arteries (17%), myocarditis (6%), ARVC (4%) and
channelopathies (3.6%).27 In Italy, investigators in the Veneto region
conducted a prospective cohort study enrolling individuals ,36
years of age involved in competitive sports between 1979 and
1999. ARVC was found as a cause of SCD in 24% of these athletes,
followed by atherosclerotic CAD (20%), anomalous origin of coron-
ary arteries (14%) and mitral valve prolapse (12%).26 In older ath-
letes (.35–40 years), as in the general population, coronary
atherosclerotic disease accounts for more than half of cases.29
Pre-participation screening appears efficient790 in preventing SCD,
but the screening programmes vary greatly in European countries and
between Europe and the US.791 Cardiac screening should be adapted
to the age of the athlete to account for age-specific risk factors. In
young athletes (≤35 years of age), screening should focus on inher-
itable cardiomyopathies and channelopathies (see Sections 8 and 9).
In older athletes, CAD is the most common cause of SCD and
screening should also be targeted to detect signs of ischaemia.792
The European Association of Cardiovascular Prevention and Re-
habilitation has issued recommendations for cardiovascular
evaluation of middle-aged/senior active individuals engaged in leis-
ure time sport activities.792 The risk-assessment scheme for active
middle-aged individuals is outlined in Figure 4.
Recently Menafoglio et al.785 assessed the implications on the
workload, yield and economic costs of this preventive strategy
in 785 athletes ages 35–56 years engaged in high-intensity sport.
A new cardiovascular abnormality was established in 2.8% of ath-
letes and the cost was $199 per athlete. The authors concluded
that the overall evaluation seems to be feasible with a reasonable
cost.785
It is important that coaches and staff at sporting facilities are
trained to face emergency situations, perform cardiopulmonary
resuscitation and use automatic external defibrillators.179,786
12.8 Wolff–Parkinson–White syndrome
Management of patients with Wolff-Parkinson-White
Syndrome
Recommendations Classa Levelb Ref.c
Ablation is recommended in patients
with WPW syndrome resuscitated from
sudden cardiac arrest due to AF and
rapid conduction over the accessory
pathway causing VF.
I B 793
Ablation should be considered in
patients with WPW syndrome who are
symptomatic and/or who have
accessory pathways with refractory
periods ≤240 ms in duration.
IIa B 793





Wolff–Parkinson–White (WPW) syndrome is a fairly uncommon
cause of SCD, with an estimated incidence of between 0.05 and
0.2% per year.794 SCD may occur due to the development of AF
with a rapid ventricular response that degenerates to VF.795 The
principal risk factor for SCD is the presence of an accessory pathway
with short antegrade refractoriness. In a recent 8-year prospective
registry of 2169 patients with WPW syndrome, SCD occurred pri-
marily in patients with accessory pathway antegrade refractory per-
iods ≤240 ms and AV re-entrant tachycardia initiating AF.793
An EPS with ablation is recommended in patients with WPW syn-
drome resuscitated from aborted cardiac arrest due to AF and rapid
conduction over the accessory pathway causing VF.796 An EPS
should be considered and ablation performed if the patient is symp-
tomatic (e.g. with syncope or palpitations) and/or the refractory
period of the accessory pathway is ≤240 ms.793 The EPS should in-
clude measurement of the shortest pre-excited RR interval during
induced AF (or the shortest pre-excited RR interval during rapid at-
rial pacing), determination of the number and location of accessory
pathways, the anterograde and retrograde characteristics of the ac-
cessory pathways and AV node and the effective refractory period
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ECG = electrocardiogram; PA = physical activity;  SCORE = systematic coronary risk evaluation.
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of the accessory pathways and of the ventricle at multiple cycle
lengths.
Treatment with calcium antagonists (verapamil) or digoxin
should be avoided in patients with WPW because these medica-
tions may enhance antegrade conduction through the accessory
pathway by increasing the refractory period in the AV node.
12.9 Prevention of sudden cardiac death
in the elderly
The use of anti-arrhythmic drugs in elderly patients should be ad-
justed to account for decreased renal and hepatic clearance,
changes in body composition and the presence of co-morbidities.
The risk of drug interactions should also be taken into consideration
and dose adjustment may be required. In the absence of specific
contraindications, beta-blockers should be considered in elderly pa-
tients after acute myocardial infarction, as they have been shown to
prevent SCD in patients .65 years of age.797
ICDs are used extensively in the elderly: subgroup analyses in
both the AVID and MADIT-II trials demonstrated equivalent bene-
fits from ICD in older and younger patients.63,153 A meta-analysis
combining data from trials on primary prevention of SCD [Multicen-
ter UnSustained Tachycardia Trial (MUSTT), MADIT-II, DEFINITE
and SCD-HeFT] found that ICD therapy reduces all-cause mortality
in patients ≥75 years of age in the absence of ICD-related compli-
cations [HR 0.73 (95% CI 0.51, 0.974), P ¼ 0.03].798 Interestingly,
however, a different meta-analysis suggested that ICD therapy might
be less beneficial in elderly patients with severe LV dysfunction [HR
0.75 (95% CI 0.61, 0.91)].799 Pooled data from secondary preven-
tion trials (AVID, CASH and CIDS) revealed that ICD therapy sig-
nificantly reduced all-cause and arrhythmic death in patients ≤75
years old, but not in patients ≥75 years [all-cause death HR 1.06
(95% CI 0.69, 1.64), P ¼ 0.79; arrhythmic death HR 0.90 (95% CI
0.42, 1.95), P ¼ 0.79].800 Observational studies and registry data
from everyday clinical practice in primary prevention demonstrate
that age alone should not preclude device implantation.801,802
The decision to implant an ICD should consider the conse-
quences of the device on quality of life: in a MADIT-II substudy,
no significant decrease in quality-adjusted life-years for patients
≥65 years was established.803 In general, age is not among the cri-
teria considered for appropriate use of the ICD, as octogenarians
who die suddenly can be highly functional even in the month before
their death.804 Clinical judgement coupled with the wishes of the pa-
tient and/or family may contribute to the decision to deviate from
standard recommendations for the use of the ICD.
12.10 End-of-life issues
Management of end-of-life issues
Recommendations Classa Levelb Ref.c
Discussion of end-of-life issues with
patients who qualify for the implant of an
ICD should be considered before
implantation and at significant points




ICD deactivation should be considered








Terminally ill patients frequently develop conditions predisposing to
arrhythmias (hypoxia, pain and electrolyte disturbances) and up to
20% of those with an ICD receive shocks in the last weeks of their
life.805,807,808
Discussing deactivation of the ICD with the patient and family to
prevent undue distress and pain to a person who is dying is an im-
portant but often neglected necessity. Individual consideration
should be given to the patient’s desires, honouring both informed
consent and informed refusal. When patients are unable to make
this decision themselves, a family member or surrogate decision ma-
ker should be heard or the living will of the patient should be com-
plied with, if such exists.805,808,809
Owing to the complexity of the issue, exhaustive information
on how to implement the recommendations can be found in
two consensus documents by the EHRA805 and the Heart Rhythm
Society.809 In addition, local rules and legislation should be taken
into account.
Deactivation can be done by device programming or, if this is
not available, by application of a magnet directly over the device.
It may be preferable to suspend only antitachycardia therapies
and maintain pacing for bradycardia to avoid symptomatic
deterioration.
13. Gaps in evidence
† The first clinical manifestation of sudden death is often le-
thal. Therefore identification of patients at risk for sudden
death remains the philosopher’s stone of sudden death pre-
vention. Risk stratification for primary prevention of SCD
with invasive and non-invasive techniques is still unsatisfac-
tory. Novel approaches including genetic profiling, ECG
screening and imaging techniques need to be assessed. Re-
search into the best methods to detect asymptomatic popu-
lations at risk for sudden death is urgently needed. Simple
and cheap methods appropriate for mass screening are
needed.
† Ensuring an effective and rapid chain of care is of utmost import-
ance to improve survival of sudden death victims. More research
is needed to evaluate the optimal design of such survival chains
including pre-hospital care and in-hospital protocols.
† The successes in preventing CAD and HF due to myocardial in-
farctions have substantially reduced sudden death rates. Further
research into the other causes of sudden death is needed to fur-
ther reduce sudden death rates.
† More than half of sudden death victims have a preserved LV func-
tion. Specific research programmes to understand the mechan-
isms causing sudden death in patients with preserved LV
function is urgently needed, probably requiring interdisciplinary
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approaches including cardiologists, geneticists, epidemiologists,
and basic and translational scientists. Such research should en-
compass better detection of patients with inherited cardiomyop-
athies and inherited arrhythmogenic disorders, sudden death risk
stratification in patients with HF and preserved EF and sudden
death risk assessment in patients with AF.
† Wearable defibrillators may be an interesting therapeutic option
in selected patients but require larger randomized trials before
clear indications can be fully defined.
† Randomized trials on the feasibility of risk stratification with inva-
sive electrophysiological study early after myocardial infarction
are warranted.
† More than a decade has passed since the publication of landmark
RCTs on primary prevention of SCD, which have served until the
present as the basis for ICD use in patients with LV systolic dys-
function and HF. Patient profiles and medical treatments have
changed significantly since then: today’s patients are older and
have more co-morbidities such as AF, chronic kidney disease
and others. Thus new clinical trials are needed to assess the po-
tential benefit of primary prevention of SCD with an ICD for to-
day’s patient population. As no relevant new RCTs are under
way, data from prospective registries might shed more light on
this clinically very important issue.
† More research is needed to establish evidence-based interven-
tions to reduce the psychosocial impact and optimize care and
support for patients and families at risk of SCD.
† Many patients with reduced ejection fraction will experience
an improvement in LVEF over time. Some of these patients
will receive a defibrillator without a clear need, while others
may remain at risk for sudden death despite recovery of LV
function. More research into the best assessment of these pa-
tients is needed to allow better, personalized sudden death
management.
† The use of CRT(-D) in patients with AF and the place of AV nodal
ablation has not been well defined outside of observational data-
sets. There is a clear need for adequately powered randomized
trials in this common patient group.
† The field of inherited arrhythmias and cardiomyopathies has
faced major advances in the last 20 years, mainly due to the wide-
spread availability of genetic diagnosis and the availability of clin-
ical data from large registries. However, key gaps in evidence still
exist. A large number of patients with primary inherited arrhyth-
mias and cardiomyopathies still die before a diagnosis is made,
thus suggesting the need for improved diagnostic approaches.
Knowledge gaps also exist in risk-stratification schemes for dis-
eases such as Brugada syndrome, SQTS, ARVC and most of
the non-ischaemic dilated cardiomyopathies.
† VTs worsen the prognosis of patients with a variety of structural
heart diseases. New anti-arrhythmic or other medical therapy is
urgently needed to allow a broader population to be protected
from first or recurrent life-threatening VAs. It remains to be
tested whether specific anti-arrhythmic treatment can improve
that prognosis. While catheter ablation of recurrent VT in pa-
tients with structural heart disease has been shown to significant-
ly reduce the number of VT recurrences, the impact of VT
catheter ablation on mortality is unclear and warrants
investigation.
14. To do and not to do messages
from the guidelines
General population Classa Levelb
The analysis of blood and other adequately
collected body fluids for toxicology and molecular
pathology is recommended in all victims of
unexplained sudden death.
I C
It is recommended that public access defibrillation
be established at sites where cardiac arrest is
relatively common and suitable storage is available
(e.g. schools, sports stadiums, large stations,
casinos, etc.) or at sites where no other access to
defibrillation is available (e.g. trains, cruise ships,
airplanes, etc.).
I B
Patients with ICD indications
Discussion of quality-of-life issues is
recommended before ICD implant and during
disease progression in all patients.
I C
Ischaemic heart disease
Re-evaluation of LVEF 6–12 weeks after
myocardial infarction is recommended to assess
the potential need for primary prevention ICD
implantation.
I C
Patients with heart failure
ICD therapy is recommended to reduce SCD in
patients with symptomatic HF (NYHA class II or
III) and LVEF ≤35% after ≥3 months of optimal
medical therapy who are expected to survive at
least 1 year with good functional status:
– Ischaemic aetiology and at least 6 weeks after
myocardial infarction
I A
– Non-ischaemic aetiology I B
To reduce all-cause mortality, CRT-D is
recommended in patients with a QRS duration
≥130 ms, with an LVEF ≤30% and with an LBBB
despite at least 3 months of optimal
pharmacological therapy who are expected to
survive at least 1 year with good functional status.
I A
To reduce all-cause mortality, CRT is
recommended in patients with an LVEF ≤35% and
LBBB despite at least 3 months of optimal
pharmacological therapy who are expected to
survive at least 1 year with good functional status:
– With a QRS duration .150 ms I A
– With a QRS duration of 120–150 ms I B
Inherited arrhythmogenic diseases
Avoidance of competitive sports is recommended
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Emerging recommendations
Flecainide should be considered in addition to
beta-blockers in patients with a diagnosis of CPVT
who experience recurrent syncope or
polymorphic/bidirectional VT while on
beta-blockers when there are risks/
contraindications for an ICD or an ICD is not
available or is rejected by the patient.
IIa C
An ICD should be considered in patients with
DCM and a confirmed disease-causing LMNA
mutation and clinical risk factors.
IIa B
ARVC ¼ arrhythmogenic right ventricular cardiomyopathy; CPVT ¼
catecholaminergic polymorphic ventricular tachycardia; CRT-D ¼ cardiac
resynchronization therapy defibrillator; DCM ¼ dilated cardiomyopathy; HF ¼
heart failure; ICD ¼ implantable cardioverter defibrillator; LBBB ¼ left bundle
branch block; LMNA ¼ lamin A/C; LVEF¼ left ventricular ejection fraction; ms¼
milliseconds; NYHA ¼ New York Heart Association; SCD ¼ sudden cardiac
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